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The fluoroquinolones are a class of potent antibacterial agents that have been used in
the treatment of infectious diseases for the previous two decades. Fluoroquinolones
cause cell death through interactions with Class II topoisomerases. These enzymes
are key players in maintaining cellular integrity in bacteria and the disruption of
these proteins through mutational events cause severe cellular damage and death.
Until recently, the use of fluoroquinolones was limited to the treatment of gram-
negative infections, the introduction of extended-spectrum quinolones now allows
the use of these compounds against gram-positive pathogens which cause severe
respiratory tract infections. Respiratory tract infections are a predominant indication
for antibacterial prescribing in both hospital and community acquired respiratory
illness.
Initially the antibacterial activity of the extended-spectrum fluoroquinolones was
assessed against the three major respiratory pathogens and compared with other
similar antibiotics. Prior to this sensitivity study the current MIC testing protocols for
the quinolones were evaluated. It was found that carbon dioxide incubation adversely
affected the media and antibacterial efficacy of the antibiotic subsequently resulting
in elevated MICs for all the fluoroquinolones. This effect was not confined to
organisms that required carbon dioxide incubation conditions for growth. Gram-
negative pathogens such as Ps. aeruginosa also exhibited significant MIC increases
in reduced air conditions. The quinolone MICs reported for S. pneumoniae were also
increased in reduced air conditions in comparison to air. These observations
prompted all further sensitivity testing to be performed in ambient air conditions.
The sensitivity survey was done on 909 isolates recovered from nine centres from
around the United Kingdom. Sensitivity was determined by testing each isolate for
its minimum inhibitory concentration (MIC) by agar dilution. Against all three
respiratory pathogens the extended-spectrum fluoroquinolones were found to be the
most bactericidal. Ciprofloxacin retained its activity against both H. influenzae and
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M. catarrhalis, although activity against S. pneumoniae was variable. Tetracycline
was found to be the least active against all three species.
Thirty-one clinical pneumococcal isolates that exhibited decreased sensitivity to the
fluoroquinolones were found to express a combination of resistance mechanisms.
Efflux inhibition studies have shown that all the selected pneumococcal isolates
demonstrated a reduction in susceptibility to ciprofloxacin and norfloxacin in the
presence of reserpine (efflux pump inhibitor). No such effect was observed with
either of the extended-spectrum quinolones (moxifloxacin and gatifloxacin) tested.
Sequencing analysis of 11 representative isolates revealed that none of the organisms
sustained a genetic mutation in either gyrA or parC except for two strains: 7368,
which demonstrated a Lysine 137 —► Asparagine change and BPL27, which has a
Aspartic acid 83 —> Asparagine mutation. Both these strains exhibited a MIC of
4mg/l to ciprofloxacin but remained sensitive to moxifloxacin. Other isolates that
exhibited identical MICs were found not to possess these genetic changes.
Previous research has suggested that the primary fluoroquinolone target in gram-
negative bacteria is DNA gyrase A and within gram-positive bacteria is
topoisomerase IV. In vitro mutation studies with anti-gram positive quinolones such
as gatifloxacin and sparfloxacin have shown that gyrA is the primary intracellular
target in S. pneumoniae. Therefore to ascertain the primary target of rnoxifloxacin
within S. pneumoniae, stepwise selection of four different pneumococcal phenotypes
(laboratory strain S. pneumoniae R6, penicillin intermediate and resistant clinical
isolates 285 and 158 and pmrA efflux hyperexpresser P1Z1/IN27) was done. The in
vitro studies, indicated that the development of moxifloxacin resistance was through
a combination of mutations within the target genes and efflux pump expression.
There were two pathways of resistance development where the first started with a
Serine80 —> Tyrosine change accompanied by the apparent induction of an efflux
pump. This was followed by a Serine79 —> Tyrosine mutation in ParC with the loss
of the efflux pump. The second pathway showed no initial change in any of the target
genes but was accompanied by the switching on of an efflux pump. No additional
mutations were detected in either the parE and gyrB genes.
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Accumulation assays show that uptake is dramatically reduced in mutants after
moxifloxacin challenge in comparison to the respective parent strains. The
contribution of the efflux pump pmrA was analysed in isogenic moxifloxacin
mutants. Northern blot analysis demonstrated the expression of a pmrA or a pmrA
like pump in first-step and some second-step mutants indicating that efflux may
contribute to moxifloxacin resistance to a greater extent than previously assumed.
Therefore, these data suggest that a pmrA like pump may contribute to the efflux
mediated resistance towards moxifloxacin, although the contribution of this efflux
mechanism was not evaluated in clinical isolates.
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In 1969, the US Surgeon General testifying to the congress made the historic
statement "the time has come to close the book on infectious diseases"1. He made
these statements at an optimistic time when more than 25,000 antibiotic products had
been developed and antibiotic resistance was not a major public health issue. Three
decades on, we look to a dwindling resource of treatment options and the prevalence
of antibiotic resistance is sufficiently serious to threaten a future, which could date
back to the pre-antibiotic era. The widespread use of antibiotics in clinical therapy
began with the introduction of the penicillins in the 1940s, the quinolones in 1964,
the cephalosporins in 1975, the fluoroquinolones and carbapenems in the 1980s.
1
Quote taken from: Report on regional medical programs to the President and the Congress.
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Resistance in the target bacteria has swiftly followed the use of each of these agents.
However, this situation has also been compounded by the indiscriminate use of
antibiotics in veterinary medicine. Selection pressure exerted by these compounds
has led to the rising rates of resistance in traditional hospital pathogens but has also
selected for resistance in non-traditional pathogens. Unfortunately, this situation has
severe repercussions in other aspects of clinical treatment. Procedures such as
transplantation and surgery require antibiotic therapy and the viability of using these
practices are compromised. The inevitable cost of antibiotic resistance is the loss of
these valuable compounds from clinical use, leading to the dire prospect of revisiting
the pre-antibiotic era.
1.2 History of Antibiotics
Until the end of the nineteenth century, traditional remedies derived from minerals
and plants were used in the treatment of infectious diseases. Honey, for example,
known for its anti-inflammatory and anti-microbial properties was employed in the
treatment of wound infections. This natural remedy is now experiencing a resurgence
in the form of granulated sugar in combination with debriding agents for the
treatment ofwounds (Durodie, 1984; Chirife et al, 1982).
Despite the obvious potential of natural potions, the search for substances with
increasing antibacterial potency has always been sought. Here, Paul Ehrlich's
seminal work in the first decade of this century must be mentioned. Ehrlich proposed
almost all the fundamental concepts, which have governed the subsequent work on
synthetic antimicrobial agents. Ehrlich recognised the need to develop synthetic
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compounds that would interfere rapidly with the metabolism of infectious agents and
subsequently kill these microbes but not adversely affect the host. He defined his
three requirements for the treatment of infectious diseases with synthetic compounds:
efficacy, convenience and low toxicity (Ehrlich, 1913). He was searching for the
therapia sterilans magna, the one dose treatment that would cure all. His initial
experiments began by using chemically synthesised agents developed by the German
dye industry (Kasten, 1996). At that time three distinct lines were produced namely
red, blue and yellow. The red line gave rise to the predecessors of sulphonamides
(Domagk, 1935), which are used in the treatment of infectious diseases today. The
second group of dyes that were produced were the aniline dyes of which methylene
blue was found to demonstrate antimicrobial properties and subsequently used
widely as antimalarials in the 1890s (Gutmann & Ehrlich, 1891). The yellow line of
dyes gave rise to one of the most potent and widely used antimicrobial agents today:
the quinolones. The initial derivatives of this yellow line were the chloroquines from
which the first napthyridone nalidixic acid was synthesised. The current analogues of
each of these dye lines are still used in clinical therapy today.
Ehrlich's greatest practical success came with the effective treatment for human
syphilis with Salvarasan (compound 606) derived from the aniline dyes in 1910
(Ehrlich, 1910). The new drug when administered early during the course of
infection was able to destroy the spirochetes. Unfortunately, Ehrlich's dream of an
ideal antimicrobial agent, a 'magic bullet' was not truly realised with Salvarasan
since the drug was found to be toxic in large doses with side effects, and in lower
doses would cause the spirochetes to develop resistance rapidly (Kasten, 1996).
Nevertheless, Salvarasan and its derivative neo-salavarasan together with bismuth
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therapy were used as first line therapy against syphilis until the introduction of
penicillin in the 1940s (Work & Work, 1948). In essence, Ehrlich paved the way for
the use of synthetic compounds in the treatment of infectious diseases and with
salvarasan proved that it could be done. The pathway to the discovery and
development of sulfa drugs and penicillin clearly began with Ehrlich's pioneering
research on dyes as potential chemotherapeutic agents (Ehrlich, 1913) and
encouraged the work of others (Kasten, 1996) in the investigation of dyestuffs for
further bactericidal and bacteriostatic properties.
As an aftermath of Ehrlich's work on dye chemotherapy, a screening programme of
the stockpile of new dyes produced by the German chemical laboratories was
initiated and directed by Gerhard Domagk, an experimental pathologist. In 1935,
Domagk publicly announced that Prontosil, a compound consisting of a sulfonamide
group attached to the dye chrysoidin, was effective in attacking streptococcal
infections in animals without causing damage to the hosts (Domagk, 1935; reviewed
by Otten, 1986). The enhanced antibacterial properties of sulfanilimide and the other
new sulfa derivatives was a success in medicinal chemistry and further proved the
therapeutic use of synthetic compounds as antibacterials (Kasten, 1996). Synthetic
drug development did much for the advances in antimicrobial chemotherapy, with far
reaching effects on the treatment of current infections with analogues of previously
synthesised compounds.
The discovery and development of the quinolone class of agents were very much in
this manner. Whilst pursuing new compounds based on the structure of quinines for
the treatment ofmalaria, a derivative of the 1,8-napthyridine molecule that possessed
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antibacterial activity was produced. By 1962, George Lesher and colleagues (Lesher,
1962) had developed nalidixic acid. However, it was only in 1964 that nalidixic acid
was available for the treatment of urinary tract infections and was the first quinolone
of its class in clinical use (Andriole, 1991). Its poor serum tissue concentrations and
its limited spectrum of activity compromised the efficacy of nalidixic acid (Norris &
Mandell, 1988). Production of other quinolone compounds continued and 20 years
later a significant development in the quinolone pharmacore corresponded with
enhanced activity of these agents in clinical treatment. Koga et al (1980) observed
that modifications at the C6 and C7 positions in the quinolone nucleus brought
improved clinical efficacy and absorption. The subsequent addition of the fluorine
atom at these positions created the more potent group of agents known as the
"Fluoroquinolones". Since Lesher's initial report, 10,000 analogues of nalidixic acid
and the fluoroquinolones have been synthesised. Some of these compounds have
been extensively developed and used, making these agents one of the most relied
upon class of antibacterials in clinical use.
1.3 Quinolones
The discovery and development of the quinolones was hailed as one of the most
exciting advances in antimicrobial chemotherapy. The quinolone class of antibiotics
possesses a primary structure that is known as the quinolone pharmacore (Mitscher et
al, 1990). The quinolone pharmacore is defined as the minimum structural unit in a
drug that has measurable and typical pharmacological activity (Tillotson 1996;
Domagala 1994). This minimum unit itself is often of low potency and specificity.
The function of the other portions of the drug molecule, like the auxopharmacophore
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provides tighter receptor fit, greater selectivity, more useful pharmacokinetic
characteristics and solubility of the quinolones (Mitscher et al, 1990). The
pharmacophoric unit consists of the pyridone ring and its associated carboxyl group















Figure 1.1: Structure of Quinolone Pharmacore and Nalidixic Acid
The auxopharmacore is defined by a variety of substitutions at the different carbon
positions. It has been shown that modifications at certain positions such as C2, C3
and C4 could interact and markedly decrease the basic mode of quinolone drug
action (Mitscher et al, 1990). For example, at positions 2,3,4 binding to DNA bases
occurs. These bases are open to interaction with new hydrogen binding partners by
the action ofDNA gyrase, therefore any large chemical additions at position 2 would
result in stearic hindrance at positions 3 and 4 which would compromise the action of
the drug on its target (Tillotson, 1996). Therefore, very little variation is observed at
the Nl, C2, C3 and C4 positions. However, 3 other positions namely C6, C7 and C8
can receive a wide range of substituents that enhance the efficacy of the quinolone.
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1.3.1 Position 1
The earliest quinolones possessed nitrogen-bearing modifications at position 1. This
was fortuitous, as subsequent work has shown that any other substitutions like
oxygen (Hogberg et al, 1984a) and carbon (Hogberg et al, 1984b) were found to be
unsuitable. The substituent attached at N1 controls antibacterial potency and the
cyclopropyl group in particular has been found to improve in vivo efficacy and
activity against the anaerobes (Domagala, 1994); for example ciprofloxacin (See
Figure 1.2a) has an Nl- cyclopropyl substituent which gives potent activity against
enterobacteriaceae and difloxacin, which possesses a N1-fluorophenyl substituent, is
the most active quinolone against Chlamydia trachomatis (Chu & Fernandes, 1989).
Against S. pneumoniae it has been shown that compounds that possess a
2,4-difluorophenyl at the N-l position like tosufioxacin (See Figure 1.2b) had







Figure 1.2: Structure of Ciprofloxacin and Tosufloxacin
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1.3.2 Position 5
Initial research into the modifications at this position involved the introduction of the
1,5-napthyridines at this position. This did not yield any significant progress in the
pharmacokinetics and efficacy of the quinolone (Mitscher et al, 1990). Recent
investigations have shown that large moieties should not be introduced at this site
such as fluorine, chlorine and alkyl or nitro lead to compounds with decreased
activity (Jack, 1986). However, substituent combinations of (l-cyclopropyl-6-8,
difluoroquinolone) as seen with sparfloxacin (See Figure 1.3a) and grepafloxacin
(See Figure 1.3b) have shown increased activity against gram-positive bacteria. Both
compounds also show enhanced activity against gram-positive bacteria (Domagala,
1994) with, sparfloxacin extending its potency against gram-negative bacteria.
CH3
(a) Sparfloxacin (b) Grepafloxacin
Figure 1.3: Structure of Sparfloxacin and Grepafloxacin
1.3.3 Position 6
It was the addition of the fluorine atom at the carbon 6 position that developed the
fluoroquinolones (Koga et al, 1980). The introduction of the fluorine atom
dramatically enhances the potency of the drug. This single atom can provide more
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than 10 fold increases in gyrase inhibition and up to 100-fold improvement in MIC
(Domagala, 1994) which is indicated by the amount of drug required to inhibit DNA
gyrase and the penetration of the drug through the cell membranes in comparison to
nalidixic acid.
1.3.4 Position 7
This position is the most significant within the quinolone molecule as modifications
at this location can dictate the activity and pharmacokinetic profile of the drug
(Domagala, 1994; Tillotson, 1996). Chemical additions at this position are linked to
the quinolone nucleus via nitrogen, carbon, sulphur, or oxygen molecules (Petersen
et al, 1996). The most common substituents at position 7 are the aminopyrolidones
and the piperazines. Quinolones that have an unsubstituted piperazine ring such as
ciprofloxacin and norfloxacin have been found to demonstrate good activity against
gram-negatives (Sanchez et al, 1988), while grepafloxacin, which has a 3-methyl
piperazine and sparfloxacin with a 3,5-dimethyl piperazine (Perry et al, 1999),
contain substituted piperazine rings which exhibit greater activity against gram-
positives and are believed to provide increased penetration into bacterial cells
(Domagala, 1994).
Generally, aminopyrolidine modifications confer increased protection against gram-
positive bacteria but a pyrolidine ring without the amino group is detrimental to
activity (Domagala, 1994). Generally, compounds that possess the 7-amino-
pyrolidine ring are more active against gram-positives than those that possess a 7-
piperazine ring. Clinafloxacin (See Figure 1.4a) which has a 3-amino pyrolidine
substituent (Mitsuyama, 1999) and gatifloxacin (See Figure 1.4b) which has a 3-
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amino, 4-methyl substituent (Appelbaum & Hunter, 2000). Both trovafloxacin (See
Figure 1.4c) (Brighty & Gootz, 1997) and clinafloxacin (Ednie et al, 1999) have
enhanced activity over ciprofloxacin against gram-positive cocci and anaerobes
whilst maintaining good activity against gram-negative pathogens (Chu &
Fernandes, 1989). Gemifloxacin (See Figure 1.4d) possesses an unusual pyrolidine
ring that has a 3-aminomethyl and 4-methyloximino substituent which has been











(c) Trovafloxacin (d) Gemifloxacin
Figure 1.4: Structure of Clinafloxacin, Gatifloxacin, Trovafloxacin, and
Gemifloxacin
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The other unusual side chain substituent at position 7 is a bicyclic ring fused to the
pyrolidone ring, which is found in both trovafloxacin and moxifioxacin (Child et al,
1995; Dalhoff, 1999; Appelbaum & Hunter, 2000). Both these compounds
demonstrate good activity against gram-positives (Dalhoff, 1999; Gootz et al, 1996).
1.3.5 Position 8
Substitutions at this position has been implicated in marked improvements in activity
against both gram-positive and anaerobic bacteria (Domagala, 1994), although
activity against gram-negative bacteria is reduced. The most productive substituents
with respect to pharmacokinetics and potency are the fluoro, chloro and methoxy
groups as other groups tend to decrease both in vitro and in vivo efficacy (Tillotson,
1996; Domagala, 1994). In addition, to the enhanced antibacterial activity, these
compounds have also been found to interact more specifically with humans. The
substitutions at this site have been associated with the severe side effects of
phototoxicity that fluoroquinolone use is able to cause (Paton & Reeves, 1991). The
naphthyridones have a nitrogen in the place of the carbon in the ring as seen in
trovafloxacin and gemifloxacin. Quinolones that possess changes at the C'8 position
are ciprofloxacin, clinafloxacin, moxifioxacin (See Figure 1.5a), and gatifloxacin
(See Figure 1.5b) respectively. Gatifloxacin and moxifioxacin both possess the
methoxy substitution at the C8 position which confers good anaerobic activity and








Figure 1.5: Structure ofMoxifloxacin and Gatifloxacin
1.3.6 Quinolone Generations
The successful and widespread use of ciprofloxacin has demonstrated the potential of
the fluoroquinolones in the treatment of a wide range of infections although activity
against gram-positive infections has been variable. Thus, the major thrust of
fluoroquinolone research has been to develop compounds with improved activity
against gram-positives such as staphylococci, particularly MRSA and streptococci.
Each quinolone generation has been designed to maintain and enhance activity whilst
minimising the risk of adverse effects. The quinolone progenitors namely the
napthyridone and the quinolone pharmacore (See Figure 1.1a) are structurally similar
and subsequent agents have been developed on the basis of these fundamental
structures.
1.3.6.1 Generation I
The first generation quinolone, flumequine possessed anti-pseudomonal activity and
was used until reports of ocular toxicity removed it from clinical use (Rohlfing et al,
1976). The first generation napthyridone derivative nalidixic acid was used widely in
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the treatment of urinary tract infections caused by gram-negative bacteria but was
subsequently removed because of poor serum and tissue concentrations (Andriole,
1991). Resistance to both agents developed rapidly, thereby rendering them useless
against bacterial pathogens.
1.3.6.2 Generation Ha
The next fluoroquinolone derivative, ciprofloxacin had predominantly gram-negative
activity and has been widely available since the 1980s (Thomson, 1999). The
addition of the piperazine group at position 7 was instrumental in the enhanced
potency of this antibiotic. The launch and use of ciprofloxacin revolutionised the
treatment of gram-negative infections like bacteriaemia (Krumpe et al, 1999).
Ciprofloxacin also possessed exceptional activity against pseudomonal infections in
children with cystic fibrosis (Campoli-Richards et al, 1988). The only shortfall of
ciprofloxacin was its reduced and variable activity against gram-positive bacteria
especially S. pneumoniae and methicillin resistant Staphylococcus aureus (MRSA)
(Ball, 1994). Certain adverse effects were associated with ciprofloxacin use such as
CNS effects and photoxicity (Domagala, 1994).
1.3.6.3 Generation lib
This generation of quinolones was developed with activity against both gram-
positive and gram-negative bacteria, thereby enabling this class of agents to be used
against the pneumococcus. Grepafloxacin is an example of a lib quinolone, which
possesses activity against both gram-negative and gram-positive pathogens.
Grepafloxacin differs from ciprofloxacin by the 2-methyl group substitutions it
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possesses at position 5 at the heterocyclic ring and in the piperazine ring at C7. The
methyl substituent at position 7 has been associated with enhanced gram-positive
activity as well as increased phototoxic potential (Stahlman & Schwabe, 1997). This
property has underlined the removal of sparfloxacin/grepafloxacin from clinical use.
The napthyridone derivatives enoxacin and tosufloxacin were also removed from
clinical treatment after reports of increased resistance and severe adverse effects
(Hooper, 1998).
1.3.6.4 Generation Ilia
Examples of generation Ilia are compounds like gatifloxacin and moxifloxacin.
Structurally, gatifloxacin and moxifloxacin are similar although moxifloxacin
possesses an azabicyclo substitution at position 7, in contrast to gatifloxacin, which
retains a piperazinyl group. Both these agents have excellent activity against
S. pneumoniae regardless of penicillin and macrolide sensitivities (Bruggemann et al,
1997) and have no reported adverse effects (Balfour & Wiseman, 1999; Perry et al,
1999). In contrast, agents such as trovafloxacin (napthyridone derivative) and
clinafloxacin both of which share structural similarities have been shown to induce
severe hepatotoxicity and hypoglycaemia in humans. Both agents have been
subsequently withdrawn from clinical therapy (Ball, 2000).
1.3.6.5 Generation IHb
Gemifloxacin which is a napthyridone derivative with a 1-cyclopropyl group is the
only drug of this generation. Gemifloxacin has markedly better activity against both
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gram-positive and negative bacteria and in some cases has been found to surpass the
action of Ilia quinolones in in-vitro studies (Marchese et al, 2000).
Figure 1.6: Diagrammatic Representation of the Quinolone Generations
(Adapted from Wise, 2000)
Figure 1.6 shows the evolution of quinolone compounds beginning with agents with
modest activity against gram-negatives to broad-spectrum activity against both gram-
positive and negative bacteria.
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1.3.7 Structure and Toxicity Relationships
Therapeutic drug use has always been associated with some form of adverse reaction
in man. One of the initial side-effects implicated with quinolone use was arthropathic
damage in weight-bearing joints of animals when high doses of the drug were
administered over a prolonged period (Ingham et al, 1977). The most severe adverse
reaction that has caused fluoroquinolones to be removed from clinical use is
phototoxicity. Phototoxicity has been found to be almost always non-immunogenic
(Paton & Reeves, 1991) and appears to be a class effect for most of the known
quinolone agents although they differ markedly from each other in the levels of
phototoxic risk inducible in humans (Domagala, 1994). Quinolone photoreactivity is
oxygen dependent. Generally, when quinolones are exposed to UVA radiation, three
molecular outcomes may result: the quinolone gradually decomposes (Matsumoto et
al, 1992), the quinolones passes light energy onto oxygen forming singlet oxygen,
which is a powerful oxidizing agent and radical generator (Robertson et al, 1991), or
the quinoione returns to its ground state unchanged (Foote, 1976). The quinolones,
which are the most phototoxic are those that induce singlet oxygen and radicals
subsequently causing severe tissue damage (Foote, 1976).
Quinolones, which reach high concentrations or accumulate in the skin, have a
higher risk of producing phototoxic events. It has been shown that the possession of a
halogen, such as fluorine or chlorine at position 8 of the fluoroquinolone nucleus
contributes to severe phototoxicity (Domagala, 1994). Understandably, the
phototoxic potential of a drug has a direct impact on its therapeutic properties.
Compounds that have shown exceptional in vitro antibacterial activity but phototoxic
potential have been dropped from further development as seen with BAY Y3118 or
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with the recommended limited clinical use of sitafloxacin and clinafloxacin. Newer
compounds such as moxifloxacin and gemifloxacin which exhibit similar in vitro
activity as the afore-mentioned compounds but alternate C8 substitutions are still
capable of inducing a mild phototoxic reaction which is within the safety margins
associated with quinolone use (Man et al, 1999).
The previous decade has seen the removal of several fluoroquinolones from clinical
use after being awarded the 'pink letter', which warned all doctors of the phototoxic
and carcinogenic potential of the drugs. Sparfloxacin was removed from clinical
treatment in October 1994 due to reports of phototoxicity and photocarcinogenicity
(Ministry of Health & Welfare Bulletin, Japan, 1994). More recently, grepafloxacin
v/as found to induce severe cardiovascular episodes in patients prior to its removal
from clinical treatment (Glaxo Wellcome, 1999). Fourteen cases of severe liver
failure were reported and implicated with trovafloxacin use. Although trovafloxacin
has not been removed from clinical therapy, caution is advised when administering to
patients (Nightingale, 1999). Quinolone use is able to induce other side effects that
include gastrointestinal upset, skin rash and arthropathy. These side effects are
mediated by this class of agents and cannot be moderated by molecular variation
(Tillotson 1996; Domagala 1994).
1.3.8 Drug-drug Interactions with Fluoroquinolones
Quinolones are able to interact with theophylline or non-steroidal anti-inflammatory
drugs (NSAIDS). Quinolones with alkylated piperazines and pyrolidines such as
clinafloxacin and trovafloxacin have fewer effects with NSAIDs than those with
unsubstituted piperazines like ciprofloxacin (Tillotson, 1996). Since the piperazine
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ring at position 7 mimics the structure of y-aminobutyric acid (GABA) it is able to
antagonise GABA receptor binding in the brain, thereby resulting in heightened CNS
excitation (Tillotson, 1996). Despite the inhibitory activities of fluoroquinolones on
GABA neurons, there are few reported NSAID-induced CNS effects associated with
quinolone use.
Enoxacin was the first quinolone reported to increase theophylline concentrations
leading to severe adverse reaction (Wijnands et al, 1984). Quinolone and
theophylline interaction occurs, when the metabolic breakdown pathway mediated by
cytochrome p450 enzymes is inhibited by quinolones thereby causing an
accumulation of theophylline which subsequently results in convulsions. These side
effects have been observed most frequently with quinolone compounds that possess
substituents at position 7 (Tillotson, 1996).
1.3.9 Anti-gram Positive Quinolones
The majority of fluoroquinolones that have been in clinical use till recently,
possessed excellent in vitro and in vivo activity against gram-negative organisms and
moderate activity against gram-positive bacteria. These older agents have been used
in the treatment of selected respiratory tract infections, but concerns have remained
regarding their efficacy in infections caused by marginally susceptible organisms like
Streptococcus pneumoniae (Legg & Bint, 1999). Ciprofloxacin, the forerunner of the
fluoroquinolones has been used with variable success against pneumococcal
pneumonia. Reports of therapeutic failure with ciprofloxacin has led clinicians to
question the efficacy of quinolones as first-line empirical therapy in the treatment of
respiratory tract infections caused by the pneumococcus and other gram-positive
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pathogens (Perez-Trallero et al, 1990; Kuehnert et al, 1999; Barry et al, 1999). This
scepticism was further validated by the microbiological eradication success rate
being more pronounced with B-lactams such as amoxycillin and penicillin rather than
ciprofloxacin for the pneumococcus (Balfour & Wiseman, 1999). The limitations of
quinolones such as ciprofloxacin coupled with increasing penicillin and macrolide
resistance in S. pneumoniae (Felmingham & Washington, 1999) urgently indicates
the need for new treatment options. This has prompted pharmaceutical companies to
focus on the development of broader spectrum fluoroquinolone agents with enhanced
activity against gram-positive pathogens. In the last two years, antimicrobial agents
such as moxifloxacin and gatifloxacin with enhanced activity against gram-positive
bacteria have been launched. This is timely, as respiratory tract infections (RTI) are
prime indications for antibacterial prescribing both in the community and hospital
and where current recommendations for the treatment of RTIs include the single use
of a drug and combination regimens (Finch, 1995). The new fluoroquinolones are
principal candidates for this, as they possess a broad antibacterial spectrum and rapid
bactericidal activity.
1.3.10 Moxifloxacin
Moxifloxacin is an 8-methoxy quinolone which is an enantiometrically pure 6-fluoro,
8 methoxy quinolone carboxylic acid (Balfour & Wiseman, 1999) (See Figure 1.5a).
Due to its C7 and C8 modifications it possesses enhanced activity towards gram-
positive pathogens, particularly, the pneumococcus (Balfour & Wiseman, 1999). In
vitro testing has shown that moxifloxacin demonstrates good activity against
S. pneumoniae regardless of penicillin and macrolide susceptibilities and was found
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to be 8-fold more active compared to both ciprofloxacin or levofloxacin (Balfour &
Wiseman, 1999; Dalhoff, 1999). It is also as potent as ciprofloxacin against other
gram-negative respiratory pathogens such as H. influenzae and M. catarrhalis
(Dalhoff et al, 1996). The currently reported MIC50 and MIC90 values of
S. pneumoniae against moxifloxacin are 0.12-0.25mg/l (Dalhoff, 1999) which is well
below the recommended breakpoint value for moxifloxacin (Andrews et al, 1999).
The clinical success of the new fluoroquinolone agents is dependent on their efficacy
against pathogens previously resistant to older agents of the same class.
Moxifloxacin was able to retain its potency against isolates with reduced
susceptibility to ciprofloxacin with an MIC50 of 0.25mg/l (Piddock et al, 1998; Pong
et al, 1999). The correlation of in vitro with in vivo activity is crucial in determining
the clinical utility of any antibiotic. In vivo studies have shown that moxifloxacin
administered once a day achieved bacteriological success rates of approximately
90% or higher in community acquired pneumoniae (CAP) and acute exacerbation of
chronic bronchitis (AECB) (Balfour & Wiseman, 1999). This single dosing regimen
of 400mg of moxifloxacin was as effective as lg of amoxycillin three times a day
(Balfour & Wiseman, 1999). In comparison with cefuroxime axetil, moxifloxacin
had a 11% higher success rate in the eradication of Streptococcus pneumoniae
(Siegert et al, 2000). Post antibiotic effect of more than lhr was observed at 4x MIC
against S. pneumoniae, E. coli, and H. influenzae with moxifloxacin (Balfour &
Wiseman, 1999). This improved activity observed is attributed to the bulky C7
substituent of moxifloxacin, which in other quinolones like sparfloxacin and
ciprofloxacin has also been linked to enhanced efficacy (Chu & Femandes, 1989;
Balfour & Wiseman, 1999; Hunter & Appelbaum, 2000). The C8 methoxy group
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confers light stability therefore moxifloxacin has a low propensity for causing
phototoxic or CNS excitatory effect (Balfour & Wiseman, 1999). The only side
effect implicated with moxifloxacin use is gastrointestinal disturbance (von Keutz &
Schulter, 1999).
1.4 Bacterial Topoisomerases
DNA topology modulates every physiological function within the cell. In bacteria,
this topology determines the essential cellular processes such as DNA replication and
transcription levels of various promoters. These cellular functions are dependent on
the appropriate level of DNA supercoiling being maintained in the cell (Wang,
1985). In bacteria, these negative superhelical turns are introduced into DNA by a
class of enzymes known as DNA topoisomerases.
Topoisomerases fall into two general categories: Type I and Type II. This
categorisation is based on the biochemical mechanisms responsible for DNA strand
passage. Type 1 topoisomerases are monomeric enzymes which include
topoisomerase I and III. In E. coli, topoisomerase I and III are active as dimers
consisting of a single type subunit encoded by topA and topB genes (Gellert, 1981;
Hooper, 1998). Topoisomerase I and III have the ability to unlink or decatenate
interlocked DNA circles and do so by characteristically catalysing single stranded
DNA cleavage and strand passage in the absence of ATP (i.e. removing negative
superhelical twists without ATP) (Hooper, 1998; Roca 1995).
Type II topoisomerases encompass DNA gyrase and topoisomerase IV in bacteria
and topoisomerase II in eukaryotic cells. These enzymes are multi-subunit proteins,
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which require energy cofactors for activity (Hooper, 1998; Roca 1995). Unlike type I
topoisomerases, DNA gyrase and topoisomerase IV mediate double-strand breakage
with the passage of another helix through the transient break by a process requiring
ATP hydrolysis (See Fig.7) (Drlica & Zhao, 1997; Watt & Hickson 1994). These
reactions are essential in maintaining the appropriate state of DNA supercoiling and
separation of daughter DNA molecules during cell division. Type I and type II
topoisomerases are found in all bacterial cells and act opposingly on superhelical
DNA, to maintain the optimal DNA conformation within the cell (Gellert, 1981).
Major interest in these enzymes particularly the type II topoisomerases stem from the
fact that they play an essential role in DNA maintenance and are primary cellular
targets for some of the most widely prescribed antibiotic and anticancer agents
currently used in the treatment of human disease.
1.4.1 DNA Gyrase
1.4.1.1 GyrA Subunit
Gellert et al (1976) first isolated the Type II DNA topoisomerase, DNA gyrase from
E. coli. DNA gyrase is a multi-subunit enzyme consisting of two GyrA and GyrB
subunits, encoded by gyrA and gyrB genes respectively where the active enzyme
presents as an A2B2 complex. All enzyme activities requires both subunits but certain
domains mediate both functions (Gellert. 1981). Mechanistically, gyrase binds to
DNA, where a segment of approximately 130bp wraps around the protein. This
wrapped DNA is cleaved in both strands with a 4-base pair stagger between the
break sites, which results in the formation of DNA-protein covalent bonds between
the GyrA subunits and the DNA (Roca, 1995) (See Figure 1.7). Another segment of
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DNA is passed through this double-stranded break before it is resealed (Mizuuchi et
al, 1980). Catalytic supercoiling mediated by DNA gyrase A requires the hydrolysis
of ATP (See Figure 1.8). The fact that DNA gyrase breaks both strands of DNA is
unique in comparison to the other type 1 topoisomerases that nick only one strand. A
further distinction is that the cleavage that DNA gyrase institutes is highly site
specific (Fisher et al, 1981; Morrison et al, 1979).
Figure 1.7: Mechanistic Action of DNA Gyrase
(Taken from Roca, 1995)
(a) DNA gyrase binds to the DNA. Unlike other Type II topoisomerases DNA gyrase wraps around
the flanking DNA regions, thereby bringing the amino terminal ends of the enzyme to the
entrance of the T-segment ofDNA.
(b) Upon ATP binding, the DNA flanks are captured and transported. The inversion of the positive
node facilitates negative supercoiling ofDNA.
In E. coll, DNA gyrase A mediated strand breakage and reunion has been found to
occur at Tyrosine-122 (Horowitz & Wang, 1987). In vivo studies have shown that
DNA gyrase is essential for DNA replication and is involved in both initiation and
elongation (growing-point propagation) of DNA as determined by the patterns of
replication arrest observed in both gyrA and gyrB conditional lethal mutants (Wang,
1985).
In DNA replication, gyrase functions by introducing negative supercoils, to facilitate
binding of initiation proteins to DNA and enhancing DNA strand unwinding during
fork propagation. Inactivated DNA gyrase in dividing bacteria accumulates partially
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segregated nucleoids that completely segregate upon addition of purified DNA
gyrase (Wang, 1985; Fisher et al, 1981).
T
Figure 1.8: Mechanistic Action of Type II DNA Topoisomerases
(Taken from Roca, 1995)
Two gate mechanism of type II topoisomerases.
(a) DNA gyrase forms an open clamp, which binds to the DNA duplex enabling the second duplex
DNA to lodge in the G-segment, bound enzyme leaving the clamp open.
(b) The binding of ATP shuts the protein gates, which are composed of the amino-terminal domains
of each homodimer.
(c) With the T segment outside, the second gate closes and the rejoined G-segments remains inside
the protein. The enzyme returns to the open clamp form after ATP hydrolysis and release of
products.
N: denotes the amino terminal domains of the enzyme
G & T segments: indicates independent segments of DNA.
DNA gyrase is also involved in transcription at least indirectly, because negative
supercoiling of DNA can increase expression of some operons and decrease
expression of others. In addition, the enzyme may also be involved more directly in
the removal of positive supercoils accumulating ahead of RNA polymerase as it
progresses along DNA templates (Wang, 1985). In short, damage in DNA gyrase
38 Introduction
results in the complete inhibition of replicative DNA synthesis and subsequently
results in cell death (Cozzarelli, 1980).
1.4.1.2 GyrB Subunit
GyrB, is a 90-kDa fragment in E. coli which complexes with GyrA and functions by
supporting DNA relaxation but not supercoiling or ATP hydrolysis (Wang, 1985).
The N-terminal domain of GyrB contains the ATP binding site as elucidated with
X-ray crystallography and also has been found to be homologous to the amino
terminal part of the eukaryotic topoisomerase II (Drlica & Zhao, 1997; Hooper,
1998). The ATPase activity of DNA gyrase B is competitively inhibited by the
coumarin derivatives such as novobiocin which are structurally unrelated to
quinolones (Maxwell, 1993). It has been shown that genetic mutations associated
with novobiocin resistance are clustered around the 5' (N-terminal) region of the
GyrB gene as described in S. pneumoniae (Munoz et al, 1995). However, genetic
mutations sustained within the C-terminal region of the subunit are associated with
quinolone resistance as seen in E. coli (Yoshida et al, 1991) and S. pneumoniae (Pan
& Fisher, 1998). It appears that apart from the ATPase activity, GyrB is also
involved in DNA binding and strand passing (Cozzarelli, 1980).
In combination, the A and B subunits ofDNA gyrase are able to introduce supercoils
by relaxing negative supercoils in the presence of ATP and positive supercoils in the




In 1990, Kato et al discovered a homolog of gyrase that was subsequently called
topoisomerase IV. Topoisomerase IV bears a similar arrangement to DNA gyrase. It
consists of 2 ParC and 2 ParE subunits (Kato et al, 1990). Analysis of the E. call
nucleotide sequences of parC and parE genes indicates homology to the A and B
subunits of DNA gyrase respectively and that the parE gene is located upstream of
parC (Peng & Marians, 1993). Homology between DNA gyrase and
topoisomerase IV is also seen in gram-positive bacteria like S. pneumoniae (Pan &
Fisher, 1996b).
Like other topoisomerase II enzymes, topoisomerase IV also employs a double
strand mode of passage (Roca, 1995). However, the fundamental means by which
this is achieved differs between DNA gyrase and topoisomerase IV. DNA gyrase
wraps itself around the DNA unlike topoisomerase IV (Peng & Marians, 1995). This
mode of wrapping favours intra-molecular bonding rather than intermolecular bonds
which has been found to have a deleterious impact on the decatenating activity of the
enzyme (Peng & Marians, 1995) as is the case with DNA gyrase A where the
decatenating potential of this enzyme is poor in comparison to its supercoiling and
relaxing activities.
The superior DNA decatenating capacity of topoisomerase IV relative to gyrase
could explain the functional differences between the enzymes. The primary feature
of topoisomerase IV is its ability to remove catenanes before the round of DNA
replication is complete in comparison to DNA gyrase, where this is only done after
the replication cycle is complete (Hooper, 1998). Studies with E. coli and
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S. typhimurium that sustain temperature sensitive mutations in topoisomerase IV,
were found to accumulate supercoiled catenated plasmids in vivo within minutes of
the non-permissible temperature (Kato et al, 1990). Furthermore, mutations within
parC and parE subunits resulted in mutants with cellular phenotypes consistent with
the absence of an enzyme involved in chromosomal segregation (Adams et al, 1992).
Electron microscopy has shown that although DNA gyrase is able to supercoil
catenanes, which are products of DNA synthesis in cells, it is unable to unlink them.
It is now apparent that catenanes borne out of the processes of recombination and
tangling are unlinked by DNA gyrase and those arising from replication are resolved
by topoisomerase IV (Adams et al, 1992). Deficiencies in topoisomerase IV lead to
an accumulation of catenated plasmids in both S. typhimurium and E. coli cells which
suggests a stage in chromosomal partitioning catalysed by topoisomerase IV for
which DNA gyrase cannot substitute (Kato et al, 1990). It has also been shown that
DNA synthesis is not significantly affected in topoisomerase IV mutant
S. typhimurium cells although they sustain severe defects in chromosomal
partitioning. In contrast, inactivation of DNA gyrase introduced by mutation or drug
binding has been shown to severely inhibit DNA synthesis resulting in cell death
(Adams et al, 1992; Khodursky et al, 1995). This is validated in nature where
bacterial species like Mycobacteria spp and Helicobacter spp (Hooper, 1998) do not
possess topoisomerase IV, which implies that either DNA gyrase or an equivalent of
topoisomerase IV have compensated for the absence of the enzyme. These
observations indicate a division of labour between the type II bacterial
topoisomerases when both are present and given the level of homology shared
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between the enzymes it is possible that there may be an overlap in function where
only one is present.
1.4.3 Intracellular Drug Targets
Despite differences in both biochemical and catalytic characteristics, the crucial
feature common to all topoisomerases is the strand passage event. The ability to pass
a single or double stranded DNA segment freely through another comes with a heavy
price. To maintain genomic integrity during this cleavage event, topoisomerases
attach covalently via phosphotylrosyl bonds to the newly synthesised DNA. Usually,
these covalent-DNA enzyme complexes are temporary catalytic intermediates, which
exist in low intracellular concentrations within the cell (Maxwell, 1997; Froelich-
Ammon & Osheroff, 1995) and are subsequently, tolerated by the cell. There are
certain physiological conditions and natural or synthesised compounds that are able
to prolong the lifespan of these catalytic intermediates resulting in severe damage to
the cell. This unique and essential function of topoisomerases within bacterial cells
secures the role of these essential enzymes as excellent drug targets (Drlica &
Franco, 1988) and has been exploited by pharmaceuticals resulting in the production
of potent classes of antibiotics and anti-cancer agents (See Table 1.1).
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Bacterial Gyrase (A subunit)
Topoisomerase IV (Subunit C/ E)
Acridines N-AMSA Eukaryotic topoisomerase II
Alkaloids Camptothecin Eukaryotic topoisomerase II
Table 1.1: Bacterial and Eukaryotic Topoisomerase II Inhibitors
(Adapted from Drlica & Franco, 1988)
Topoisomerase II inhibitors can be divided into either topoisomerase poisons or
inhibitors. Quinolones are termed "topoisomerase poisons" as they disrupt the DNA-
breakage reunion reaction, thus disrupting DNA supercoiling. Kreuzer and Cozzarelli
(1979) proposed the " poison hypothesis" where the interaction of the quinolone with
DNA gyrase converts it into cellular poison. This cellular poison is presumed to be
the quinolone-DNA-gyrase complex, which inhibits the passage of RNA
polymerases, thereby inhibiting DNA transcription (Kreuzer & Cozzarelli, 1979;
Willmott et al, 1994). Coumarins, on the other hand, interact with the ATPase
subunit of DNA gyrase without trapping the DNA enzyme reaction intermediate and
are termed "topoisomerase inhibitors"(Gellert, 1976; Drlica & Franco, 1988). The
eukaryotic topoisomerase inhibitors are purported to work in a similar manner to the
quinolones (Hsiang et al, 1985).
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1.5 Quinolone Mode ofAction
1.5.1 Mode of Binding
Quinolone resistance mutations have been shown to occur in the genes encoding both
DNA gyrase and topoisomerase IV clearly implying a role for both enzymes in
quinolone binding. However, drug binding studies have been unable to pinpoint the
exact position of binding within these enzymes to the quinolone. Most investigations
have sought to elucidate the interactions of DNA gyrase with the quinolones,
although relatively little is known about the mechanistic aspects of interaction with
topoisomerase IV. Given the level of homology between both the enzymes, it may be
possible to speculate that the quinolone enzyme interactions would be similar.
1.5.2 Binding of Quinolones to DNA
The initial experiments aimed at elucidating the mode of quinolone action measured
the binding of radio-labelled norfloxacin to calf thymus DNA using the equilibrium
dialysis method (Bourguigon et al, 1973). No binding was detected in these
experiments indicating that nalidixic acid did not bind to double stranded or
supercoiled DNA. Shen & Pernet (1985) repeated this experiment with radiolabelled
norfloxacin and found that both equilibrium dialysis and membrane filtration
techniques failed to detect any appreciable level of drug binding to DNA gyrase.
Further analysis showed that quinolones bound poorly to relaxed double stranded
DNA instead of supercoiled DNA (Palu el al, 1988). Characterisation of this
interaction has shown that the binding of norfloxacin to DNA preferentially occurred
in the presence of single stranded DNA. This observation indicated that quinolone-
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DNA interaction occurred via hydrogen bonding to the exposed bases in the single
stranded region (Shen et al, 1989a) thereby suggesting that drug binding to relaxed
double stranded DNA was weak in contrast to drug binding to supercoiled DNA. The
drug binding to supercoiled DNA was subsequently described to occur in a highly
co-operative manner to a saturable site (Shen et al, 1989a). Subsequent experiments
have confirmed this quinolone-DNA interaction, albeit in a magnesium dependent
manner (Palu et al, 1992).
1.5.3 Effect of DNA Gyrase on Quinolone Binding
Several studies have now confirmed that quinolones do not show significant levels of
binding to either DNA gyrase or DNA alone (Shen & Pernet, 1985; Palu et al, 1992;
Critchlow & Maxwell, 1996) but do so to the DNA gyrase-DNA complex. The
conditions in which binding occurs are selective, requiring the presence of a non-
nydrolysable ATP analogue ADPNP to a mixture of DNA gyrase and DNA (Shen et
al, 1989b). Similarities between quinolone binding to supercoiled DNA via a
saturable site and the formation of a saturable quinolone binding site after the
binding of DNA gyrase and variable DNA forms (i.e. linear/relaxed) led to the
proposal of the following model (Shen et al, 1989c).
1.5.4 Co-operative Quinolone-DNA Binding Model.
Shen et al (1989c) proposed this model based on the interaction of the quinolone
DNA and gyrase. The binding of DNA gyrase to relaxed DNA cleaves both strands
with a 4bp stagger in the presence of ATP. The quinolones bind to the Tyrl22
region, the active site of DNA gyrase, via hydrogen bonding between the single
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stranded DNA and the carbonyl and carboxyl groups at positions 3 and 4 on the
quinolone nucleus (Shen et al, 1989c) (See Figure 1.9). Four or more drug molecules
are thought to bind to the DNA in the pocket by forming strong intermolecular bonds
(See Figure 1.9a).























Figure 1.9: Cooperative Quinolone DNA Binding Model
(Taken from Shen et al (1989c))
Co-operative quinolone-DNA binding model proposed by Shen et al (1989c). Filled and hatched
boxes represent the quinolone molecules inside a gyrase-induced single-stranded DNA binding site.
Figure 1.9a represents the quinolone molecule stacking in the co-operative quinolone-DNA binding
model.
The drug binding occurs either by ring stacking of quinolone rings which are
hydrogen bonded to the same DNA strand or by tail to tail hydrophobic interactions
with the N-l, C-2 and C-8 substituents of the quinolone molecules which are
hydrogen bonded to single stranded DNA (Shen et al, 1989c). Shen et al (1989c)
postulated that substituents within the quinolone structure, particularly at the C-7
position were involved in the drug-enzyme interactions. This model hinges on DNA
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cleavage by DNA gyrase. Studies involving DNA gyrase mutants with substitutions
at tyrosine 122, were found to bind quinolones at similar levels to the wild type DNA
gyrase (Reece & Maxwell, 1991; Critchlow & Maxwell, 1996). From these results, it
is clear that DNA cleavage may not be a necessity in the formation of the DNA-
gyrase and quinolone complex thereby contesting the model proposed by Shen et al
(1989c).
1.5.5 Magnesium Bridge Model
The requirement of a fixed concentration ofmagnesium ions for norfloxacin binding
to DNA has been demonstrated by Palu et al (1992). The model proposes that
quinolone binding to DNA occurs via a magnesium bridge rather than hydrogen
bonds (See Figure 1.10). The quinolones are stabilised through the stacking
interactions between the single stranded DNA base and the quinolone planar system.
Unlike the Shen model, no cooperativity is required for the drug-DNA-gyrase
complex formation, although both models concur that quinolone interactions occurs
via either the C-7 and N-l substituents of the quinolone nucleus. Further experiments
have confirmed the presence of magnesium ions between the carboxylate and ketone
groups of the quinolone molecule (Lecomte et al, 1994) and phase partitioning has
shown that the binding of DNA to fluoroquinolones is dependent on the drug's




Figure 1.10: Schematic Representation of the Palumbo Model.
(Taken from Palumbo et al, 1993)
Quinolone drugs are proposed to bind via a magnesium ion bridge between the C-3
and C-4 groups and the phosphate groups of DNA. Interactions between the gyrase
and the drug are proposed to occur via the C-7 and N-l substituents of the quinolone
(Palumbo et al, 1993). Both the Shen and Palumbo models, propose that quinolones
bind to single stranded DNA after strand cleavage by DNA gyrase.
1.5.6 Other Binding Models
Several other quinolone binding models have been proposed, albeit with less
supporting evidence. Yoshida et al (1993) proposed that quinolone binding would
occur in the pocket of the DNA-gyrase complex that appears during the cleavage-
reunion event and where quinolone binding is mediated equally by both gyrA and
gyrB proteins. Current evidence does support the proposed interaction of the
quinolone resistant DNA gyrase and the gyrA and gyrB proteins with the quinolones,
as point mutations sustained within these genes have been shown to cause quinolone
resistance (Yoshida et al, 1993; Willmott & Maxwell, 1993). Therefore, mutations
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sustained within the gyrA and gyrB proteins can alter the optimal confirmation of the
binding pocket resulting in reduced binding and a subsequent increase in resistance.
Another model proposed by Fan et al (1995) is based on the quinobenzoxazine
model of binding. Quinobenzoxazines are a group of drugs that are structural
analogues of norfloxacin, which possess no antibacterial activity but are able to
exclusively inhibit mammalian topoisomerase II. The Fan (1995) model suggests that
quinobenzoxazines bind to DNA in a magnesium dependent manner. However, this
hypothesis is based on the drug binding to unwound duplex DNA and not to single
stranded DNA and this has been shown not to be the case with bacterial
topoisomerases (Shen & Pernet, 1985).
1.5.7 Quinolone Binding to Quinolone Resistant Mutants of DNA
Gyrase
Mutations sustained within the A and B subunits of DNA gyrase have been shown to
confer quinolone resistance on both intact bacteria and purified gyrase. Genetic
changes associated with quinolone resistance have been found to occur most
commonly at position 83 in the E. coli gyrA. In gram-positive bacteria, mutations
shown to cause quinolone resistance occur at position 80 or 81, which is analogous to
83 in the E. coli GyrA protein. These quinolone resistance mutations occur in the
amino terminal region of subunit A close to the active site of the enzyme (Tyr 122).
Site directed mutagenesis of Serine 83 —> Tryptophan in E. coli (Willmot &
Maxwell, 1993) has been shown to significantly decrease norfloxacin binding to the
DNA/DNA gyrase complex suggesting that the amino acid at position 83 interacts
with the quinolone. However, other investigators have shown that similar mutations
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of Serine83 —» Leucine in gyrA and Lysine447 —» Glutamic acid in gyrB binds to
quinolones at the same levels as the wild type gyrA and gyrB in E. coli (Yoshida et
al, 1993) although, the Aspartic acid 426 —* Asparagine substitution in GyrB has
been shown to bind lesser quinolone (Yoshida et al, 1993). The susceptibility to
quinolones is compromised by mutations within the gyrB subunit at positions 426
and 447 in clinical isolates of E. coli (Yamagishi et al, 1986) thereby lending support
to the proposed quinolone pocket model (Yoshida et al 1993). The suggestion that
both GyrA and GyrB act in concert and mutations within the subunits can dictate a
loss in binding and subsequent decrease in susceptibility to the fluoroquinolones is
supported by clinical and laboratory evidence thereby securing a role for these
enzymes in quinolone binding.
1.5.8 DNA Gyrase Quinolone Binding Models: A Critique
There is currently no scientific evidence to pinpoint the exact amino acid within
DNA gyrase which is directly or indirectly involved in quinolone binding and which
position and substitution within the quinolone pharmacore interacts with the enzyme.
Both the Shen (1989) and Palumbo models (1993), propose that drug-DNA
interactions occur either by hydrogen bonding or via the magnesium ion bridge
between the C3 and C4 substituents and the DNA phosphate backbone.
Investigations into the position of the Mg2+ ions during the binding event favour the
latter hypothesis (Palu et al, 1992). Another position where the C3 and C4
substituents on the quinolone molecule can interact with the gyrA protein is Serine83.
Single point mutations introduced at this position have been shown to reduce
quinolone binding drastically (Willmot & Maxwell, 1993) and changes at this
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position have been shown to decrease susceptibility to the quinolones in E. coli and
other bacterial species (Hooper, 2000).
Both the Shen and Palumbo models suggest that the C7 position of the quinolone
nucleus interacts with the DNA gyrase. Given the variability of modifications at this
position, it seems an unlikely candidate for drug/DNA/gyrase interaction although it
has been shown that substitutions at the C-7 position are able to alter intracellular
interactions in S. pneumoniae (Alovera et al, 2000) and Yoshida et al (1993), have
also found evidence that supports the involvement of the C7- piperazine substituents
with subunit B ofDNA gyrase in E. coli.
The Shen and Palumbo models suggest that binding occurs to single stranded DNA
sites that are exposed after DNA cleavage by gyrase. Binding experiments performed
with active site mutants bearing mutations at Tyrl22 to either phenyalanine or serine
in the gyrA protein have shown that binding to quinolone still occurs at levels
consistent with the wild type enzyme (Critchlow & Maxwell, 1996). This result
implies that DNA cleavage is not necessary for drug binding and questions the single
stranded DNA binding prerequisite put forward by both models. Although, it is
possible that a precleavage event occurs where a complex of gyrase, DNA, and the
quinolone is formed prior to a more stable complex being established.
To further elucidate the mechanics of drug-binding, parallels may have to be drawn
from the interactions of eukaryotic topoisomerase II and DNA. This model proposes
the intercalation of the drug into the internucleotide space next to the cleaved
phosphodiester bonds which in turn support the interaction with DNA gyrase
residues (Freudenreich & Kreuzer, 1993). This interaction would be similar
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regardless of the presence and absence of the cleavage event, although the presence
of the quinolones may push the equilibrium towards cleavage. Modelling techniques
support this proposal, where intercalation of the fluoroquinolones with DNA and
DNA gyrase via the C6 and C7 position of the quinolones in the presence of
magnesium ions has been observed (Llorente, 1996).
It is now accepted that quinolones bind to the DNA and DNA gyrase complex in the
presence of magnesium ions however the exact mechanistic details involving
quinolone interaction are vague and remain to be elucidated.
1.6 Mechanisms of Quinolone Resistance
When the fluoroquinolones were initially introduced into clinical therapy, resistance
was considered to be a rare event. This was due to the apparent difficulty in raising
laboratory mutants of E. coli (Smith, 1984) after quinolone challenge and the
chromosomal mutations were found to be recessive to the wild type suggesting that
interspecies transfer was unlikely. Despite these early optimistic predictions
fluoroquinolone resistance has emerged in a number of clinically relevant species.
With the advent of rapid molecular techniques, quinolone mediated resistance has
been mapped to mutations within a specific region called the quinolone resistance
determining region (QRDR) within the target genes i.e. type II topoisomerases.
Recently, fluoroquinolone resistance has also been found to be mediated through the
hyper-expression of efflux pumps (Brenwald et al, 1998; Ubukata et al, 1989;
Nikaido 1998). Other mechanisms of resistance such as enzymatic destruction of the
fluoroquinolones were presumed to be unlikely as quinolones are totally synthetic
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molecules and the presence of enzymes in nature to degrade these agents is therefore
improbable. Plasmid mediated quinolone resistance was thought to be impossible
because firstly certain resistance plasmids were found to increase quinolone
susceptibility (Crumplin & Smith, 1981) and secondly, quinolones tended to
eliminate plasmids (Hooper et al, 1984) by inhibiting both replication (Uhlin &
Nordstrom, 1985) and transfer (Wiesser & Wiedemann, 1985). Apart from the
inhibitory properties of the quinolones, the apparent absence of quinolone destroying
enzymes and plasmid mediated resistance was attributed to the amount of quinolone
usage. Today, quinolone usage accounts for 11% of all antibiotic prescriptions
(Thomson, 1999) and thus, it is not surprising to note that the first instance of
plasmid mediated fluoroquinolone resistance in a clinical isolate of Klebsiella
pneumoniae has been identified (Martinez et al, 1998).
Quinolones are bactericidal antibiotics and exposure to these agents interferes with
essential cellular processes resulting in cell death. Challenge with quinolones
generally selects for resistance in pre-existing mutants within a bacterial population;
however, it has now been shown that adaptive mutations can also appear after
prolonged exposure to the antibiotic (Riesenfeld, 1997). This finding has far reaching
consequences in a clinical setting where quinolones secreted from the body after a
course of antibiotics could expose bacterial populations to low concentrations of the
antibiotic, thereby priming the bacteria for the next antibiotic onslaught.
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1.6.1 Target Site Modifications
1.6.1.1 Mutations in GyrA
It has now been accepted that fluoroquinolones attack bacteria by inhibiting the
action of the type II topoisomerases within the cell. Gellert et al (1976) made the first
association that quinolones target bacterial DNA gyrase by demonstrating the
inhibition of DNA gyrase with nalidixic acid. The first molecular characterisation of
a quinolone resistance mutation in gyrA was reported by Yoshida et al (1988).
Subsequent cloning and sequencing of the gyrA gene from the quinolone resistant
bacteria found mutations in the N-terminus region of the GyrA polypeptide close to
the tyrosine residue 122, which is covalently bound to DNA during DNA cleavage
(Yoshida et al, 1988). In E. coli, fluoroquinolone resistance associated mutations
were found to consistently occur within the same region spanning from codon 67 to
106 which has since been termed the QRDR (Piddock, 1999). This region has been
found to be highly conserved across different bacterial species. In S. pneumoniae
mutations within the homologous region have also been associated with quinolone
resistance (Balas et al, 1998; Pan & Fisher, 1996a). In E. coli, changes within the
QRDR have been found to occur most frequently at Serine 83 which is altered to
either Leucine or Tryptophan resulting in a 32-fold increase in resistance to
ciprofloxacin (Yoshida et al, 1993; Yoshida et al, 1988). Other positions within the
QRDR of the gyrA gene have also been associated with quinolone resistance,
however, in comparison to the change that occurs at position 83 the decreases in
susceptibility are not as pronounced. Mutations at position 83 have been shown to
co-exist with other mutations at position 87 within the gyrA QRDR of E. coli. In
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S. pneumoniae, the changes that occur at gyrA are similar to E. coli except that the
analogous region to Serine 83 is mapped at position 80 within the pneumococcal
genome (Balas et al, 1998). Mutations, which occur at position 81, are usually
substitutions from serine to phenyalanine or tyrosine (Janoir et al, 1996; Gootz et al,
1996). Certain mutations in E. coli like Glycine81 to Aspartate or Glutamic acid 106
to Arginine in gyrA have been found to confer increased resistance to the
fluoroquinolones rather than nalidixic acid (Moniot-Ville et al, 1991). In
S. pneumoniae, gyrA mutations have been found to result in increased resistance to
the broad-spectrum quinolones (sparfloxacin, moxifloxacin) rather than the older
agents (ciprofloxacin) (Fukuda & Hiramatsu, 1999). Double gyrA mutations
sustained within the QRDR of E. coli and K. pneumoniae are usually at positions 83
and 87 and can coexist resulting in high-level resistance (Weigel et al, 1998;
Deguchi et al, 1997). In contrast, both clinical and laboratory isolates of
S. pneumoniae have been found to sustain single but not double gyrA mutations
(Jones et al, 2000; Bast et al, 2000a; Pan & Fisher, 1996a; Pan & Fisher, 1997; Pan
& Fisher, 1998).
1.6.1.2 Mutations in GyrB
The first description of mutations sustained within GyrB was reported by Yamagishi
et al (1986) when nalidixic acid resistant mutants of E. coli were analysed for
mutations. Two mutants sustained changes within gyrB at Asp426 —► Asn and
Lys447 —> Glu, resulting in resistance to acidic quinolones such as nalidixic acid
(MIC = 32-128mg/l). However, the mutant with the Lys447 —* Glu, mutation was
found to be 4-fold more susceptible than the wild type to fluoroquinolones like
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ciprofloxacin. GyrB mutations associated with fluoroquinolone resistance have also
been reported in quinolone resistant Ps. aeruginosa (Yoshida et al, 1990a) and
N. gonorrhoea (Deguchi et al, 1996). In gram-positive bacteria, S. aureus and
S. pneumoniae have been found to sustain mutations in gyrB related to quinolone
resistance. In fluoroquinolone resistant laboratory mutants of S. aureus (Schmitz et
al, 1998a) and S. pneumoniae (Pan & Fisher, 1998) mutations within gyrB at
Asp437 —* Asn, Arg458 —* Gin, and Glu474 —» Lys respectively, were identified
defining the presence of an analogous region in gram-positive bacteria.
1.6.1.3 Occurrence of gyrA and gyrB Mutations
In gram-negative bacteria, the occurrence of gyrB mutations have been found to be
relatively lower than gyrA mutations. A survey of 16 clinical isolates of E. coli
identified that 15 of the isolates sustained changes within gyrA and 1 isolate with a
change in gyrB (Vila et al, 1994). In addition, another study showed that when 18
laboratory mutants of E. coli selected with norfloxacin and lomefloxacin, no mutants
with gyrB mutations were identified (Tavio et al, 1999). Therefore, it appears that in
laboratory selected mutants the frequency of mutations in gyrA is clearly higher than
gyrB mutations. This is also represented in the clinical situation where there is a clear
predominance of gyrA mutations over gyrB changes in conferring clinical levels of
fluoroquinolone resistance. The minimal contribution of gyrB mutations in the
development of fluoroquinolone resistance is also represented in other gram-negative
species like Ps. aeruginosa (Yoshida et al, 1990a) and A. baumanii (Vila et al,
1997).
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In gram-positive bacteria, like S. aureus, gyrB mutations are thought to act in concert
with gyrA mutations to confer fluoroquinolone resistance, although, a survey done
with 116 clinical isolates showed that mutations sustained within gyrB were silent
with no resulting amino acid changes (Schmitz et al, 1998a). In S. pneumoniae, gyrB
changes of Asp435 —■> Asn and Glu474 —» Lys identified in laboratory mutants
selected with ciprofloxacin (Pan & Fisher, 1996a) and clinafloxacin (Pan & Fisher,
1998) were also associated with quinolone resistance. In both sets of mutation
studies, only one mutant sustained the change in gyrB. With the clinafloxacin
mutation study, the gyrB mutation of Glu474 —> Lys was the only change identified
in that clone in contrast, to the gyrB mutation (Asp435 —* Asn) observed within the
ciprofloxacin selected mutant where the change was sustained together with either
gyrA or parC substitutions. A survey done with clinical isolates of S. pneumoniae
indicated that none of the isolates sustained a mutation within gyrB (Jorgensen et al,
1999) although another study by Fleaton et al (1999) has identified the
Glu474 —> Lys change in combination with a parE and parC mutation in two clinical
pneumococcal isolates.
The apparent rarity of single gyrB mutations within both clinical and laboratory
mutants indicates a secondary contributory role of these changes towards the
development of fluoroquinolone resistance. Thus, it does appear that gyrA mutations
play a bigger role in resistance development in both gram-negative and gram-positive
bacteria.
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1.6.1.4 Mutations in ParC
Enzyme inhibition studies done on the E. coli topoisomerase IV enzyme, found that
30 times more antibiotic was required to inhibit topoisomerase IV rather than DNA
gyrase in E. coli (Kato et al, 1990). Studies by Hoshino et al (1994) demonstrated
that fluoroquinolones were able to exert considerable activity against
topoisomerase IV mediated catenation particularly in gyrA mutants. These
observations clearly indicate a role for topoisomerase IV as a secondary target for the
fluoroquinolones in gram-negative bacteria in the absence of a sensitive gyrA and
contribute significantly to the decrease in susceptibility to these agents. This
phenomenon is seen with the other gram-negative species like K. pneumoniae
(Weigel et al, 1999), Ps. aeruginosa (Yoshida et al, 1990a) and N. gonorrhoeae
(Deguchi et al, 1996).
In gram-positive bacteria, topoisomerase IV (Ferrero et al, 1995) was presumed to be
the primary fluoroquinolone target as initial in vitro mutation studies with S. aureus
demonstrated that mutants sustained changes within parC prior to gyrA. Mutants
sustaining both parC and gyrA changes were found to exhibit the least susceptibility
to ciprofloxacin. The changes associated with the decrease in fluoroquinolone
susceptibility in parC are situated at position 80 analogous to Serine83 within the
E. coli gyrA.
Other gram-positive species like S. pneumoniae (Pan & Fisher, 1996a) and
E.faecalis (Kanematsu et al, 1998) were also found to sustain mutations within parC
after ciprofloxacin challenge lending to support to the assumption that
topoisomerase IV was the primary target of quinolones in gram-positive bacteria.
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However, subsequent in vitro studies involving S. pneumoniae and fluoroquinolones
such as sparfloxacin (Pan & Fisher, 1997), gatifloxacin (Fukuda & Hiramatsu, 1999)
and gemifloxacin (Heaton et al, 1999) have demonstrated that the mutants harbour
mutations within gyrA prior to changes within parC. In S. pneumoniae, the mutations
that occur within parC (Ser79 —> Tyr) confer low to intermediate levels (i.e. 8mg/l)
of resistance but when coupled with a gyrA mutation, the decrease in susceptibility is
8-fold higher (Pan et al, 1996a; Fukuda & Hiramatsu, 1999; Heaton et al, 1999).
1.6.1.5 Mutations in ParE
Only recently have mutations within the parE subunit been associated with
quinolone resistance. Mutation studies involving S. pneumoniae challenged with
ciprofloxacin (Pan & Fisher, 1996a) and clinafloxacin (Pan & Fisher, 1998) have
shown that none of the ciprofloxacin selected mutants sustained a parE mutation
although only one clinafloxacin mutant harboured a change of Pro454 —> Ser.
Studies involving both clinical isolates and laboratory mutants of S. pneumoniae
indicate that changes within the parE subunit confers low level resistance to the
quinolones and are usually present in combination with either a parC or gyrA
mutation (Jorgensen et al, 1999). In contrast, a survey done with 20 quinolone
resistant isolates of E. coli found none of the isolates sustained a mutation in parE
(Ruiz et al, 1997).
1.6.1.6 Occurrence ofparC and parE Mutations
In clinical isolates of S. pneumoniae, changes within parC precede gyrA changes
resulting in high-level fluoroquinolone resistance. Changes within parE are found in
59 Introduction
clinical isolates albeit, at a much lower frequency than parC, where parE changes on
its own or in combination with a parC mutation contribute to low to intermediate
levels of fluoroquinolone resistance (Jones et al, 2000; Bast et al, 2000a; Perichon et
al, 1997). In gram-negative bacteria, studies have shown no evidence of the
involvement of parE mutations within clinical isolates with respect to
fluoroquinolone resistance and the prevalence of these changes within laboratory
mutants is largely unknown. Clinical and laboratory mutants of E. coli demonstrate
that parC changes are associated with contributing to higher levels of resistance to
the fluoroquinolones and are always found in combination with gyrA mutations
(Weigel et al, 1998; Tavio et al, 1999).
1.6.1.7 Primary and Secondary Quinolone Targets
Controversy surrounds the debate about the targets of quinolone action within gram-
positive bacteria. In gram-negative bacteria, consistent changes within the QRDR of
gyrA with quinolone challenge supports the assumption that gyrA is the primary
target (Tavio et al, 1999). In contrast, in gram-positive bacteria particularly,
S. pneumoniae this does not appear to be the case. Stepwise selection of
S. pneumoniae with various quinolones have shown different patterns of mutation
development (See Table 1.2).
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Clinafloxacin++ GyrA + ParC —
Gatifloxacin GyrA ParC
Gemifloxacin GyrA ParC
Table 1.2: Targets in S. pneumoniae after Quinolone Challenge
J = some in vitro mutation studies have shown changes in the ParE subunit as well as the ParC.
ft = Clinatloxacin selection induces changes in both gyrA and purC subunits.
It has been shown that mutants selected with ciprofloxacin and trovafloxacin
sustaining changes within topoisomerase IV (ParC) show no resistance to
sparfloxacin and gatifloxacin but exhibit cross resistance to one another. This
indicates that parC is the likely target of ciprofloxacin (Fukuda & Hiramatsu, 1999;
Pan & Fisher, 1996a) and trovafloxacin (Gootz et al, 1996). In contrast, mutants
selected with sparfloxacin, gatifloxacin and gemifloxacin exhibited no cross
resistance to the other quinolones except to each other (Fukuda & Hiramatsu, 1999).
This observation corresponds to that made in S. aureus where mutations that confer
resistance to one quinolone do not necessarily confer resistance to other quinolones
(Takahashi et al, 1998, Durham, 2000). Clinafloxacin is unique in its ability to select
for mutations in both targets (Pan & Fisher, 1998).
Therefore, it is tempting to speculate that structural modifications of the
aforementioned quinolones are able to dictate the choice of target within
S. pneumoniae. In fact, studies now show that the addition of a
benzenesulfonylamido group to the C-7 piperazinyl ring of ciprofloxacin markedly
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affects potency in S. pneumoniae and more importantly changes the specificity of the
quinolone target from topoisomerase IV to DNA gyrase A (Alovero et al, 2000).
Enzyme inhibitory studies of fluoroquinolones on recombinant proteins of
pneumococcal type II topoisomerases (ParC and GyrA) reveal discrepancies with the
in vitro data presented in Table 1.2. As it has been demonstrated that the
concentration of fluoroquinolones, like ciprofloxacin and sparfloxacin, required to
inhibit wild-type topoisomerase IV were 8-16 times lower than that required to
inhibit wild type DNA gyrase (Morrissey & George, 2000) implying that
topoisomerase IV is the genuine target of quinolones like ciprofloxacin and
sparfloxacin. Further studies done with ciprofloxacin, sparfloxacin and clinafloxacin,
which have differential activity against the pneumococcal topoisomerases,
demonstrated that all the quinolones tested preferentially inhibited topoisomerase IV
rather than gyrA (Pan & Fisher, 1999). This result also concurs with inhibitory
studies performed with staphylococcal topoisomerase proteins (Blanche et al, 1996).
So why the discrepancy? One reason for the differential activities that are observed
with cell bound topoisomerases and purified enzymes could be due to the failure of
conditions within the enzyme assays to simulate the in vivo conditions like the
2+
presence of a specific DNA template, Mg ions, polyamine, and ATP concentrations.
A further point is the possibility of mutations outwith the QRDR which may not be
detected by the techniques used to determine the mutations for the in vitro studies,
but may manifest itself when the entire topoisomerase is purified and exposed to the
quinolone.
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Does the topology of the topoisomerases differ between both gram-negative and
positive bacteria? In fact the cloning and characterisation of the pneumococcal gyrA
(Balas et al, 1998) has illustrated differences to that of the E. coli gyrA. The extended
-10 sites that occur within the promoter box in the pneumococcus (Sabelnikov et al,
1995) result in overexpression of gyrA when expressed in other hosts, therefore the
reproducibility of the exact function and properties of the native pneumococcal
protein is lost. Finally, it is possible that quinolones may be unevenly distributed
within the bacterial cell thereby affecting complex formation with the
topoisomerases differently. This could be important if the enzymes themselves are
distributed in a non-uniform manner as seen with B. subtilis where topoisomerase IV
has a bipolar localisation and gyrase is associated with a nucleoid (Huang et al,
1998). In S. pneumoniae, the intracellular positions of both topoisomerase IV and
DNA gyrase have not been determined. It is apparent from these points that neither
mutation experiments or enzyme assays will independently answer the question of
quinolone targets within S. pneumoniae.
1.6.1.8 Efflux Pumps
Efflux pumps are ubiquitous components of the bacterial cell walls that allow them
to be a formidable factor in antimicrobial resistance (Levy, 1992). The efflux of
cytotoxic agents is defined as an active, unidirectional export of compounds from the
bacterial cytoplasm into the external medium. This transport is usually protein-
mediated and performed by a uniport mechanism coupled to ATP hydrolysis or by an
antiport mechanism in which drug efflux is linked to proton influx i.e. energised by
the proton motive force (PMF) (Paulsen et al, 1996).
63 Introduction
Efflux pumps can be classified under four main groups based upon sequence
homology, molecular architecture and mechanism of action. The five main groups
are (i) ATP Binding cassette (ABC) Transporters, Staphylococcal (or Small)
Multidrug resistance (SMR), Resistance Nodulation Division (RND), Major
Facilitator (MF) and the recently described multi-drug and toxic compound extrusion
family (MATE) (Fevy, 1992; Nikaido, 1998; Brown et al, 1999). These pumps are
broad spectrum, which allows them to efflux a range of toxic substances including
antimicrobial compounds (reviewed by Poole, 2000).
Efflux pumps are thought to perform a dual action. Two schools of thought exist, in
the first where pumps are thought to perform a physiological function and
incidentally pump out antimicrobial agents and in the second where the pumps are
purely present to combat antibiotic challenge. Initial studies involving knock out
multi-drug efflux pump mutants demonstrated, no obvious deficiencies in
physiological function except for an increase in antibiotic susceptibility (Neyfakh,
1997). Investigations into the evolution of these pumps indicates that multi-drug
transporters do not share common homology even within the superfamilies but do so
with substrate-specific transporters. This indicates that multi-drug transporters may
possess a dual function by promoting the efflux of both specific metabolites and
cytotoxic drugs (Neyfakh, 1997).
Both gram-positive and gram-negative bacteria possess cytoplasmic barriers to
reduce the transport of toxins into the cell. However, gram-negative bacteria possess
an outer membrane with specialised porins that limit cellular transport to hydrophilic
rather than hydrophobic molecules. Therefore, in gram-negative bacteria a dual
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cellular barrier has to be crossed prior to gaining entry into the cell proper, unlike in
gram-positive bacteria, where only one barrier needs to be breached. The assembly
of efflux pumps mirror these differences and structurally the gram-negative efflux













Gram-positive cell Gram negative cell
Figure 1.11: Variable Configurations of Bacterial Efflux Pumps
(Taken from Nikaido, 1998)
Bacterial multidrug efflux pumps exist in two different configurations within gram-negative and
positive bacteria. In the gram-positive cell (left), drugs diffuse in unhindered and are pumped out
(dashed arrows). In gram-negative bacteria, drugs diffuse through the outer membrane via specialised
porins and are extruded within the periplasmic space (solid arrows). Drug molecules are captured
within the bilayer although this may not be the mechanism with all families of transporters. Complex
efflux machinery only occurs in gram-negative bacteria although drug efflux from the cytoplasm
occurs in both species.
LPS = lipopolysaccharide
OM = outer membrane
IM = inner membrane
The Resistance Nodulation division (RND) and multi-drug and toxic compound
extrusion (MATE) group of efflux pumps seem to be restricted to gram-negative
bacteria (reviewed by Poole, 2000). The RND pumps possess translocases
(12-transmembrane alpha helices and are believed to act as monomers) and these
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pumps occur in concert with a linker protein and outer membrane channel. The
AcrAB-TolC E. coli pump and the MexAB-OprM of Ps. aeruginosa are examples
(Nikaido, 1998). The substrate profile of the RND family of pumps is diverse and
includes antibiotics, dyes, and detergents (Nikaido, 1998). Homologs of the RND
pump have been identified in other gram-negative species such as Neisseria
gonorrhoeae and Haemophilus influenzae. Apart from possibly providing an initial
defence against antibiotic challenge, the hyper-expression of efflux pumps can also
manifest a multi-drug resistant phenotype.
The initial investigations of efflux pumps in gram-positive bacteria were limited to
Staphylococcus aureus. The pumps, qacA and smr identified in this organism were
found to be plasmid mediated (Nikaido, 1998). However, plasmid mediated efflux
pumps cannot be considered to be the sole contributory factor for the reduction in
susceptibility as plasmids generally harbour other resistance genes. The majority of
gram-positive efflux pumps are chromosomal in origin and tend to be classified
under the following groups: SMR (Small multi-drug Resistance), ABC (ATP-binding
cassette) or MFS (Major Facilitator Superfamily) group and are energised by ATP
hydrolysis or proton motive force (PMF) (Paulsen et al, 1996). With the SMR and
MFS multi-drug transporters, the range of compounds that are pumped tends to be
limited as in the case of qacA (cationic dyes, quaternary amines, and
fluoroquinolones) (Rouch et al, 1990) (See Figure 1.12). Bit, a pump identified in
Bacillus suhtilis exports out spermidine (a natural polyamine) and is postulated to be
simultaneously involved in the physiological efflux of polyamines (Neyfakh, 1997).
It is recognised as a possible multi-drug efflux pump as there may be certain cationic
antibiotic drugs that mimic the structures of polyamines. This observation supports
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Figure 1.12: Diagrammatic Representation of Efflux Pumps
(Taken from Paulsen et al, 1996)
Diagrammatic representation of efflux pumps found in bacteria. The Staphylococcus aureus QacA,
EmrB and Smr proteins. The Pseudomonas aeruginosa MexB proteins utilise the proton gradient for
energy. In contrast, the multi-drug efflux pump P-gycoprotein is driven by ATP hydrolysis.
The ABC transporters are different as they mimic the human P-glycoprotein in its
wide substrate specificity. The other gram-positive pumps LmrA and the MFS pump
LmrP, have been shown to capture their substrates from within the bilipid layer
(inner leaflet of cytoplasm) (Bolhuis et al, 1996). The MFS group of membrane
transporter proteins have been found to be present in bacteria and higher eukaryotes
and have been divided into five distinct function clusters involved in (i) drug
resistance (ii) sugar uptake (iii) uptake of Krebs cycles intermediates (iv) phosphate
ester/phosphate antiport and (v) oligosacharide uptake (Marger & Saier, 1993).
Examples of the proton motive force dependent 12 transmembrane segment drug
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efflux proteins include the streptococcal efflux pump PmrA (Gill et al, 1999), B.
subtilis pump BmrA (Neyfakh et al, 1991) and the staphylococcal pump NorA
(Yoshida et al, 1990). PmrA, BmrA and NorA all possess a similar substrate range
i.e. acridine orange, ethidium bromide and fluoroquinolones such as norfloxacin and
ciprofloxacin (Brenwald et al, 1997; Neyfakh et al, 1991; Yoshida et al, 1990b).
Sequence alignment of pmrA with other gram-positive pumps such as BmrA and
NorA has identified 24% homology (Gill et al, 1999). Transmembrane segment
prediction of PmrA has also indicated the presence of 12TMSs, which indicates
similarity to other 12-TMS proton dependent pumps such as NorA (Paulsen et al,
1996). It has been shown that drug transport and resistance mediated by NorA, BmrA
and PmrA is inhibited by the mammalian P-glycoprotein pump inhibitor reserpine
(Neyfakh et al, 1991) which allows the phenotypic analysis of these gram-positive
efflux pumps (Neyfakh et al, 1991). If an efflux pump were expressed, a reduction
would be observed with the antibiotic and reserpine combination to the antibiotic
only. However, the shortfall of this technique is that a reduction may only be
observed with pumps, that are reserpine sensitive.
1.6.1.9 Contribution of Efflux Pump Expression to Fluoroquinolone Resistance
Two independent studies investigating the expression of the efflux pump pmrA in
clinical streptococcal isolates have shown that increased efflux expression is the most
prevalent mechanism of resistance to the fluoroquinolones (Brenwald, et al, 1998;
Morrissey et al, 1999). It has been demonstrated that inhibition of the pmrA pump
increases susceptibility to ciprofloxacin, norfloxacin (Gill et al, 1999) and ofloxacin
(Broskey et al, 2000). Reserpine inhibition has been shown to suppress the in vitro
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emergence of ciprofloxacin resistance in S. pneumoniae clearly indicating that efflux
mediated mechanisms play a role in fluoroquinolone resistance (Markham, 1999).
PmrA does not appear to have any effect on the newer generation hydrophobic
quinolones such as grepafloxacin (Morrissey et al, 1999) and gemifloxacin (Heaton
et al, 1999, Broskey et al 2000) indicating that reserpine potentiation of the
fluoroquinolone sensitivity is restricted to the older agents.
In S. aureus, inhibition of the efflux pump NorA with reserpine has been found to
increase the level of susceptibility to ciprofloxacin by four-fold (Neyfakh et al,
1991). NorA and PmrA, exhibit similar substrate ranges and have been shown to
efflux some hydrophilic quinolones such as ciprofloxacin and appear not to export
other compounds like moxifloxacin (reviewed by Poole, 2000). In S. aureus, the
increased efflux of quinolones has been attributed to either the overexpression of the
wild type gene (Kaatz & Seo, 1995) or a single nucleotide change within the NorA
promoter (Ng et al, 1994). Mutations resulting in altered substrate specificities of the
BmrA and NorA pumps have been found mainly within the C-terminal regions of
these proteins (Griffith et al, 1992). Fluoroquinolone resistance mediated by the
streptococcal efflux pump PmrA is thought to be the hyperexpression of the pump as
it has been detected in fluoroquinolone susceptible strains. Unlike NorA and BmrA,
which are induced by the substrates they efflux (Paulsen, 1996), the exact inducer of
pmrA has not been deduced although the regulator gene mtrA has been identified
(Gill etal, 1999).
In gram-negative bacteria, like Ps. aeruginosa fluoroquinolones have been found to
select for efflux type mutants (Kohler et al, 1997) prior to topoisomerase mutations.
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This trend also extends to B-lactam drugs, where a study of carbenicillin resistant
Ps. aeruginosa show that almost 80% of the strains did not produce carbenicillin-
hydrolysing B-lactamases but exhibited elevated efflux (Bert et al, 1996). Thus, it
does appear that in both gram-positive and gram-negative bacteria, the expression of
the efflux pump precedes the presence of target mutations, which could imply that
efflux mutations are precursors in the development of resistance. However, efflux
has not been characterised as a mechanism of resistance for all antibiotics thereby
questioning the specific conditions that could favour the selection of efflux mutants.
One factor appears to be the reduced activity of antibiotics against the target bacteria
thereby inducing the efflux phenotype as observed with the carbenicillin resistant
Ps. aeruginosa and quinolone resistant S. aureus and S. pneumoniae (Nikaido, 1998;
Brenwald et al, 1998). Secondly, the absence of conventional resistance mechanisms
against antibiotics such as the fluoroquinolones and carbenicillin, has encouraged the
emergence of efflux mutants.
Efflux pumps are present in bacteria and their role in the development of antibiotic
resistance is still being established. It is interesting to note that the prevalence and
expression of efflux pumps are most frequent in bacteria like Ps. aeruginosa,
S. aureus and S. pneumoniae that are only moderately susceptible to some
antibiotics. This adaptability demands different treatment options through the design
and development of efflux inhibitors.
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1.6.2 Other Mechanisms of Resistance
1.6.2.1 Plasmid Mediated Resistance
The first confirmed report of plasmid mediated quinolone resistance was from a
clinical isolate of K. pneumoniae (Martinez et al, 1998). This multi-drug resistance
plasmid was found to harbour resistance to aztreonam, ceftazidime, kanamycin,
gentamicin, tobramycin, trimethoprim, mercuric chloride and ciprofloxacin and
conferred reduced susceptibilities to these agents when transferred. However, clinical
levels of resistance were only observed when the plasmid was transferred into an
outer membrane deficient strain. Although, the possibility for plasmid mediated
fluoroquinolone resistance to become a clinical reality may exist, no further reports
of plasmid mediated quinolone resistance have been noted.
1.6.2.2 Adaptive Mutations
Adaptive mutations arise through prolonged antibiotic exposure in non-dividing or
slowly dividing cells. Adaptive mutations also give rise to phenotypes, which allow
cell growth with no fitness cost. This effectively implies that adaptive mutations
allow growth inhibited bacteria to resume growth after the antibiotic pressure is
removed. This phenomenon has been characterised in E. coli MG1655 cells after
exposure to ciprofloxacin over a 7 day period (Riesenfeld et al, 1997). Although
quinolones are bactericidal, they nurture a population that may be described as being
non culturable but viable. Clinically, the implications of this mechanism are
enormous as cessation of antibiotic treatment may encourage the emergence of
resistant bacterial cells. The actual prevalence of this mechanism in in vivo
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conditions and in other species is largely unknown. It remains to be seen whether the
newer bactericidal quinolones are able to induce such mutations. Thus, the changes
associated with adaptive mutations may allow the prolonged survival of bacterial
cells leading to resistance development.
Both plasmid mediated resistance and adaptive mutations have only recently been
characterised in gram-negative bacteria and the extent of these mechanisms are still
largely unknown in gram-positive bacteria.
1.6.2.3 Horizontal Transfer of Fluoroquinolone Resistance Determinants
In naturally transformable S. pneumoniae, resistance to the (3-lactam antibiotics has
been attributed to penicillin-binding protein alterations resulting from genetic
exchanges with commensal viridans streptococci of the oral flora (Tomasz, 1997;
Sibold et al, 1994). Recently, studies describing the emergence of fluoroquinolone
resistance in viridans streptococci have been documented (Yan et al, 2000; Fernandiz
et al, 1999; Gonzalez et al, 1998) questioning the possibility of interspecies transfer
of altered genes mediating quinolone resistance. In a study done by Janoir et al
(1999) it was found that high-level fluoroquinolone resistant pneumococcal
transformants were obtained at low frequencies when a double ParC-GyrA quinolone
resistant mutant of S. mitis was used as a donor. Analysis of clinical isolates of both
S. pneumoniae and viridans streptococci support the possibility of horizontal transfer
of resistant topoisomerase genes (Fernandiz et al, 2000) although only a small
number of isolates were investigated. Statistically, the clinical occurrence of this
event has been determined to occur at <1% (Bast et al, 2000b) and would require the
presence of highly competent cells for DNA uptake.
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1.7 Respiratory Tract Infections
Community and hospital acquired respiratory tract infections are a major public
health issue and these infections are the predominant indication for antibacterial
prescribing in both the community and hospital (Finch, 1995). Respiratory infections
are caused by a multitude of bacterial species however, pathogens such as
Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis have
been implicated more frequently than others. This observation is validated by studies
that have demonstrated the presence of these pathogens in acute exacerbation of
acute bronchitis (AECB) and community acquired pneumonia (CAP), a common
cause of hospital and community consultations (Moine et al, 1994). The status of
these pathogens in causing severe infections in both the community and hospital, has
enormous implications in their control and treatment.
1.7.1 The Pneumococcal Problem
S. pneumoniae was first described by Klebs in 1875 (reviewed by Austrian, 1981). It
has been known for more than 100 years as the most important bacterial pathogen of
respiratory tract infections in adults and children (Flarwell & Brown, 2000).
S. pneumoniae is a resident of the upper respiratory tract in healthy individuals and at
any one given time up to 60% of people in a community can carry this bacterium in
the mucosal epithelium of the nasopharynx (Johnston, 1991). However, it has been
observed that most infections do not occur after prolonged carriage but follow on
after the acquisition of different serotypes (Alonso de Velasco et al, 1995). This
observation suggests that the immune status of the host at the moment of colonisation
and the pathogenic potential of the infecting strain, determines whether the bacterium
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remains a non-infectious resident of the nasopharynx or becomes invasive (Johnston,
1991). S. pneumoniae causes a variety of other infections which include meningitis,
sinusitis, osteomyelitis, otitis media, bronchitis and soft tissue infections (Tuomanen
et al, 1995).
1.7.1.1 Virulence Factors
The exact mechanism of pneumococcal pathogenesis is still largely unknown
although it is thought to be mediated by the immune cascade reaction (Tuomanen et
al, 1995). This cascade results in extensive inflammation, which presents itself as a
complete disruption of the bronchial epithelium and its protective function. This
extensive cellular damage and its subsequent complications are responsible for the
morbidity and mortality associated with pneumococcal infections (Alonso de
Velasco et al, 1995).
1.7.1.2 Capsule Polysaccharide
Since the beginning, the polysaccharide capsule has long been recognised to be the
principal virulence determinant of the pneumococcus. Eighty-four distinct serotypes
have been identified according to the antigenic compositions of the capsules.
Serotyping of these capsules can be done by the Quellung reaction, where specific
antibodies react with capsular antigens on the capsular surface of the organism. More
than 80% of pneumococcal infections are caused by 23 of the 84 distinct serotypes
(Tuomanen et al, 1995). Encapsulated strains were found to be at least 10" times
more virulent than strains lacking the capsule (Johnston, 1991). Despite, being
attributed to the pathogenic potential of the bacterium, the capsule itself is non-toxic
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in its pure form. However, it seems to enhance virulence by protecting the bacterium
from ingestion by the host's phagocytes (Tuomanen et ai 1995; Finland et aL 1932).
1.7.1.3 Cell Wall and Cell Wall Polysaacharide
There is no evidence to support the role of the by-products and degradation of the
pneumococcus in the clinical manifestation of pneumococcal disease. Although,
constituents of the cell wall particularly the phosphorylcholine residue of the
C-polysaacharide have been shown to induce the inflammatory cascade by inducing
antibody response and complement activation (Johnston 1991).
1.7.1.4 Pneumococcal Protein Antigens and Toxins
Various proteins have been implicated in pneumococcal pathogenicity, although only
a few have been proven to be genuine virulence factors. One of the enzymes
produced by S. pneumoniae is neuraminadase, which facilitates the attachment of the
bacteria to the epithelial cells by cleaving sialic acid from the host glycolipids and
gangliosides. Partially purified neuraminadase has been shown to induce meningitis¬
like symptoms in mice, although this has been disputed due to possible
contamination of the neuraminadase preparations (Alonso de Velasco et ai, 1995).
Pneumolysin is an intracellular protein that belongs to the family of thiol-activated
toxins. This enzyme is not secreted by the pneumococcus but released during
autolysis. At high concentrations, pneumolysin forms oligomers on mammalian cell
membranes, giving rise to transmembrane pores that result in cell lysis (Boulnois,
1992). Pneumolysin is also known to stimulate the production of inflammatory
cytokines and complement activation (Alonso de Velasco et al, 1995). This
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inevitably results in extensive cellular damage of the bronchial epithelium disrupting
functions like cilia beating and the migration of neutrophils. Pneumolysin release has
been shown to mediate the effects of autolysin. Autolysin-deficient strains are less
virulent than autolysin producing variants and immunisation with autolysin confers
some protection in mice (Alonso de Velasco et al, 1995; Watson et al, 1995).
Pneumococcal surface protein A is associated with the structural and antigenic
variability between different pneumococcal strains and is found in most of the
clinical isolates of Streptococcus pneumoniae. The exact functions of this surface
protein are still unknown however, the introduction of surface protein A deficient
strains into experimental animals, has been shown to reduce virulence and prolong
survival (Alonso de Velasco et al, 1995).
There are still many questions pertaining to the molecular mechanisms of
pathogenesis associated with pneumococcal infections. The recent discovery of
hydrogen peroxide production by the pneumococcus and its toxic effects on rat
alveolar epithelium (Johnston, 1991) introduces a new component to the
pathogenesis puzzle. Suffice it to say, that many aspects of the host-bacterium
relationship are still unknown.
1.7.1.5 Epidemiology and Risk Factors for Colonisation
Mortality associated with bacteriaemic pneumonia remains at 25% and has remained
unchanged for over 40 years despite advances in antimicrobial chemotherapy
(Kramer et al, 1987). In the UK alone, the pneumococcus is responsible for 30-50%
of community acquired pneumonia and 8% of nosocomial pneumonia (Obaro et al,
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1996). It is also a major factor in chronic bronchitis affecting more than 1 million
individuals and is responsible for 5% of all deaths. Globally, the pneumococcus
accounts for 1 million deaths each year in children under the age of 5 years
(Leowski, 1986). The initial introduction and use of penicillin against pneumococcal
pneumonia reduced the fatality rate of the disease from 30% to as low as 5%.
Predisposing risk factors have been found to include age, social status,
immunocompetence and correspondingly pneumonia has been found to be a major
cause ofmortality either in the very young or old (Obaro et al, 1996).
1.7.1.6 Antibiotic Resistance in S. pneumoniae
There were early indications that antibiotics had a limited lifespan against
S. pneumoniae. Optochin, which is currently used in the identification of
pneumococci, was once in widespread use for the treatment of pneumococcal
infections (Moore et al, 1917). It was abandoned from clinical therapy because of
toxicity and resistance in clinical isolates. Laboratory mediated penicillin resistance
was reported in the year prior to the first successful use of the drug for pneumococcal
pneumonia. However, it was not until the 1960s that the first penicillin resistant
clinical isolate of S. pneumoniae was identified (Kislak et al, 1965). Despite these
early indications of resistance development, penicillin has remained the preferred
choice of drug and continues to be used in cases of penicillin sensitive pneumococcal
infections. The last few years have seen a rapid increase in the number of
antibacterial agents used in the treatment of pneumococcal pneumoniae. This
massive effort is due to the high incidence of pneumococcal infections worldwide
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and, secondly, the lack of therapeutic agents unaffected by the current resistance
mechanisms in the pneumococci (Harwell & Brown, 2000).
Current surveillance data from 1992 to 1996 for community acquired pneumonia
shows an increasing trend in antibiotic resistance to the commonly used antibiotic
agents. Data confirmed that the clinical utility of penicillin, macrolides and other
classes of antimicrobials were seriously compromised by the increasing prevalence
of resistance in recent clinical isolates of S. pneumoniae to these compounds
worldwide (Felmingham & Washington, 1999). The high rates of penicillin
resistance found in Spain in the early 1990s, where more than 50% of clinical
pneumococci were resistant to one or more antibiotics are now apparent in France,
China and the USA (Felmingham & Washington, 1999). Penicillin resistant
pneumococci have also been found to harbour diminished susceptibility to other
agents like the aminopenicillins, cephalosporins and carbapenams (Felmingham &
Washington, 1999). This situation has arisen because of the common targets within
the bacterium that are shared by all three classes of agents. Macrolide resistance,
particularly in France, Spain, Italy and China, is increasing both in association with
and independently of penicillin resistance. In the UK alone, erythromycin resistance
has risen from 2.8% to 8.6% between 1990 to 1995 (Felmingham & Washington,
1999). The prevalence of fluoroquinolone resistance in S. pneumoniae has only been
studied recently. In Canada, it has been shown that fluoroquinolone resistance
increased from 0% in 1993 to 1.7% in 1998 (Chen et al, 1999). An increase in
fluoroquinolone resistance was also reported in South Korea (15%) and Hong Kong
(12%) where the incidence of pneumococcal strains with multiple resistance is high
(Lee et al, 1995; Ho et al, 1999). In the UK, the surveillance data published to date
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indicates that pneumococcal resistance to the fluoroquinolones is still low
(Felmingham & Washington, 1999; Linares et al, 1999).
1.7.2 Haemophilus Influenzae and Moraxella Catarrhalis
Both H. influenzae and M. catarrhalis are respiratory tract commensals, which co-
reside in the nasopharynx. The entry of these bacteria into the lower respiratory tract
combined with an immunocompromised host can result in severe lower respiratory
tract infections (Finch, 1995). Haemophilus influenzae is a major cause ofAECB and
acute bacterial rhinosinusitis. The presence of M. catarrhalis has also been
demonstrated in these infections, albeit at a lower proportion. The mechanism, by
which H. influenzae and M. catarrhalis cause disease is not entirely clear, however,
recent work has revealed that it is similar to that of the pneumococcus (Sethi, 2000;
Karalus & Campagnari, 2000).
1.7.2.1 Antibiotic Resistance in H. influenzae and M. catarrhalis
Infections caused by both H. influenzae and M. catarrhalis are treated primarily by
B-lactams. However, B-lactamase enzymes are widespread in both species rendering
B-lactam agents like amoxycillin useless (Schito et al, 1997). B-lactam inhibitor
combinations like amoxiclav have been used with success although inhibitor resistant
TEM (IRT) have been isolated in some strains of H. influenzae (Marchese & Schito,
2000). The proportion of B-lactamase producing strains of H. influenzae have risen
worldwide as observed in China 38%, USA, Spain, France and Belgium 20-30%,
UK and Czech Republic 14.2%, 13% and in the Netherlands and Germany >10%
(Felmingham & Washington, 1999). There has also been an emergence of B-
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lactamase negative, ampicillin-resistant strains, which occur only rarely.
Azithromycin resistance is rare in H. influenzae, although reports of clarithromycin
and erythromycin resistance are increasing (Schito et al, 1997; Felmingham &
Washington, 1999). The only mechanism of resistance of any clinical relevance in
M. catarrhalis is B-lactamase production, with more than 90% of isolates doing so
(Schito et al, 1997), which implies that all amino-penicillins and penicillins are
ineffective against M. catarrhalis. The use of the fluoroquinolones has been rather
limited with these bacteria and since the activity of these agents is rapid and
extremely potent, resistance has not arisen as prolifically as seen with the other
classes of antibacterials. Both H. influenzae and M. catarrhalis are exquisitely
sensitive to ciprofloxacin, an older generation quinolone with excellent activity
against gram-negative bacteria. Surveillance data from the Alexander Project shows
that out of 11, 539 clinical isolates of H. influenzae tested only 12 strains were found
to be resistant and out of 2998 clinical isolates of M. catarrhalis only 1 strain was
classed as resistant to fluoroquinolones. This is indeed the case, as very few reports
have outlined resistance to fluoroquinolones with either species (Felmingham &
Washington, 1999).
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1.8 Aims of this Thesis
1. To investigate the fluoroquinolone sensitivities in clinical isolates of
S. pneumoniae, H. influenzae and M catarrhalis from centres around the United
Kingdom.
2. To investigate the mechanisms of fluoroquinolone resistance in laboratory
generated mutants of S. pneumoniae to various quinolones and the contribution
of these mechanisms to resistance to other fluoroquinolone agents.
3. To investigate the mechanisms of fluoroquinolone resistance in clinical isolates
of S. pneumoniae.
2 Materials and Methods
2.1 Bacterial Strains
Nine hundred and nine clinical isolates of S. pneumoniae, H. influenzae and
M. catarrhalis (See Appendix I) were sent from 9 clinical centres around the United
Kingdom and Ireland. Isolate distribution from the various centres is shown in the
Figure 2.1 below. The standard bacterial strains used for experiments within this
thesis are shown in Table 2.3. All strains were stored at -70°C in cryovials (Alpha
Laboratories, Eastleigh, Herts).
Other bacterial isolates used in the execution of the experiments for this thesis are
shown in Table 2.4. Verification of individual species was done by rapid diagnostic
tests described in Section 2.2 .









































Numerical figures indicate the number of isolates obtained from respective centres.
The required strains were each inoculated into Todd Hewitt Broth and incubated
statically overnight at 37°C in 5% CO2. Nine hundred microlitres of the overnight
broth culture was thoroughly mixed with lOOjul of sterile glycerol at a final
concentration of 10% v/v and immediately frozen at -70°C. Strains were subcultured
directly from the stock to solid media, for verification of phenotype and purity prior
to use. Mutant clones obtained from mutation studies were subcultured onto non¬
selective media (Columbia agar base supplemented with 5% defibrinated horse
blood) prior to cryo storage.
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Laboratory Standards Source
Ps. aeruginosa NCTC 10662 National Collection of Type Cultures,
E. coli 10418
London
E. coli P-lactamase positive
K. pneumoniae NCTC 8773
S. aureus NCTC 6571
Methicillin Resistant S. aureus SI 13
E. faecalis NCTC 51299
E. faecalis NCTC 12697
El. influenzae
H. influenzae P-lactamase positive
M. catarrhal is
M. catarrhalis p-lactamase positive
S. pneumoniae NCTC 7465
S. pneumoniae 126
S. pneumoniae 11080
S. pneumoniae NCTC 13593
S. pneumoniae R6 Penicillin susceptible, non-capsulated strain
from Dr P.V. Adrian, Department of
Medical Microbiolgy, University of
Witwatersrand, Johannesburg, South Africa.
S. pneumoniae P1Z1/IN27 S. pneumoniae R6 transformed with DNA
from spontaneous norfloxacin mutant from
Dr. N. P. Brenwald, University of
Birmingham, Birmingham, UK
Table 2.3: Laboratory Standards Used in Experiments.
Clinical Isolates Source
7 Penicillin resistant pneumococci
collected from centres around the UK
Dr. A. Bamarouf culture collection,
University of Edinburgh, Edinburgh,
Scotland
13 ciprofloxacin intermediate strains
collected from the Royal Infirmary of
Edinburgh
Miss F. Walsh culture collection,
University of Edinburgh, Edinburgh,
Scotland
Table 2.4: Clinical Pneumococcal Isolates Used in Resistance Study
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2.2 Identification of Bacterial Isolates
2.2.1 Streptococcus pneumoniae
Streptococcus pneumoniae isolates were subcultured onto Columbia agar plates
supplemented with 5% defibrinated horse blood. The optochin sensitivity test was
performed according to Bowers and Jefferies (1955), distinguishing the pneumococci
from viridans streptococci. Optochin discs (Mast Diagnostics, UK) were placed on
the confluent region of the subculture prior to incubation at 37°C in 5-10% CO2. The
identity of the pneumococcus was determined when growth inhibition was observed
at least 5mm from the margin of the optochin disc.
2.2.2 Haemophilus influenzae
Haemophilus influenzae were flood seeded onto a nutrient agar plate (Oxoid, UK)
deficient in X and V factors (Mast Diagnostics, UK). One half of the plate was
overlaid with discs impregnated with X and V factors separately and XV factors in
combination. If growth was only observed around the X and V combination disc,
then a positive identification of H. influenzae was assumed (Kilian, 1974).
2.2.3 Moraxella catarrhalis
A modification of the butyrate hydrolysis strip test (Deader et al, 1989) was used in
the identification of M. catarrhalis. Colonies of M. catarrhalis were emulsified in
sterile water and a swab soaked in this emulsion was dipped into a solution of
tributyrin tablets (MAST Diagnostics, UK) dissolved in water. If a colour change of
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yellow to pink was observed, then a positive identification of M. catarrhalis was
deduced.
2.3 Growth Media
All growth media and components were sterilised by autoclaving for 15 minutes at
121°C and cooled prior to bacterial inoculation.
2.3.1 Media
All media powders were obtained from Oxoid (Basingstoke, UK) and made up as
single strength solutions with distilled water according to the manufacturer's
instructions. The media used in these experiments were Brain Heart Infusion (BHI)
broth, Todd Hewitt (TH) broth, Columbia agar base.
2.3.1.1 Blood Agar
S. pneumoniae and M. catarrhalis strains were subcultured onto blood agar plates.
Columbia agar was prepared as described before prior to the addition of 5%
defibrinated horse blood and incubated in 5% CO2 conditions overnight.
2.3.1.2 Chocolate Blood Agar
Haemophilus influenzae strains were grown on lysed blood plates due to the
nutritional requirement of the X and V factors. After the addition of 5% defibrinated
horse blood to Columbia agar the agar blood mixture was reheated until the whole
red blood cells were lysed.
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2.4 Chemical Reagents
All reagents used were supplied by Sigma chemicals (Dorset, UK) unless otherwise
stated.
2.5 Antibacterial Susceptibility Testing
2.5.1 Antimicrobial Agents
The antimicrobial agents were supplied by various manufacturers found in Table 2.5.
Solutions of antimicrobial agents were freshly prepared prior to use in the diluents
shown in the table below.
2.5.2 Minimum Inhibitory Concentrations (MICs)
Minimum inhibitory concentrations were performed on Columbia agar base
supplemented with 5% defibrinated horse blood following the recommendations of
the British Society for Antimicrobial Chemotherapy guidelines (Phillips et al, 1991)
for susceptibility testing. MICs were determined by the doubling agar dilution
method. Agar containing the appropriate concentrations of antimicrobial agents was
inoculated with a 2pl spot of test organisms dispensed from a multipoint inoculator
(Denley, Billinghurst, Surrey). Bacterial strains to be tested were inoculated into
4.5ml of Todd Hewitt broth or Brain Heart Infusion and incubated at 37°C in 5%
CO2 atmosphere overnight.
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Table 2.5: Antimicrobial Agents and Their Solvents
Turbidity of S. pneumoniae cultures was determined to be at 0.5 McFarland standard
equivalent to 107 cfu prior to inoculation onto antibiotic containing plates. Cultures
of H. influenzae and M. catarrhalis were diluted to 104 cfu in physiological saline
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before use. Inoculated petri dishes were incubated overnight at 37°C in ambient air
conditions in stacks of no more than 3 petri dishes. NCTC standard strains of
S. pneumoniae, H. influenzae and M. catarrhalis were used to validate the
experiment.
2.5.2.1 Reserpine Inhibition
Reserpine, a plant alkaloid and efflux pump inhibitor, was added at a concentration
of lOmg/1, to the plates with appropriate antibiotic dilutions. A control plate with no
antibiotic was also set up to ensure unimpaired growth of isolates in the presence of
reserpine. The strain S. pneumoniae P1Z1/IN27 which exhibits four-fold reduction in
the presence of reserpine to norfloxacin was used as a control (Brenwald et al, 1997).
2.5.3 Epsilon Test (E-Test)
The E-test (AB Biodisk, Cambridge, UK) employs a more stringent and convenient
method of determining the susceptibilities of bacterial isolates. It comprises a plastic
strip embedded with an antibiotic gradient. Overnight broth cultures were used to
flood-seed Columbia agar plates supplemented with 5% defibrinated blood. The
plastic strips were impregnated on the surface of the agar plates. The plates were then
incubated overnight at 37°C in ambient air or in 5% CO2 in stacks of no more than 3
petri dishes. The manufacturer's instructions were followed in the interpretation of
the results.
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2.6 Viable Counts
Bacterial strains were grown overnight in 5ml of TH broth by static incubation at
37°C in 5-10% CO2 Serial dilutions of 1 in 10 and 1 in 100 were made in sterile
physiological saline. Subsequently, 0.1ml from each dilution was taken and spread
onto Columbia agar base plates supplemented with 5% defibrinated horse blood. The
plates were then incubated at 37°C in 5-10% CO2 overnight. The number of colony
forming units per plate were determined with a colony counter (Anderman,
Kingston-upon-Thames, UK) and the viable counts within the undiluted cultures
were calculated by taking the dilution factor into consideration.
2.7 Mutation Studies
2.7.1 Selecting Quinolone-Resistant Mutants
Quinolone resistant mutants were selected according to the method outlined by
Janoir et al (1996). Mutant clones were obtained by exposing parent strains of
S. pneumoniae to stepwise multiples of the MIC to the appropriate quinolone.
Exposure to each drug was achieved by plating lOOpl of log phase culture onto
antibiotic containing plates and incubated for 72 hours at 37°C in 5% CO2
conditions. Individual clones were selected and subcultured onto non-selective blood
agar plates prior to further manipulations. Subsequent generations were raised by
challenging of selected clones from each generation. Viable counts were performed
simultaneously with mutant selection to allow mutation frequencies to be
determined.
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2.8 Isolation of Chromosomal DNA
S. pneumoniae isolates were subcultured on Columbia agar supplemented with 5%
defibrinated horse blood and incubated in 5% CO2 at 37°C overnight. Individual
colonies were emulsified in sterile milliQ water and boiled for 10 minutes.
Subsequently, the crude lysate was used as template for polymerase chain reaction
analysis.
2.9 DNA Amplification by Polymerase Chain Reaction
Amplification of the quinolone resistance determining region (QRDR) was
performed by PCR. The amplification parameters of the QRDR were as described by
Pan & Fisher (1996a).








lOpl — — Promega, UK
25mM MgCl2 3 pi 50mM 2.5mM Promega, UK
4mM dntp
solution'1








1 pi lOpmol lOpmol/pl Oswel
Technologies





lOpl — — —
Taq
Polymerase
2 2 Units lU/pl Promega, UK
Table 2.6: Components Used in PCR Reaction.
tf
4mM dntp stock solution:
ImM dATP, ImM dCTP, ImM dGTP. ImM dTTP in lOmM Tris-Cl (pH 7.5)
+
For different primers sets used see Table 2.7
Each PCR reaction was performed in a total volume of lOOpl (Table 2.6) prepared in
a 0.5ml polypropylene microcentrifuge tube (Alpha Laboratories, UK) with
Cyclogene thermocycler (Techne, Cambridge, UK) with a heated lid, thereby
negating the need for a sterile oil overlay. Each reaction mixture was subjected to 25
or 30 cycles, with each of the three steps: denaturation, annealing and extension.
Different cycling protocols were used to amplify the different topoisomerases: gyrA,
gyrB, parC, parE and the streptococcal efflux pump (PmrA). Primers used for each
of the PCR experiments are shown in Table 2.7.
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Table 2.7: Primer Oligonucleotide Sequences Used in PCR.
Primers designed with Primer 3 software (http://www.genome.wi.mit.edu/cgi-bin/primer)
The cycling parameters for the different genes are shown in Table 2.8 and Table 2.9
respectively. To validate the reaction, negative and positive controls were
incorporated. All primers were synthesised and HPLC purified by Oswel DNA
(Southampton, UK) services. All expected PCR product sizes are detailed in Table
2.10.
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Segment Temperature Time Cycles
1 95.0 5mins 1
2a 94.0 lmin 25
2b 55.0 2mins
2c 72.0 3mins
3 72.0 7mins 1
Table 2.8: PCR Heating Cycle Protocol for Topoisomerase Genes
(gyrA, gyrB, parC and part )
Segment Temperature Time Cycles
1 94.0 5mins 1
2a 94.0 30s 30
2b 55.0 30s
2c 72.0 30s
3 4.0 24hrs —
Table 2.9: PCR Heating Cycle Protocol for Streptococcal Efflux Pump
Gene (pmrA)
PCR Reaction Expected Product Size
DNA Gyrase (Subunit A) 382bp
DNA Gyrase (Subunit B) 444bp
Topoisomerase IV (Subunit C) 366bp
Topoisomerase IV (Subunit E) 357bp
Streptococcal Efflux Pump (PmrA) 1200bp
Table 2.10: Expected Product Sizes for PCR
2.10 Analysis of PCR Products
PCR products were separated at neutral pH values in 2% w/v agarose (GIBCO BRL,
Life Technologies, UK) gels in TAE buffer [40mM Tris-acetate pH7.6, ImM
EDTA]. Under these conditions, double stranded DNA is negatively charged hence
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loaded near the cathode and migrates towards the anode with the application of an
electric field (Aaij & Borst, 1972). Gel electrophoresis was carried out in a
minisubcell GT (Biorad. UK) under the constant voltage of 100V (Powerpac 300,
Biorad, UK) for 40 minutes, depending on the migration of the bands. For larger gels
subcell GT (Biorad, UK) gel tanks were used. A DNA ladder (GenerulerIM, MBI,
Fermentas) was run alongside the PGR products for the verification of the sample's
molecular weight. Each DNA sample was mixed with 2jul of loading buffer
[30% w/v glycerol, 0.25% w/v bromophenol blue, 0.25% w/v xylene cyanol] before
loading the wells. The electrophoresed fragments were visualised after
electrophoresis by staining for one hour in a 50pg/ml ethidium bromide solution and
viewed on an UV transilluminator (UV products, Cambridge, UK).
2.11 Purification ofDNA
PCR products were purified with the Qiaquick PCR purification kit (Qiagen,
Germany) according to the manufacturer's instructions. The final volume for elution
of the purified products was reduced to 30pl to concentrate the DNA. The DNA
concentration of the PCR product was approximated by comparing the intensity of
bands after electrophoresis of X DNA digested with HindiII (Sigma, UK) known to
contain 0.5pg per microlitre.
2.12 Automated DNA Sequencing
PCR primers were also used as sequencing primers at a concentration of 3.2pmol per
reaction. Purified DNA was processed as described in Section 2.11 prior to
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sequencing to ensure that the required concentration of 30-90ng was achieved. The
DNA sequence was determined by the chain termination method developed by
Sanger et al (1977). Individual PCR fragments were set up in the Ready Reaction
Format for fluorescence based on dideoxy cycle sequencing (PE Applied Systems,
UK). All sequences were processed in the Department of Haematology, Royal
Infirmary of Edinburgh. Sequences were analysed by the BLAST online search
engine (http://www.ncbi.nih.gov/cgi-bin/BLAST) with the quinolone susceptible
parent strain sequence in the database. Comparisons between the sequences of the
mutant clones of clinical strains were determined by comparing the parent strains and
selected mutant progeny from each generation using the multialin interface website
(http://www.toulouse.inra.fr/multalin.html).
2.13 Probe Construction
The PCR DIG Probe synthesis kit (Roche Molecular Biochemicals, Germany) was
used to manufacture the 1.2kb DIG labelled probe for the streptococcal efflux pump
pmrA. The primers used in this PCR were synthesised by Oswel DNA service
(Southampton) designed with Primer 3 software (http://www.genome.wi.mit.edu/cgi-
bin/primer) based on the published gene sequence. Each PCR reaction was
performed in a total volume of 50pl. A positive control consisting of the PCR
reagents and template DNA from P1Z1/IN27, an efflux mutant (Gill et al, 1999) was
used. The negative control consisted of PCR reagents without any template DNA.
The cycling parameters and the reagent volumes for the labelling PCR are shown in
Table 2.9 and Table 2.11 respectively.
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The PCR products were verified by agarose gel electrophoresis as detailed in
Section 2.10 .
Reagents Volume Final Concentration
Sterile Milli Q water 27.25pl Variable
PCR Buffer with MgCL (10 X) 5pl 1 X
Dntps(Ll) 5,ul 200pM
Primer A lpl 0.1 — lpM
Primer B ljul 0.1 — lpM
Enzyme mix 0.75pl 2.6Units
Template DNA lOjul Variable
Total 50pl —
Table 2.11: Reagents Used to Synthesise Probes
2.14 Restriction Fragment Length Polymorphism (RFLP)
2.14.1 Restriction of Products from Topoisomerase PCR
RFLP was performed to distinguish between the sensitive and resistant gyrA and
parC by the loss of a single nucleotide, resulting in an amino acid change from
Serine81 —► Leucine/Phenyalanine or Serine79 —> Tyrosine/Phenylalanine
respectively (Varon & Gutmann, 2000). This substitution manifests itself through the
loss of the Hinfl recognition site of G' ANTC. Subsequently, PCR products of gyrA
and parC QRDR were restricted using Hinfl (Promega, UK). The restriction digest
comprised of lpl ofHinf1 enzyme (lOU/pl), 5pl of restriction buffer [lOmM Tris-Cl,
pH7.5, 60mM NaCL, 7mM MgCL], lpl of BSA (0.1mg/l), 4pl of milliQ water and
40j.il of amplified PCR product. Digestion was carried out for a maximum of two
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hours at 37°C. The resulting amplimers were electrophoresed on a 2% agarose gel
and visualised.
2.14.2 Restriction ofProducts from Streptococcal Efflux Pump PCR
To ensure the validity of the streptococcal efflux pump PCR fragments generated by
both the DIG probe synthesis and normal PCR, restriction digests with Cla\
(Promega, UK) was done. The conditions of the digest are as described for the Hinf1
digest.
2.15 Accumulation Assays
Accumulation assays were performed according to the procedure detailed by
Mortimer & Piddock (1991). Briefly, 40pl of overnight broth culture of the test
organism was inoculated into 10ml of pre-warmed BHI broth and incubated shaking
at 37°C until an optical density of 0.7-0.8units was reached at 660nm. Cells were
harvested by centrifugation in the Sorvall RT 6000D (Dupont, UK) at 4°C (3000rpm,
20 minutes). The resulting cell pellets were washed by resuspending in 10ml of cold
50mM phosphate buffer (pfI7.0). The mixture was recentrifuged and resuspended to
yield an optical density of 20 units at OD660- The suspension was then transferred to
a sterile McCartney bottle, placed in a static waterbath at 37°C and allowed to
equilibrate. Cell suspensions were plated to ensure purity and identity of the test
organism prior to further manipulations. At the initial time point (t=0), 500pl of cell
suspension was removed and placed on ice. Moxifloxacin were added to a final
concentration of lOpg/ml. Duplicate 500pl samples were removed at time intervals
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of 10s up to 5 minutes. Samples were centrifuged in the Sorvall RT 6000D (Dupont,
UK) at 4°C (3000 rpm, 5 minutes) and returned to ice. The supernatant was
discarded and the cell pellet was resuspended in 1ml of sterile phosphate buffer
(50mM sodium phosphate buffer, pH7.0) to remove the cell bound quinolone. The
cell suspensions were recentrifuged and resuspended in 1ml of 0.1 M glycine (pH3)
and left at room temperature for 2 hours. Resulting samples were centrifuged at
13,000rpm (11600xg) in the MSE micocentaur centrifuge for 5 minutes then
transferred to a fresh eppendorf and recentrifuged under the same conditions.
Fluorescence was measured with a F2000 fluorescence spectrophotometer (Hitachi,
UK) at the appropriate excitation and emission wavelengths detailed in Table 2.12.
The uptake of moxifloxacin from the cells was measured as an increase in
fluorescence. Graphs of fluorescence versus time (minutes) were plotted.
Drug Excitation Wavelength (nm) Emission Wavelength (nm)
Moxifloxacin 294 504
Table 2.12: Excitation and Emission Wavelength of Moxifloxacin
(Piddock & Jin, 1999)
2.16 Ribonucleic Acid (RNA) Analysis
2.16.1 RNA Extraction
Total RNA was extracted with the SV Total RNA Isolation System (Promega, UK)
from bacterial cultures grown to an optical density of 0.6-1.0 at OD6oo (Kobs, 1998).
Contaminating RNAases were eradicated from the benches and equipment by 3%
(v/v) hydrogen peroxide and RNAZAP (Ambion, UK).
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2.16.2 RNA Induction Assays
To determine whether the streptococcal efflux pump,pmrA could be induced by both
moxifloxacin and ciprofloxacin, induction experiments were done. Overnight broth
cultures of S. pneumoniae R6, S. pneumoniae P1Z1/IN27 and S. pneumoniae 285
were subcultured to three hour logarthmic phase cultures by adding 1ml of overnight
broth culture to 9ml of prewarmed TH broth. All log phase cultures were
simultaneously induced with the concentration of antibiotic equivalent to half the
MIC for both quinolones (Table 2.13). Control broth cultures with no antibiotic were
also set up. The RNA was then extracted from all broth cultures of the strains with
the SV Total RNA Isolation System (Promega, UK).
Strain Concentration (mg/1)
Ciprofloxacin Moxifloxacin
S. pneumoniae R6 0.25 0.0312
S. pneumoniae P1Z1/IN27 1 0.0312
S. pneumoniae 285 0.5 0.0312
Table 2.13: Quinolone Concentrations Used in the Induction Experiment
2.16.3 RNA Dot Blots
The RNA dot blots were prepared by spotting lOpl of extracted total RNA samples
onto nylon membranes (Amersham Pharmacia Pic, UK). The membranes were
subsequently dried and baked at 80°C for two hours prior to hybridisation and
exposure.
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2.16.4 Electrophoresis of RNA
RNA was electrophoresed on a 1% formaldehyde based agarose gel. The gel was
prepared by melting lg of agarose in 1 x MOPs buffer [200mM morphinopropane
sulfonic acid, 50mM sodium acetate and lOmM EDTA, pH7.0], After cooling, 5.4ml
of 37% (v/v) formaldehyde was added and thoroughly mixed before casting in the
gel mould. Ten microliter volumes of the frozen RNA samples were vacuum dried
with the freeze dryer (Modulyo 4L, Cryotechnics, UK) prior to further
manipulations. The formaldehyde gel loading buffer mixture comprised of 720pl
formamide, 160pl of 10 x MOPs Buffer, 260pl of 37% (v/v) formaldehyde, lOOpl of
DEPC-treated sterile MilliQ water, lOOpl of ethidium bromide (lOmg/ml), 80pl of
sterile glycerol and 80pl of saturated bromophenol blue in water. Twenty microliters
of the gel loading buffer were added to the freeze-dried samples, mixed and boiled
for two minutes prior to loading onto the gel. The gel was electrophoresed for 2-3
hours at a 100V in lx MOPs buffer. Due to the electropotential of ethidium bromide
and bromophenol blue, migration towards the cathode (-ve) and anode (+ve) will
occur respectively. To prevent unnecessary background, the topmost section of the
gel was excised, before the ethidium bromide exited the gel matrix. The presence of
intact RNA was confirmed by visualisation on a UV transilluminator. The gel was
then soaked in 2 changes of 10 x SSC buffer [20 x SSC: 3M NaCl, 0.3M Na citrate,
pH7] for 20 minutes separately, to ensure the removal of the formaldehyde from the
gel and finally immersed in DEPC-treated Milli Q water once prior to transfer.
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2.16.5 Northern Blot Transfer
Downward alkaline transfer to the nitrocellulose membranes was done for exactly
three hours according to the manufacturer's guidelines (Turboblotter[M, Schleicher
and Schuell). Following neutralisation and transfer, the RNA was immobilised by
baking at 80°C for 2 hours. Blots were then stored at 4°C until use.
2.16.6 Hybridisation of Northern Blots
Hybridisation of northern blot filters was carried out following the protocol detailed
by StratageneIM (1999). The probe used was a fluorescein labelled PCR fragment of
the streptococcal efflux pump pmrA (as described in Section 2.13 ) and added at a
concentration between 5-25ng/ml (according to manufacturer's recommendations for
DIG labelling kit). The hybridisation buffer [5 x SSC, 50% deionized formamide,
2% Blocking agent, 0.1% (w/v) N-lauroylsarcosine, 0.02% (w/v) SDS] was warmed
to 42°C with the nylon membrane before the addition of the probe. Approximately,
25ng/'ml of probe was boiled for 5 minutes, chilled immediately and added to the
remaining hybridisation solution. The blot was hybridised overnight at 42°C in a
hybrisation oven (Hybridiser, HB-1D, Techne, UK). The blot was then washed in
0.1% SSC and 0.1% (w/v) SDS thrice, separately for an hour at 68°C each time with
gentle shaking.
2.16.7 Detection of Blots
The detection of digoxigenin-labelled nucleic acids was done according to the
manufacturer's guidelines (Boehringer Mannheim, Germany). Autoradiography was
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carried out by exposure to Hyperfilm X-Ray film (Amersham Pharmacia Pic, UK) at




The results of the research executed for the completion of this thesis has been
divided into six sections. The first section describes the discrepancies observed with
the susceptibility testing when performed under different incubation conditions. This
illustrates the requirement for a unified testing procedure within different
laboratories to allow direct comparisons of susceptibility data and also the influence
variable testing conditions have on the subsequent categorisation of strains as
sensitive, intermediate or resistant. The second section applies the observations of the
first section in the testing procedure of a UK wide susceptibility study involving
respiratory isolates namely S. pneumoniae, H. influenzae and M. catarrhalis. Clinical
isolates of S. pneumoniae that showed decreased susceptibility to the
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fluoroquinolones were further analysed to determine the mechanisms of resistance to
these antibacterials.
To investigate the selection pressure exerted by the newer extended-spectrum
quinolones on the current clinical pneumococcal population, laboratory mutants were
generated from isolates with different pneumococcal phenotypes by moxifloxacin
challenge. These data hold crucial significance as they not only track the evolution of
resistance mechanisms that a given population experiences when challenged with
moxifloxacin and older agents such as ciprofloxacin and norfloxacin but also
disputes the hypothesis that topoisomerase IV is the primary target of all
fluoroquinolones in S. pneumoniae.
Fluoroquinolone resistance has also been attributed to arise through efflux pump
mutations. In S. pneumoniae, the recently described pump pmrA has been shown to
play a role in the acquisition of ciprofloxacin and norfloxacin resistance. To
determine whether pmrA does contribute to the evolution of moxifloxacin resistance,
inhibition studies using an efflux pump inhibitor reserpine were conducted with
isogenic mutants derived after moxifloxacin challenge and clinical pneumococcal
isolates with reduced fluoroquinolone susceptibility. In order to determine
moxifloxacin uptake within resistant mutants, accumulation assays using the
fluorescence technique were done. Further analysis of the role of the efflux pump
was evaluated through northern blot analysis.
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3.2 Susceptibility Testing
The assessment of the efficacy of antibacterial agents in vitro has been traditionally
determined by doubling agar dilutions. The validity of this procedure is governed by
several factors i.e. media used, incubation conditions which readily affect the
outcome of the sensitivity results. Different incubation conditions are required by
different species of bacteria and some of these incubation conditions have been
shown to affect the activity of some classes of antibiotics e.g. macrolides (Phillips et
al, 1991). The BSAC guidelines state that "10% (v/v) carbon dioxide in the
atmosphere will reduce the pH of the media surface thereby affecting the growth of
the organism or the antibacterial action of some antibiotics e.g. aminoglycosides,
macrolides and quinolones". The acidification of media by the decrease in pH has
been shown to directly affect the antibacterial activity of antibiotics such as the
macrolides and quinolones, which are pH dependent in their in vitro activity (Phillips
et al, 1991).
The recent introduction of anti gram-positive quinolones with extended efficacy
towards pathogens which are grown in reduced air conditions requires a reassessment
of the testing procedure. A study done by Bruggemann et al (1997) demonstrated the
reducing effects carbon dioxide had on the testing media and the activity of the
antibiotic that was incorporated in it. Carbon dioxide incubation was demonstrated to
reduce the pH on the agar surface from 7.40 to 6.98 and subsequently the MICs
reported from those plates incubated in the CO2 rich atmosphere were elevated in
comparison to those obtained in air. This prompted the investigators to perform all
subsequent sensitivity testing in air. Therefore, to verify this and elucidate the effect
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of incubation in oxygen enriched and oxygen-reduced atmosphere (5% carbon
dioxide), the MICs of 18 NCTC standard strains were determined under both
conditions.
The MICs were determined, by the doubling agar dilution method and the Epsilon
test (E-Test), for the following extended-spectrum fluoroquinolones trovafloxacin,
moxifloxacin, grepafloxacin, and an older comparator ciprofloxacin. Two sets of
MIC plates were inoculated with the multipoint inoculator. All isolates were also
inoculated onto antibiotic-free plates to confirm growth under both incubation
conditions. The plates were read after an 18 hour incubation period, where, the
lowest concentration of antibiotic that inhibited growth was defined as the MIC and
single colonies or hazy growth were ignored. The MIC was expressed as milligrams
per litre and the increases in the MICs were recorded for the carbon dioxide
incubations and compared against oxygen.
3.2.1 Doubling Agar Dilution Results in Oxygen and Carbon
Dioxide Incubation.
Against S. pneumoniae, 2—A fold increases in the MIC were observed with all the
quinolones tested under the reduced air conditions (5% carbon dioxide) (See
Table 3.1). With S. pneumoniae NCTC 13593 and NCTC 126 the four-fold increase
in moxifloxacin MIC recorded under reduced air conditions would have resulted in
the categorisation of this strain as resistant to moxifloxacin based on the
recommended breakpoint value (Andrews et al, 1999). Similarly, for S. pneumoniae
R6 a four-fold increase was observed with ciprofloxacin from 0.25mg/l to lmg/1,
resulting in the classification of this strain as being intermediately resistant to
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ciprofloxacin. Interestingly, the trovafloxacin MIC was 2—4-fold lower when
incubated in carbon dioxide for both S. pneumoniae R6 and S. pneumoniae NCTC
7465 although, an 8-fold increase in the trovafloxacin MIC was observed with both



















Spn R6 0.0312 0.0625 0.125 0.0625 0.25 1
Spn 7465 0.0312 0.0625 0.5 0.0625 0.25 0.25
Spn 13593 0.25 1 0.5 0.5 16 64
Spn 126 1 4 0.5 4 16 64
Spn 11050 0.125 0.5 <0.0039 0.5 8 8
Hi <0.0039 0.0312 0.0078 0.0312 <0.0039 0.0625
Hi B+ve 0.0312 0.125 0.0312 0.25 0.0078 0.0312
M.cat 0.0312 0.125 0.0312 0.0312 0.125 0.25
M. cat B+ve 0.0312 0.0625 0.0078 0.0312 0.0312 0.0625
E.coli 0.0156 0.0312 0.0078 0.0312 0.0156 0.0312
E.coli B+ve 0.0312 0.0625 0.0156 0.0312 0.0156 0.0312
Kpn 8773 0.0312 0.0625 0.0156 0.0312 0.0156 0.0312
Ps. aero 0.5 2 1 0.5 0.125 0.125
E.faec 51299 0.0625 0.125 0.0312 0.125 0.25 0.5
E.faec 12697 0.0625 0.125 0.0312 0.125 0.25 0.5
S.aer 6571 0.0156 0.0312 0.0156 0.0312 0.0625 0.125
MRSA SI 13 0.0156 0.0312 0.0078 0.0312 0.5 0.5
EMRSA 15 1 2 2 1 32 32
Table 3.1: Minimum Inhibitory Concentration of Control Strains Done in
Oxygen and Carbon Dioxide Incubation
Against ciprofloxacin, a four-fold increase was observed with carbon dioxide
incubation except for S. pneumoniae 7465 and 11050. Against both H. influenzae and
M. catarrhalis MIC increases of 1-A fold, were observed with all the
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fluoroquinolones when values from the reduced air atmosphere were compared to
oxygen incubation. Similarly, against gram-negative pathogens such as E. coli,
K. pneumoniae and Ps. aeruginosa 2^1-fold increases in the MICs were observed in
the 5% carbon dioxide incubation. The most pronounced increase was seen with
Ps. aeruginosa and moxifloxacin where a four-fold increase in the MIC was
observed in carbon dioxide incubation. This is the highest increase that was recorded
for an organism, which does not require reduced air conditions for growth.
E. faecalis and S. aureus showed moderate 2-fold increases to all the
fluoroquinolones tested under reduced air conditions (5% carbon dioxide).
3.2.2 Epsilon Test Results in Oxygen and Carbon Dioxide
To further elucidate the differences in oxygen and 5% carbon dioxide incubations,
MIC determinations were performed with the E-test strips, where the antibiotic is not
incorporated into the media. The results obtained with the E-test mirrored those of
the doubling agar dilution method. Columbia agar plates supplemented with 5%
defibrinated horse blood were flood-seeded with standardised overnight cultures of
the organism under test. The results given in Table 3.2 are the results obtained in












Spn 7465 0.064 0.032 0.016 0.094 0.008
Spn 126 0.25 0.094 0.75 1.5 4
Spn 11080 0.19 0.25 0.38 2 6
Spn 13593 0.25 0.38 0.50 2 8
Hi 0.016 0.008 0.004 0.012 0.012
Hi B+ve 0.25 0.25 0.125 0.50 0.25
M.cat 0.047 0.047 0.012 0.047 0.023
M. cat B+ve 0.064 0.016 0.012 0.047 0.047
E.coli 10418 0.008 0.002 0.004 0.016 0.006
E.coli B+ve 0.023 0.016 0.008 0.032 0.008
Kpn 8773 0.032 0.032 0.032 0.016 0.023
Ps. aero 0.50 0.38 0.125 0.38 0.094
E.faec 51299 0.125 0.125 0.25 0.75 0.38
E.faec 12697 0.125 0.094 0.25 0.75 0.38
S.aer 6571 0.023 0.006 0.023 0.094 0.094
MRSA SI 13 0.064 0.016 0.094 0.25 0.50













Spn 7465 0.064 0.094 0.094 0.125 0.19
Spn 126 0.25 0.25 3 3 8
Spn 11080 0.25 0.25 0.75
-) 12
Spn 13593 0.25 0.38 1.5 6 12
Hi 0.047 0.012 0.016 0.016 0.012
Hi B+ve 0.25 0.38 0.125 0.50 0.38
M.cat 0.064 0.016 0.023 0.047 0.032
M. cat B+ve 0.047 0.008 0.008 0.032 0.023
E.coli 10418 0.016 0.004 0.023 0.023 0.016
E.coli B+ve 0.25 0.016 0.032 0.094 0.032
Kpn 8773 0.125 0.032 0.064 0.094 0.047
Ps.aero 1.5 0.19 0.19 0.38 0.125
E.faec 51299 0.25 0.19 0.38 1.0 0.75
E.faec 12697 0.125 0.125 0.25 1.0 0.5
S.aer 6571 0.047 0.012 0.064 0.19 0.094
MRSA SI 13 0.125 0.023 0.125 0.25 0.75


















































































□ Moxifloxacin■ Trovafloxacin ■ Levofloxacin
IB Ciprofloxacin □ Grepafloxacin
(a) Organisms not Requiring Carbon Dioxide for Growth
Bacterial Strain
■ Trovafloxacin ■ Levofloxacin
■ Ciprofloxacin □ Grepafloxacin
(b) Organisms Requiring Carbon Dioxide for Growth
□ Moxifloxacin
Figure 3.1: Differentials Between Carbon Dioxide and Oxygen Athmosphere
Increases in MICs observed in C02 are represented by bars above the horizontal axis, increases in 02
are represented by bars below the horizontal axis.
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With the key respiratory pathogens (S. pneumoniae, H. influenzae and M. catarrhalis
differentials observed between 5% carbon dioxide and oxygen ranged from 1.3-23.7
times. Some increases were observed with oxygen incubation but these were not as
pronounced as those observed in carbon dioxide incubations. A graphical description
of this relationship between the MICs is shown in Figure 3.1. Only a 1.3 fold
increase in the moxifloxacin MIC was observed with S. pneumoniae 11080 in
contrast to the results obtained with the doubling agar dilutions. Against
enterobacteriaceae and Ps. aeruginosa, there were increases observed with all the
fluoroquinolones tested. Again, a 3-fold increase in the moxifloxacin MIC was
observed with Ps. aeruginosa when incubated in 5% carbon dioxide conditions.
Thus, it appears that 5% carbon dioxide incubations do have an effect on the
antibacterial potency of the fluoroquinolones and is similar to that reported with the
macrolides (Johnson et al, 1999).
Interestingly, with both incubation conditions, increases were observed with the
trovafloxacin MIC values obtained in air in comparison to the 5% carbon dioxide
incubation. With the doubling agar dilution method, 2-8 fold increases were
observed with the trovafloxacin MIC and Ps. aeruginosa and S. pneumoniae 7465
when compared with the 5% carbon dioxide incubation MIC.
3.2.3 Concluding Remarks
Consistently, elevated MICs were observed in the control organisms when incubation
was performed in a oxygen reduced atmosphere (5% carbon dioxide). The increases
were observed with both gram-positive pathogens which are traditionally incubated
in carbon dioxide and gram-negative pathogens like Ps. aeruginosa and E. coli
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which are not. Generally, all the quinolones except trovafloxacin tested exhibited
increased MICs in 5% carbon dioxide conditions. In both susceptibility testing
procedures, it was found that the most pronounced increases were observed with the
pneumococcal isolates when tested against grepafloxacin, levofloxacin and
ciprofloxacin. Elevated MICs hinder the interpretation of the genuine potency of the
compound being tested and also the susceptibility profile of the target clinical
population. Therefore, the subsequent survey performed all incubations for MIC
determinations in air.
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3.3 Moxifloxacin Sensitivity Study
Nine hundred and nine clinical respiratory isolates were collected from nine
geographically distinct centres across the United Kingdom (See Figure 2.1). Clinical
isolates ofStreptococcus pneumoniae (n=257), Haemophilus influenzae (n=399) and
Moraxella catarrhalis (n=253) were obtained between March 1998 and April 1999.
Identification of the isolates was carried out in the individual centres prior to their
arrival in Edinburgh. However, some isolates were reanalysed through the standard
biochemical tests and API 20NE tests in Edinburgh to reconfirm the identity before
experimental manipulations. The strains were designated with prefixes indicating the
species type and strain numbers sequentially. The original site of isolation or any
further details regarding patient information of all the clinical isolates was not
provided by the participating centers. Susceptibility profiles (MICs) were determined
by the doubling agar dilution method to penicillin, amoxycillin and
amoxycillin+clavulanic acid, cefotaxime, tetracycline, clarithromycin, moxifloxacin,
trovafloxacin, grepafloxacin, sparfloxacin, levofloxacin and ciprofloxacin. With
some strains, the values were verified by E-test in addition to the agar dilution
method. Strains exhibiting decreased susceptibility to the fluoroquinolones were
further investigated to determine the mechanisms of resistance. Initially, the
polymerase chain reaction (PCR) was done to amplify the subunit A (gyrA) of DNA
gyrase and the C subunit iparC) of topoisomerase IV. Subsequently the products of
this reaction were examined through restriction fragment length polymorphisms and
dideoxy sequencing. These results were compared with quinolone susceptible strains
within the GenBank database to identify changes within these genes that contribute
towards fluoroquinolone resistance.
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Organism Antimicrobial Agent Range micso mic90
Streptococcus Penicillin <0.008 - 4 0.0156 1
pneumoniae Cefotaxime <0.004 - 2 0.0625 1
(n = 257) Tetracycline <0.004 - 64 0.25 32
Clarithromycin 0.004 ->16 0.0156 1
Moxifloxacin 0.004 - 0.5 0.0625 0.25
Trovafloxacin <0.004 - 1 0.0625 0.5
Grepafloxacin <0.004 - 1 0.0625 0.25
Sparfloxacin <0.004 - 2 0.0625 0.5
Levofloxacin <0.004 - 2 0.5 1
Ciprofloxacin <0.004 - 8 0.5 2
Haemophilus Amoxycillin <0.25 - 64 1 64
influenzae Amoxycillin + Clavulanic Acid <0.25 - 2 0.5 1
(n = 399) Cefotaxime <0.004 - 16 0.0312 0.0625
Tetracycline <0.004 - 16 1 4
Clarithromycin 0.016 ->16 4 8
Moxifloxacin <0.004 - 0.25 <0.004 0.0078
Trovafloxacin <0.004 - 0.5 <0.004 0.0078
Grepafloxacin <0.004 - 0.25 <0.004 0.0078
Sparfloxacin <0.004 - 0.0078 <0.004 0.0078
Levofloxacin <0.004 - 0.25 0.0156 0.0625
Ciprofloxacin <0.004 - 1 0.0078 0.0156
Moraxe11a Amoxycillin <0.125 - 32 2 16
catarrhalis Amoxycillin + Clavulanic Acid <0.125 - 2 0.25 0.5
(n = 253) Cefotaxime 0.0078 - 4 0.5 1
Tetracycline 0.004 - 2 1 2
Clarithromycin 0.004 - 16 0.0625 0.5
Moxifloxacin <0.004 - 0.25 0.0312 0.125
Trovafloxacin 0.004 - 0.5 0.0312 0.5
Grepafloxacin <0.004 - 0.5 <0.004 0.0625
Sparfloxacin <0.004 - 0.5 0.0078 0.125
Levofloxacin <0.004 - 2 0.0625 0.125
Ciprofloxacin <0.004 - 2 0.0312 0.125
Table 3.4: Minimum Inhibitory Concentration of Respiratory Pathogens
All strains were incubated overnight (18-24hrs) prior to inoculation. 18hr aerobic incubation at 37°C
following inoculation of Columbia agar plates supplemented with 5% whole horse blood
(S. pneumoniae and M. catarrhalis) and lysed blood (//. influenzae) containing the appropriate
concentration of antibiotic with 2pl of standardised test organism (0.5M McFarland) culture. All
experiments were validated by the use of the following controls: S. pneumoniae NCTC 7465,
M. catarrhalis, H. influenzae NCTC 11931.
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The MIC50 and MIC90 of 909 clinical respiratory isolates are shown in Table 3.4 with
the range of MICs observed for each antibiotic. All three respiratory pathogens
exhibit MIC50 and MIC90 below the recommended breakpoint (lmg/1) (Andrews et
al, 1999) against moxifloxacin. Against Streptococcus pneumoniae moxifloxacin and
grepafloxacin were the most potent antibacterials (MIC90 = 0.25mg/l) (See Figure
3.5). Trovafloxacin was the next most active (MIC90 = 0.5mg/l) followed by
levofloxacin and ciprofloxacin. Examining the MIC distribution for S. pneumoniae
for the fluoroquinolones demonstrated that moxifloxacin had equal or better activity
in comparison to the comparator quinolones. Penicillin was as active as cefotaxime
and clarithromycin (MIC90 = lmg/1) (See Figure 3.2, Table 3.4) against
S. pneumoniae. Versus Haemophilus influenzae grepafloxacin (MIC90 = <
0.004mg/l) was found to be the most active fluoroquinolone. Moxifloxacin and
trovafloxacin were the next most active (MIC90 = 0.0078mg/l). Clarithromycin was
the least active against Haemophilus influenzae (MIC90 = 8mg/l) (Figure 3.4, Table
3.4). Against Moraxella catarrhalis, grepafloxacin inhibited at 0.0625mg/l followed
by moxifloxacin, sparfloxacin, levofloxacin and ciprofloxacin. Trovafloxacin,
clarithromycin and tetracycline were found to have the least activity at 0.5mg/l
(MIC90) (Figure 3.3, Table 3.4). Generally, moxifloxacin was found to be 2^1-fold
more active versus the three pathogens when compared to the P-lactams, tetracycline
and clarithromycin.
P-lactam resistant H. influenzae are increasingly common and to determine the
relationship between p-lactam resistance and quinolone resistance, H. influenzae
isolates that demonstrated amoxycillin MICs > 16mg/l and < 8mg/l were sorted to











<0.25 - 2 0.5 1
Cefotaxime 0.0156 - 16 0.0312 0.0625
Tetracycline 0.0125 - 16 1 8
Clarithromycin 0.016 - 16 4 8
Moxifloxacin <0.004 - 0.125 0.0078 0.0312
Grepafloxacin <0.004 - 0.0078 <0.004 <0.004
Sparfloxacin <0.004 - 0.0078 <0.004 0.0078
Levofloxacin <0.004 - 0.25 0.0312 0.0625
Ciprofloxacin <0.004 - 1 0.0078 0.0156






<0.25 - 1 0.5 1
Cefotaxime <0.004 - 2 0.0156 0.0312
Tetracycline <0.004 - 16 1 2
Clarithromycin 0.016 - 16 4 8
Moxifloxacin <0.004 - 0.25 <0.004 0.0156
Grepafloxacin <0.004 - 0.0156 <0.004 0.0078
Sparfloxacin <0.004 - <0.004 <0.004 <0.004
Levofloxacin <0.004 - 0.0625 0.0156 0.0625
Ciprofloxacin <0.004 - 0.0156 0.0078 0.0156
Trovafloxacin <0.004 - 0.0312 <0.004 0.0156
Table 3.5: Minimum Inhibitory Concentration of Amoxycillin Sensitive and
Amoxycillin Resistant H. influenzae
As shown in Table 3.5, the quinolone MICs remain unchanged or differ by a two fold
dilution when compared for H. influenzae which show <8mg/l or >16mg/l to
amoxycillin. This result is also represented by penicillin resistant, intermediate and
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Figure 3.3: MIC50 and MIC90 of Antibiotics Tested Versus M. catarrhalis
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Figure 3.5: MIC Distribution of S. pneumoniae and Fluoroquinolones
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Analysis of the MIC data (Table 3.4) indicates the improved activity of the newer
extended-spectrum quinolones over the older comparators against gram-positive
pathogens. All three respiratory pathogens exhibit MIC50 and MIC90 below the
recommended breakpoint (lmg/1) for moxifloxacin. Unlike S. pneumoniae, both
H. influenzae and M. catarrhalis were found to be extremely sensitive to
ciprofloxacin with MIC90 values of 0.0156mg/l and 0.125mg/l respectively. The
differential activity observed between the older and the newer fluoroquinolones may
be classified according to the structural modifications of the agents. This was clearly
demonstrated by the increased efficacy of drugs such as moxifloxacin and
trovafloxacin over ciprofloxacin and levofloxacin against S. pneumoniae. This
distinction was not as obvious with H. influenzae and M. catarrhalis where all the
fluoroquinolone agents were found to be equally effective. Generally, the activity of
the quinolone class of agents surpassed that of the macrolides and the (3-lactams.
Tetracycline had the least activity of the antibiotics tested against both
S. pneumoniae and M. catarrhalis.
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3.4 Analysis of Pneumococcal Isolates with Decreased
Fluoroquinolone Sensitivity
Thirty-one pneumococcal clinical isolates tested during the survey and collected
during the course of this thesis that exhibited decreased susceptibility to the
fluoroquinolones were further examined to elucidate the mechanism of resistance to
the fluoroquinolones. Traditionally, resistance to fluoroquinolones develops by two
mechanisms: alterations within target enzymes (Type II topoisomerases) or by an
efflux mechanism. Initially, the sensitivity data were reconfirmed by the doubling
agar dilution method to norfloxacin, ciprofloxacin, moxifloxacin and gatifloxacin. To
facilitate the investigation into the efflux phenotypes of the clinical isolates, the
MICs to the following established efflux pump substrates tetracycline and ethidium
bromide were determined. The efflux pump inhibitor reserpine was used in efflux
pump inhibition studies where the pump inhibitor was added in combination with the
antibiotic. Alterations within the target genes were determined by PCR amplification
of the quinolone resistance determining region of subunit A of DNA gyrase and
subunits C and E of topoisomerase IV. Prior to dideoxy sequencing, the PCR
products were restricted with Hinfl and analysed by agarose gel electrophoresis.
Sequenced products were subsequently compared to the quinolone susceptible strains
in the GenBank database.
3.4.1 MIC Determination in the Presence of Reserpine
Of the 31 clinical isolates tested, all showed reduced susceptibility to norfloxacin
(>8mg/l) and to ciprofloxacin (>lmg/l) except for one isolate. (See Figure 3.6).
These strains could be divided into two groups on the basis of the effect of reserpine
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on their susceptibility to norfloxacin. Group A contained four strains for which the
MIC of norfloxacin was reduced only two fold or less by reserpine. Group B
contained 27 strains for which the MIC of norfloxacin was reduced four-fold or
greater by reserpine. The isolates in group B had susceptibility patterns similar to the
norfloxacin mutants as described by Brenwald et al (1997; 1998).
0.25 0.5 1 2 4 8 16 32 64 128
Fluoroquinolone MICs (mg/L)
□ Ciprofloxacin ■ Norfloxacin
Figure 3.6: Distribution of MICs of Ciprofloxacin and Norfloxacin for 31
Clinical Isolates of S. pneumoniae
The ethidium bromide MICs of the clinical isolates within both groups were varied
and no pattern could be established. In group A, the ethidium bromide MICs ranged
between 8-32mg/l. In group B, all the 27 strains showed variations in the ethidium
bromide MICs where 1 isolate had an MIC of 64mg/l. Nine strains had an MIC of
32mg/l, 12 strains at 16mg/l and 7 strains exhibited an MIC of 8mg/l. The ethidium
bromide MICs of the sensitive control R6 and the efflux mutant P1Z1/IN27 were
lmg/1 and 32mg/l respectively. The elevated MICs observed with the 27 strains in
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group B seems to indicate that the increase could be attributed to an efflux
mechanism as has been shown by Baranova et al (1997). Interestingly, 29 of the
clinical isolates tested showed no decrease in susceptibility to tetracycline in
comparison to the sensitive isolate S. pneumoniae R6. However, 4 strains (BPL12,
A919, A12825, and A8442) exhibited extremely high MICs to tetracycline, which
could possibly be attributed to a specific resistance mechanism to tetracycline.
Antibiotic MIC Range MICso MIC90
Norfloxacin 8 64 16 32
Norfloxacin + Reserpine 2 16 4 8
Ciprofloxacin 0.5 8 4 8
Ciprofloxacin + Reserpine 0.5 2 1 2
Moxifloxacin 0.0625 - 0.125 0.125 0.125
Moxifloxacin + Reserpine 0.0625 - 0.125 0.125 0.125
Gatifloxacin 0.25 - 0.5 0.5 0.5
Gatifloxacin + Reserpine 0.125 - 0.5 0.25 0.5
Tetracycline 0.25 - 128 0.5 64
Ethidium Bromide 8 64 16 32
Table 3.6: MICijoofSl Clinical Isolates with Decreased Fluoroquinolone
Susceptibility
All strains were incubated overnight (18-24hr) in TH broth prior to inoculation. 18h aerobic
incubation at 37°C following inoculation of Columbia agar plates supplemented with 5% whole horse
blood (S. pneumoniae) containing the appropriate concentration of antibiotic with 2pl of standardised
test organism (0.5M McFarland) culture. All experiments were validated by the use of the following
controls: S. pneumoniae P1Z1/ IN27 (See Materials &Methods), and S. pneumoniae R6. To ensure
that reserpine had no individual inhibitory activity, agar plates containing reserpine only were
inoculated to guarantee unhindered growth of the test organism. Strain P1Z1/IN27 exhibits a four-fold
decrease in the norfloxacin and ciprofloxacin MIC when tested in combination with reserpine. Only
2-4 fold decreases were taken to be genuine inhibition by reserpine.
Twenty-seven strains showed a 2-8 fold decrease in ciprofloxacin MIC in the
presence of reserpine. Four strains showed no reduction in the ciprofloxacin
reserpine combination MICs, but demonstrated reductions when tested against the
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norfloxacin reserpine combination. The MICs to both moxifloxacin and gatifloxacin
against all 31 clinical isolates ranged between 0.0625mg/l - 0.125mg/l and 0.25mg/l
- 0.5mg/l respectively. Both moxifloxacin and gatifloxacin MICs did not appear to
be affected by the efflux pump inhibitor reserpine as no reduction was observed (See
Table 3.6).
3.4.2 PCR Analysis of the Quinolone Resistance Determining
Region ofGyrA and ParC
Genomic DNA was isolated from overnight cultures of test organism and used as
template DNA for PCR amplification of the 382bp (encoding residues 46 to 172)
subunit A of DNA gyrase and the 366bp (encoding residues 36 to 157) subunit C of
topoisomerase IV. Control reactions with no DNA template and with genomic DNA
from S. pneumoniae R6 were set up to validate the experiment. All isolates were
analysed through PCR and restriction digests with Hinfl prior to sequencing. The
absence of amplimers after the HinfX restriction digests indicates the loss of the
serine active site and subsequent amino acid substitution within the QRDR. To
confirm the results of the restriction digest and also to eliminate the possibility of
other substitutions outwith the mutational hotspots but within the QRDR, sequence
analysis of selected isolates were done. The PCR products were purified by the
Qiaquick PCR purification spin columns and sequenced bi-directionally using the
PCR primers. The resulting electropherograms were analysed through BLAST online
search engine (http://www.ncbi.nih.gov/cgi-bin/BLAST).
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3.4.2.1 Results of QRDRs of S. pneumoniae parC and gyrA
The results of the restriction digestion analysis suggested that the Serine80 site in
gyrA and the Serine79 position in parC were unchanged (See Figure 3.7 & Figure
3.8). Therefore, to identify mutations outwith these sites isolates representing a range
of ciprofloxacin MICs were chosen for further investigation by dideoxy sequencing.
All resulting sequences were compared against the GenBank database sequences
shown in Figure 3.9 and Figure 3.10.
Figure 3.7: Agarose Gel Electrophoresis of Restricted Amplimers of gyrA PCR
Products
Composite Gel photograph of Hinfl restricted fragments of gyrA PCR. DNA Markers electrophoresed
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Figure 3.8: Agarose Gel Electrophoresis ofparC PCR products and Restricted
Products
Gel photograph ofparC PCR products and restricted products from nine clinical isolates with reduced
fluoroquinolone susceptibility. Isolate 6113 and 251 were directly sequenced after amplification. R
indicates the Hinf[ restricted parC fragments.
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261 c cgt cgc att etc tat gga atg aat gaa ttg ggt gtg
RRILYGMNELGV
46
298 acc cca gac aaa ccc cat aaa aaa tct get cgt att
TPDKPHKKSARI
334 aca ggg gat gtc atg ggt aaa tac cac cca cac ggg
TGDVMGKYHPHG
370 gat tee tct att tat gaa gee atg gtc cgt atg get
DSSIYEAMVRMA
83 87
406 caa tgg tgg age tac cgt tac atg ctt gta gat ggt
QWWXYRYMLVDG
442 cat ggg aat ttt ggt tee atg gat gga gat agt get
HGNFGSMDGDSA
478 gee get caa cgt tat acc gag gca cgt atg age aag
AAQRYTEARMSK
514 att get ctg gaa atg ctt agt gat ate aac aaa aat
IALEMLRDINKN
550 aca gtt gat ttc gtt gat aac tat gat gee aat gaa
TVDFVDNYDANE
586 egg gaa ccc ttg gtc ttg cca gcg cgt ttt cca aac
REPLVLPARFPN
622 ctt ttg gtt aat gga gca act 642
L L V N G A T
172
Figure 3.9: DNA Nucleotide Sequence of a 382 bp PCR Product Encompassing
the QRDR in the gyrA Gene from S. pneumoniae R6 (Accession Nu: AF053121)
Underlining highlights the Hinfi restriction site within the PCR fragment spanning a sequence
equivalent to the Asp82 and Ser83 codons in the E. coli gyrA. Letters under the nucleotide sequence
show the deduced protein sequence (Balas et al, 1998). Amino acid residues are numbered at the right
by analogy with the E. coli GyrA protein. Nucleotide residues highlighted in bold indicate the forward
and reverse primers used in the PCR.
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105 t ggg ttg aag ccg gtt caa cgc cgt att ctt tat
G L K P V Q R R I L Y
36
139 tct atg aat aag gat age aat act ttt gac aag
S M N K D S N T F D K
172 age tac cgt aag teg gcc aag tea gtc ggg aac
S Y R K S A K S V G N
u
205 ate atg 999 aat ttc cac cca cac ggg gat tct
I M G N F H P H G D S
n 79
238 tct ate tat gat gcc atg gtt cgt atg tea cag
S I Y D A M V R M S Q
83
271 aac tgg aaa aat c9t 9a9 att eta gtt gaa atg
N W K N R E I L V E M
304 cac ggt aat aac ggt tct atg gac gga gat cct
H G N N G S M D G D P
337 cct gcg gca atg cgt tat act gag gca cgt ttg
P A A M R Y T E A R L
370 tct gaa att gca ggc tac ctt ctt cag gat ate
S E I A G Y L L Q D I
403 gag aaa aag aca gtt cct ttt gca tgg aac ttt
E K K T V P F A W N F
436 gac gat acg gag aaa gaa cca acg gtc ttg cca




Figure 3.10: DNA Nucleotide Sequence of 366 bp PCR Product Encompassing
the QRDR in the parC Gene from S. pneumoniae R6 (Accession Nu: X95717)
Underlining highlights the oligonucleotides that constitute the QRDR of the parC gene (Pan & Fisher,
1996a). Letters under the nucleotide sequence show the deduced protein sequence. Amino acid
residues are numbered at the right by analogy with the E. coli ParC protein. Nucleotide residues
highlighted in bold indicate the forward and reverse primers used in the PCR. The amino acid residues
associated with fluoroquinolone resistance have been denoted by (U).
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GyrA Par C Par E
6113 8 0.125 — — IIe460 Val
251 8 0.125 — — IIe460 Val
5770 8 0.125 — — —
7368 4 0.125 Silent n/t change
Gly 128 Gly,
AA change
Lys 137 —> Asn
BPL 27 4 0.125 — Asp83 —> Asn -—
BPL24 4 0.125 — — —
BPL 17 4 0.125 — — —
7386 2 0.125 " " IIe460 Val,
Silent n/t change
IIe476 lie
BPL 7 1 0.125 — — —
BPL 29 1 0.125 — — —
BPL 22 1 0.125 — — —
Table 3.7: Fluoroquinolone Susceptibility and Mutations in gyrA,parC and
parE of Clinical Isolates
The strains have been sorted to show a sequential increase in ciprofloxacin MICs
ranging from l-8mg/l (See Table 3.7). From, the MIC results, it can be seen that the
moxifloxacin MICs do not increase correspondingly with those of ciprofloxacin. The
initial sequencing results show that none of the isolates sustain changes within the
QRDR encompassing gyrA although the sequencing data from parC indicates the
presence of genetic mutations within the QRDR. In isolate 7368, one silent
nucleotide change, which does not result in an amino acid change and a second
genuine mutation of Lysinel37 —> Asparagine were identified. Isolate BPL27,
sustained a mutation of Aspartic acid 83 —► Asparagine within the QRDR.
Interestingly, isolates 6113, 251 and 5770 which exhibit MICs of 8mg/l to
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ciprofloxacin did not seem to possess mutations within either gyrA or parC. All the
isolates shown in Table 3.7, express an efflux phenotype to both norfloxacin and
ciprofloxacin when tested in combination with the quinolone and inhibitor reserpine.
Efflux hyperexpression could be attributed for the levels of ciprofloxacin MICs
observed in clinical isolates 6113, 251 and 5770. Mutations within the parE gene
have been implicated in quinolone resistance. Therefore, to further characterise the
genetic mutations parE was amplified and sequenced. Sequence analysis of the 11
selected isolates, revealed that only 3 possessed changes within the parE QRDR
from Isoleucine460 —» Valine. One isolate 7386, also sustained a silent nucleotide
substitution with no resulting amino acid change (See Table 3.7).
Most of the studies investigating the mechanisms of fluoroquinolones have attributed
resistance to genetic mutations within the target genes. Recently, efflux has also been
implicated to play a role in fluoroquinolone resistance development albeit
contributing only towards low levels of resistance. In this study, out of the eleven
isolates examined by sequencing analysis, six showed no genetic changes within the
target genes. Only 1 strain (BPL 27), sustained a mutation (Asp83 —> Asn) that has
been demonstrated to contribute towards quinolone resistance in S. pneumoniae and
other bacterial species (Tavio et al, 1999; Varon & Gutmann, 2000). The mutation of
Lysl37 —» Asn in isolate 7368 has been reported in S. pneumoniae (Jones et al,
2000) although always in association with gyrA or parC changes and its exact
contribution to fluoroquinolone resistance is yet to be established. In isolate 7368, no
additional changes were found in either gyrA or parC, implying that the combination
of the Lysl37 —» Asn mutation and efflux hyperexpression may contribute towards
the elevated ciprofloxacin MIC (4mg/l). The mutation in parE (IIe460 —> Val)
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appeared in both isolates exhibiting an MIC of 8mg/l and 2mg/l thereby questioning
the precise contribution of this change. In strain, 5770, no genetic mutations were
identified within the QRDR despite sustaining a ciprofloxacin MIC of 8mg/l but
demonstrated an efflux phenotype with ciprofloxacin and norfloxacin suggesting that
efflux may contribute to higher levels of resistance than previously assumed in
S. pneumoniae. Despite, the variable genetic changes, the common denominator
amongst all the isolates investigated is the expression of the efflux phenotype with
ciprofloxacin and norfloxacin.
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3.5 Intracellular Targets ofMoxifloxacin in S. pneumoniae
The effective and efficient treatment of respiratory tract infections is a crucial focus
of antibiotic therapy today. S. pneumoniae can be identified as the single most
frequent cause of respiratory tract infections in both the community and hospital
(Finch, 1995). At the beginning of the antimicrobial era, S. pneumoniae was
exquisitely sensitive to antibiotics such as penicillin and erythromycin. Since then
the continued indiscriminate use of these antibiotics has led to the emergence of
multi-drug resistant strains (Felmingham & Washington, 1999). New therapeutic
options such as the fluoroquinolones particularly ciprofloxacin have been used
leading to the subsequent emergence of fluoroquinolone resistant isolates of
S. pneumoniae. The mechanisms by which S. pneumoniae develop fluoroquinolone
resistance is through mutations within the target genes or by the expression of efflux
mechanisms (Varon & Gutmann, 2000). The quinolone induced target mutations
have only recently been molecularly characterised identifying the precise amino acid
changes within both target genes i.e. gyrA and parC. These studies have shown that
in S. pneumoniae different fluoroquinolones induce mutations within the target genes
in a different order (See Table 1.2, page 60) contrary to what is observed in gram-
negative bacteria, where fluoroquinolone challenge has consistently introduced
mutations within DNA gyrase A prior to topoisomerase IV (Tavio et al, 1999).
In laboratory mutation studies involving S. pneumoniae, older comparators such as
norfloxacin and ciprofloxacin have been shown to induce changes in parC, in
contrast to the newer extended-spectrum quinolones, such as sparfloxacin (Pan &
Fisher, 1997) and gatifloxacin (Fukuda & Hiramatsu, 1999), which introduce
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mutations in gyrA. These results have led to the hypothesis that fundamental
differences possibly exist to fluoroquinolone-induced responses between gram-
positive and negative bacteria. To test this hypothesis and given the anti-
pneumococcal potency of moxifloxacin against S. pneumoniae the primary aim of
this experiment was to identify the in vitro target of moxifloxacin and genetically
characterise the mutations that occur with moxifloxacin challenge. To ascertain the
role of efflux, reserpine inhibition and accumulation studies were also done.
First-step mutants were generated by exposure of S. pneumoniae R6 to stepwise
multiples of moxifloxacin concentrations. Subsequent mutants were selected by
further challenge with the fluoroquinolone. Viable counts of mutants per plate with
less than 50 cfus were determined at each concentration and also on non-selective
plates so that mutation frequencies could be determined. Mutant clones were
randomly selected and purified onto non-selective blood agar prior to further
manipulations. The susceptibilities of the selected mutants were determined through
the standard doubling agar dilution as recommended by BSAC guidelines and the
genetic mutations characterised through PGR and dideoxy sequencing.
3.5.1 First Step Moxifloxacin-Selected Mutants
A total of 76 mutants spanning 5 generations were generated with serial
moxifloxacin challenge. Nine first-step mutants were selected from plates containing
0.25mg/l and 0.125mg/l of moxifloxacin. The parent strain S. pneumoniae R6 had a
moxifloxacin MIC of 0.0625mg/l and mutants were isolated from both moxifloxacin
concentrations of 0.125mg/l and 0.25mg/l. Of the 9 first-step mutants selected, the
increase in moxifloxacin MIC ranged between 1.3-2 times in comparison to the
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parent strain. Of the 7 mutant clones selected from moxifloxacin 0.25mg/l, four
possessed an MIC of 0.19mg/l, two exhibited an MIC of 0.125mg/l and one had an
MIC of 0.094mg/l, which is identical to that of the parent strain. With the two clones
selected from the 0.125mg/l, one retained the MIC of the parent strain R6 and other
showed an increase in the moxifloxacin MIC of 1.3 times compared to R6. Two
(1TS7 & 1TS9) of the four strains that exhibited the greatest increase to
moxifloxacin were chosen for further study and mutations.
3.5.2 Second Generation Moxifloxacin Mutants
3.5.2.1 Second Generation Moxifloxacin Mutants Derived From 1TS7
A total of 31 strains were generated from 1TS7 with moxifloxacin challenge (See
Appendix II). The mutants were generated from exposing 1TS7 to 1 (0.5mg/l), 2
(lmg/1) and 4 (2mg/l) x MIC of moxifloxacin and were isolated from plates up to
2mg/l. The increase in moxifloxacin MICs increased in the second generation
mutants ranged from 0.25mg/l to 2mg/l. Mutants selected from plates containing
moxifloxacin at 0.25mg/I exhibited the same moxifloxacin MICs as the parent 1TS7
and those selected from the 0.5mg/l plate sustained MICs of 0.125 - 0.25mg/l. The
highest moxifloxacin MICs of 2mg/l were produced by the mutants from the plate
containing the moxifloxacin concentration of lmg/1 The increase in moxifloxacin
MICs in comparison to the primary parent S. pneumoniae R6 and parent 1TS7 are 32
times and 4 times respectively. Mutant 2TS35, which yielded the highest increase, to
moxifloxacin was chosen to raise the third generation mutants.
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3.5.2.2 Second Generation Moxifloxacin Mutants Derived From 1TS9
Nine mutants were isolated from moxifloxacin challenge of 1TS9 at concentrations
of Mox 0.25mg/l, Mox 0.5mg/l, Mox lmg/1 and Mox 2mg/l. As seen with 1TS7, no
growth was observed on the plate containing moxifloxacin 2mg/l. All the clones
selected sustained MICs between 0.125mg/l-0.5mg/l. No further mutants were
generated from this set.
3.5.3 Third Generation Moxifloxacin Mutants Derived From 2TS35
Mutant 2TS35 was exposed to moxifloxacin concentration ranging 4-32mg/l. No
mutants were isolated from the moxifloxacin selection concentration of 32mg/l. The
susceptibility profiles of the 8 selected mutants was determined by the doubling agar
dilution method. The moxifloxacin MICs were found to range from 4-8mg/l. These
resistant strains exhibited a 64 to 128 times increase in MIC in comparison to the
primary parent S. pneumoniae R6 and a 2-fold increase with respect to 2TS35. Two
mutants (3TS57 and 3TS58) with moxifloxacin MICs of 4 and 8mg/l respectively
were selected for further mutation and analysis.
3.5.4 Fourth Generation Mutants
3.5.4.1 Fourth Generation Mutants Derived from 3TS57
Strain 3TS57 was exposed to moxifloxacin concentrations from 4-16mg/l. After the
3 day incubation period, growth was only observed on the Mox 4mg/l plate. Four
clones were selected and found to exhibit an MIC of 8mg/l to moxifloxacin. A 2-fold
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increase in the moxifloxacin MIC was observed for six mutant clones in comparison
to the parent strain 3TS57.
3.5.5 Fifth Generation Mutants Derived from 4TS68
Strain 4TS68 was challenged with moxifloxacin concentrations ranging from 16-
64mg/l. No mutant clones were isolated on moxifloxacin concentrations above that
of the parent strain (8mg/l). Three of the mutant clones selected exhibited MICs
above 16mg/l. No further mutants were raised from this set. All the mutant
moxifloxacin MICs and the increases are presented in Appendix II.
The mutation frequencies observed with each generation do not seem to vary greatly
(See Table 3.8). However, despite repeated attempts, mutant clones could not be








S. pneumoniae R6 1st OsbX<N 0.5
1TS7 2nd 1.5 x 10"8 1
1TS9 2nd 4 x 10"8 0.5*
2TS35 3rd 2 x 10~9 4*
3TS57 4th 6 x 10"9 4*
4TS68 5th 3 x 10-9 16
Table 3.8: Mutation Frequencies of All Parent Strains
Legend: * indicate that the mutant colonies were chosen from selection plates of the parent strain
MICs. The viable counts and mutation frequencies of the first, second, third, fourth and fifth
generation mutants were determined. The mutation frequency is determined by the following formula:
MF = N / VC, where MF = Mutation Frequency, N = Number ofmutants, VC = Viable count of
bacteria in lOOpl of overnight culture.
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3.5.6 Characterisation ofMoxifloxacin Induced Mutations in DNA
Gyrase and Topoisomerase IV in S. pneumoniae R6
Moxifloxacin derived mutants were genetically characterised by both PCR and
sequencing. Mutant clones were identified by means of identical MICs to the
fluoroquinolones tested. Some of the mutants that were selected exhibited a decrease
in the MIC to below that of the parent strain or that of the antibiotic selecting plate.
The MIC ranges of the 5 mutant generations are shown in the Table 3.9 below.
Mutants for further characterisation were selected from each representative groups.
Generation MIC Range
Moxifloxacin Ciprofloxacin
First 0.0625 - 0.5 0.5 - 1
Second 0.5 - 4 OO1ir)O
Third 4 32 - 64
Fourth 4 - 16 32 - 64
Fifth 8 - 16 64
Table 3.9: MIC Ranges of Moxifloxacin Mutant Generations
The relationship between the primary parent S. pneumoniae R6 and the subsequent
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Figure 3.11: Relationship Between S. pneumoniae R6, Resistant Mutants and
Their Respective MICs
3.5.6.1 Genetic Analysis of Quinolone Resistant Determining Region (QRDR) of
Resistant Mutants
The QRDR DNA sequences of the parent strain and resistant mutants were compared
to the sequence of the parent strain S. pneumoniae R6. Initially, the amplified
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products of gyrA and parC were spliced with Hinf. The 382bp gyrA PCR product
underwent cleavage at a single Hinfl (overlapping coding sequence for the conserved
serine equivalent to resistance hotspot Ser83 in E. coli) site generating two
amplimers sized at 110 and 272bp.
Figure 3.12: Agarose Gel Electrophoresis of ParC and GyrA PCR Products of
Selected First Step Mutants Derived from S. pneumoniae R6
R indicates the Hinfl restricted PCR products.
Interestingly, eight of the gyrA PCR products except 1TS7, derived from
S. pneumoniae R6, were cleaved by Hinf, indicating the absence of a mutation at
codon 80 or 81. The 366bp parC product from the wild type gene has Hinfl sites at
nucleotide positions 232 and 288 and on digestion with Hinf generates fragments
sized at 183, 127 and 56bp. Acquisition of a quinolone resistance mutation altering
the mutational hotspot Ser-79 in parC leads to the loss of the 232 restriction site and
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Hinfi cleavage resulting in the generation of two 183bp fragments. The parC PCR
product of all first generation mutants (1TS2-1TS11) retained the restriction site,
which is consistent with the absence of Ser-79 changes (See Figure 3.12). Analysis
by Hinf1 restriction fragment length polymorphism (RFLP) of the second-step
mutants revealed that derivatives of 1TS7 yielded a single 183bp band suggesting an
acquisition of a Ser79 change. The parC PCR product from the remaining second-
step mutants generated from 1TS9 retained the wild type Hinf\ digestion pattern.
However, these observations do not exclude parC mutations outwith the enzyme
recognition site. The RFLP analysis provided the evidence for a gyrA mutation in
one first-step mutant (1TS7) and parC mutations in some second-step mutants
derived from it. Second-step mutants generated from the other first-step mutant,
1TS9 (See Figure 3.13), sustained no gyrA changes.
To determine the exact amino acid change, dideoxy sequencing was done and the
results are displayed in Table 3.10. One first-step mutant (1TS7) sustained a change
of Serine (TCC) 80—» Tyrosine (TAC) in gyrA. This substitution was associated
with an eight-fold decrease in moxifloxacin susceptibility. No changes were
identified within the QRDR of the parC fragment (See Table 3.10). Subsequent
mutants of 1TS7 all maintained the gyrA mutation and developed an additional parC
mutation at codon 79, resulting in a change from Ser (TCT) 79 —> Tyrosine (TAT).
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Figure 3.13: Gel Electrophoresis of Second-step Mutants Derived from 1TS9
(R) indicates the Hinf\ restricted PCR products.
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TS1 No Change No Change 0.0625 0.5
1TS7 Ser80 —> Tyr (tcc-tac) No Change 0.5 2
1TS9 No Change No Change 0.5 2
2TS19 Ser80 Tyr (tcc-tac) No Change 0.5 1
2TS22 Ser80 —* Tyr (tcc-tac) No Change 1 1
2TS29 Ser80 —■» Tyr (tcc-tac) No Change 0.5 0.5
2TS35 Ser80 —> Tyr (tcc-tac) Ser79 —* Tyr (tct-tat) 4 32
2TS39 Ser80 —> Tyr (tcc-tac) Ser79 —> Tyr (tct-tat) 4 8
2TS47 No Change No Change 0.5 1
2TS48 No Change No Change 0.5 2
3TS53 Ser80 —> Tyr (tcc-tac) Ser79 —* Tyr (tct-tat) 4 32
3TS54 Ser80 —* Tyr (tcc-tac) Ser79 —> Tyr (tct-tat) 4 32
3TS57 Ser80 —* Tyr (tcc-tac) Ser79 —> Tyr (tct-tat) 4 32
3TS58 Ser80 —» Tyr (tcc-tac) Ser79 —* Tyr (tct-tat) 8 32
3TS59 Ser80 —> Tyr (tcc-tac) Ser79 —* Tyr (tct-tat) 4 32
4TS68 Ser80 —* Tyr (tcc-tac) Ser79 —> Tyr (tct-tat) 8 32
4TS69 Ser80 —> Tyr (tcc-tac) Ser79 —> Tyr (tct-tat) 8 16
5TS82 Ser80 —» Tyr (tcc-tac) Ser79 —> Tyr (tct-tat) 16 64
5TS86 Ser80 —> Tyr (tcc-tac) Ser79 —> Tyr (tcc-tac) 16 64
5TS91 Ser80 —> Tyr (tcc-tac) Ser79 —> Tyr (tct-tat) 16 32
Table 3.10: MIC Distribution and Corresponding Mutations within DNA
Gyrase A and Topoisomerase IV
Interestingly, 1TS9, which exhibited the same increase in moxifloxacin MIC
(0.5mg/l) as 1TS7, sustained no accompanying changes within the mutational
hotspots of the either gyrA or parC. Second-step mutants derived from 1TS9 also
demonstrated no substitutions within the Ser80 position as previously seen with
1TS7. Sequence analysis of the two second-step mutants 2TS47 and 2TS48
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generated from 1TS9 confirmed the absence of mutations within the QRDR and
correspondingly, no increases in the MIC to both ciprofloxacin and moxitloxacin
were observed with either second-step mutant. No further mutants were developed
from this series.
Since some of the mutants yielded no mutations within the QRDR of both gyrA and
parC, quinolone mutations within the other subunits were sought. Thus, the 444bp
GyrB and the 357bp ParE fragments were also analysed. Changes within gyrB and
parE that are associated with quinolone resistance are Glu474 —> Lys (Pan & Fisher,
1998) and Asp437 —> Asn respectively (Perichon et al, 1997). In all the mutants
generated with moxifloxacin challenge of S. pneumoniae R6, no changes within
either parE or gyrB were identified.
3.5.7 Concluding Remarks
These results reveal two pathways of resistance development. In the first, the
acquisition of a single gyrA mutation in mutant 1TS7 resulted in an eight-fold
increase in the moxifloxacin MIC. In the second pathway, regardless of the lack of
target mutations an eight-fold increase in the MIC was observed suggesting that, the
induction of an efflux pump may be responsible.
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3.5.8 Ciprofloxacin Selected Quinolone Resistant Mutants
The results from the previous section suggest that DNA gyrase A is the primary
target of moxifloxacin in S. pneumoniae. This interaction could be due to the
different DNA-gyrase-quinolone interactions that are formed by moxifloxacin in
comparison to other quinolones e.g. ciprofloxacin. Studies have shown that
variations in quinolone structures influence the differences in the in vitro activity
against S. pneumoniae, which suggests that the drug-topoisomerase interactions also
differ with the various agents. In order to investigate this hypothesis that different
quinolones have different cellular targets, ciprofloxacin and norfloxacin were also
used to generate mutants by challenging S. pneumoniae R6.
Ciprofloxacin selected mutants were derived from S. pneumoniae R6 as described
before (See Chapter 2, Section 2.7.1 ). To analyse the order of mutations in the
development of ciprofloxacin resistance, a series of ciprofloxacin resistant
S. pneumoniae were generated. Approximately, 107 cfu of S. pneumoniae R6 (CIP
MIC 0.5mg/l) were spread onto plates yielding 11 first-step mutants from the CIP
0.5mg/l selection plate and 12 mutants from the CIP lmg/1 plate (no mutants were
obtained on plates containing CIP 2mg/l).
Interestingly, one first-step mutant (1C5) exhibited an MIC of 4mg/l, which was 2-
fold higher than all the mutant clones selected from the CIP lmg/1 plate. Mutant 1C5
was characterised and used to select second generation mutants by further challenge
with ciprofloxacin concentrations of 4, 8 and 16mg/l. Confluent growth was
observed after 48 hours on both plates containing the CIP 4 and CIP 8mg/l. Five
mutants were selected from both the 4 and 8mg/l plates and four mutants from the
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plates containing 16mg/l. All the mutants selected from both the 4 and 8mg/l plates
sustained an MIC of 2mg/l. Mutant clones selected from the plates containing 16mg/l
were found to exhibit ciprofloxacin MICs of 32mg/l. Third generation mutants, were
generated using the second-step mutant 2C33 (2mg/l). The third-step mutants were
selected from plates containing ciprofloxacin concentrations of 8mg/l and 4mg/l.
Mutant strains were characterised in terms of susceptibility to both ciprofloxacin and
moxifloxacin, and the status of the QRDR of the parC and gyrA genes were
ascertained by PCR and sequencing. For each of the first-step mutants, there was a
minimum four-fold increase (2mg/l) and a maximum sixteen-fold increase in the
ciprofloxacin MIC (8mg/l) in comparison to the parent strain. The increases in the
ciprofloxacin MICs were accompanied by a two-fold increase in the moxifloxacin
MIC.
3.5.8.1 Genetic Analysis of Quinolone Resistant Determining Region (QRDR) of
Ciprofloxacin Resistant Mutants
First generation mutants that exhibited an MIC of 2mg/l to ciprofloxacin sustained
no change within either parC or gyrA. This observation was reproducible: no parC
alterations were detected with RFLP which was verified by the sequencing results.
One first-step mutant, 1C5, which sustained an MIC of 4mg/l, underwent a mutation
within the parC QRDR at position 79 Serine (TCT) 79 —» Phenylalanine (TTT).
Analysis of other first-step mutants, with no corresponding increases in ciprofloxacin
MIC, yielded no changes within the parC QRDR. 2C33, which was derived from
mutant 1C5 retained the change within the parC QRDR at position 79, but with no
additional changes within gyrA. The moxifloxacin MIC for both the selected mutants
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1C5 and 2C33 was observed at 0.125mg/l and 0.25mg/l respectively (See Table
3.11). This suggests that ciprofloxacin challenge does not affect the moxifloxacin
MIC. The third-step mutants sustained changes within both the gyrA and the parC
QRDR. All third-step mutants and some second-step mutants that exhibited an MIC
of 32mg/l for ciprofloxacin and 4mg/l to moxifloxacin were found to acquire a gyrA
mutation of Serine80 —» Tyrosine. This mutation within gyrA elevated the MICs to
both moxifloxacin and ciprofloxacin by 16-fold and 8-fold respectively (See Table
3.11). Changes in parE were analysed in first-step mutants to determine its possible
contribution in the development of low-level resistance to ciprofloxacin. No
mutations were sustained within parE for all of the mutants shown in Table 3.11.
Strain Antibiotic MIC ParC GyrA
Ciprofloxacin Moxifloxacin
1C1 2 0.125 — —
1C5 4 0.125 Ser79 Phe —
1C23 2 0.125 — —
2C33 4 0.25 Ser79 -> Phe —
3C49 32 4 Ser79 —> Phe Ser80 -> Tyr
Table 3.11: MIC Distribution and Corresponding Mutations within DNA
Gyrase A and Topoisomerase IV
Number prefixes indicate mutant generation.
Interestingly, nearly all of the first-step mutants selected at CIP 2mg/l sustained no
changes within the parC QRDR indicating that low-level resistance to ciprofloxacin
may not require any mutations within the QRDR. Analysis of the QRDR status of
both the parC and gyrA, it appears that the initial acquisition ofparC mutations is the
predominant route to high-level ciprofloxacin resistance.
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3.5.9 Norfloxacin Selected Quinolone Resistant Mutants
The method of selection used in selecting norfloxacin resistant mutants was as
described before (See Chapter 2, Section 2.7.1 ). The primary parent S. pneumoniae
R6 yielded an MIC of 2mg/l to norfloxacin. Based on this, antibiotic selection plates
were set up for the concentrations of 2, 4 and 8mg/l. At norfloxacin concentrations of
2 and 4mg/l, ten mutant clones were selected from the each of the plates. Fifteen
colonies were selected from the 8mg/l norfloxacin selection plate. Of the thirty-five
mutants selected, 8 mutants retained the MIC of the parent strain of 2mg/l; nine were
found to exhibit a two-fold increase in norfloxacin at 4mg/l, 4 strains yielded an MIC
of 8 and 16mg/l respectively. The mutational frequencies were calculated at
3.5 x 10~7 and 1 x 10"7 for norfloxacin concentrations of 4mg/l and 8mg/l. The
decrease in the norfloxacin sensitivities was not accompanied by corresponding
increases in the moxifloxacin MICs.







R6/1 2 0.5 0.0625 — —
R6/17 4 2 0.0625 — Ser79 Tvr
R6/25 16 2 0.0625 — Ser79 -► Phe
Table 3.12: MIC Distribution and Corresponding Mutations within DNA
Gyrase A and Topoisomerase IV of First Generation Norfloxacin Mutants
RFLP analysis of the gyrA QRDR yielded no changes within the mutational hotspot
(Serine 83) and was confirmed through dideoxy sequencing. Three mutants (R6/1,
R6/17, and R6/25) were chosen for further analysis on the basis of their norfloxacin
MICs. Genetic characterisation of these mutants verified the presence of mutations
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within the parC subunit of topoisomerase IV (See Table 3.12). Two mutants R6/17
and R6/25 sustained mutations within parC at position 79. Interestingly, R6/17
sustained a mutation where Serine (TCT) 79 —» Tyrosine (TAT) and R6/25
harboured a change where the Serine (TCT) 79 —» Phenylalanine (TTT). This
mutation from serine to both tyrosine and phenylalanine consists of a single
nucleotide substitution.
Both the mutations in parC have contributed to an increase to both norfloxacin and
ciprofloxacin MICs, although an eight-fold increase is observed with R6/25 that
sustained the Serine80 —► Phenylalanine change in comparison to R6/17 that only
exhibited a two-fold increase with the tyrosine substitution. The change from serine a
polar hydrophilic amino acid to phenylalanine a non-polar hydrophobic amino acid
was followed by an eight-fold increase towards the selecting agent, norfloxacin
indicating that hydrophobic amino acid substitutions may contribute towards a
greater decrease in susceptibility profiles of mutants in comparison to the minimal
increase observed with the substitution to tyrosine, which is also a polar hydrophilic
amino acid like serine.
3.5.10 Concluding Remarks
It is clear from the results presented in the previous chapters and the published
literature that quinolones that structurally differ induce mutational changes within the
topoisomerases in a different order. The target preferences set out by moxifloxacin,
ciprofloxacin and norfloxacin indicate the relative importance of cell-killing
pathways mediated through the topoisomerases in S. pneumoniae. Of the three
quinolones employed as selecting agents, moxifloxacin retains enhanced potency
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against S. pneumoniae and incidentally selects for gyrA mutations. This is in contrast
to ciprofloxacin, which exhibits variable activity, and norfloxacin, which has little or
no activity against S. pneumoniae and select for parC mutations. All the mutation
studies described above were performed with a laboratory strain S. pneumoniae R6.
To correlate the mutations and susceptibility profiles with the clinical situation,
mutation studies on clinically relevant isolates of S. pneumoniae were performed.
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3.5.11 Moxifloxacin Generated Mutants from Penicillin
Intermediate Strain S. pneumoniae 285
Worldwide initiatives involved in the evaluation of susceptibility profiles of clinical
pneumococci have outlined the increased emergence of strains with reduced
susceptibilities to both the (3-lactams and macrolide agents (Felmingham &
Washington, 1999). This has shifted the focus toward treatment options to another
class of agents: the fluoroquinolones. The recent introduction of extended-spectrum
quinolones such as moxifloxacin and gatifloxacin provide a therapeutic alternative.
Studies have now shown that the current clinical populations of pneumococci exhibit
unique characteristics. Firstly, an increasing number of pneumococcal strains
demonstrate reduced susceptibility to penicillin and erythromycin and in some cases
to ciprofloxacin. Secondly, analysis of clinical isolates with reduced fluoroquinolone
susceptibility implicates the preferential expression of efflux pumps as a resistance
mechanism in comparison to target mutations (Brenwald et al, 1998; Morrissey et al,
1999). The new extended-spectrum quinolones are directed toward these phenotypes
in the clinical situation.
Therefore, the aim was firstly to elucidate the preferred targets of moxifloxacin
action in clinical pneumococcal isolates and secondly to verify the relevance of the
mutations observed with moxifloxacin challenged laboratory strain R6. Quinolone-
resistant mutants were selected from clinical isolates of a penicillin intermediate
isolate 285 (2mg/L) and penicillin resistant isolate 158 (8mg/L).
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3.5.11.1 First Step Moxifloxacin Mutants Derived from Penicillin Intermediate
S. pneumoniae 285
Penicillin intermediate S. pneumoniae 285 exhibited an MIC of 0.0625mg/l to
moxifloxacin and lmg/1 to ciprofloxacin. Correspondingly, the isolate was
challenged with moxifloxacin concentrations of 0.125mg/l and 0.25mg/l where 4
mutants were selected from the 0.125mg/l and 14 mutant clones from the 0.25mg/l
plates respectively. The analysis of the sensitivities of the 18 first-generation mutants
exhibited the following ranges to moxifloxacin (0.0625-0.25mg/l) and ciprofloxacin
(l-8mg/l). All the first-generation mutants sustained a 2-8 fold increase in MIC to
ciprofloxacin and 2-4 fold increase to moxifloxacin. Restriction fragment analysis of
the first generation mutants with HinJ\ indicated the absence of the loss of the serine
at codon 83 (E. coli numbering). 285/3, which sustained the highest moxifloxacin
MIC, was used to select the second-generation mutants.
3.5.11.2 Second Step Moxifloxacin Mutants Derived from Penicillin
Intermediate S. pneumoniae 285
Second generation mutants were selected with moxifloxacin concentrations of
0.5mg/l and lmg/1. Selected clones were subcultured and tested against moxifloxacin
and ciprofloxacin. The majority of second-step mutants exhibited moxifloxacin
MICs of lmg/1 except for two mutants (285/30 and 285/31) that demonstrated an
MIC of 2mg/l to moxifloxacin. Both these mutants sustained an eight-fold increase in
the moxifloxacin MIC in comparison to the parent 285/3. A corresponding increase
in the ciprofloxacin MIC was also observed, with 285/31 yielding an MIC of 32mg/l
and 285/30 had an MIC of 4mg/l. 285/31 was chosen for further analysis and also
used to generate third generation mutants.
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3.5.11.3 Third Step Moxifloxacin Mutants Derived from Penicillin Intermediate
S. pneumoniae 285
Strain 285/31 was challenged with moxifloxacin concentrations of 4 and 8mg/l. Ten
colonies were chosen from the moxifloxacin 4mg/l selection plate and 5 colonies
from the 8mg/l plate. The mutants were tested and found to exhibit a moxifloxacin
MIC range of 4-8mg/l. The ciprofloxacin MIC range was observed at 32-64mg/I for
the third-step mutants. Moxifloxacin MICs of all 285 mutant series are presented in
Appendix III.
MIC Generation












Figure 3.14: Relationship Between S. pneumoniae 285, Resistant Mutants and
Their Respective MICs
Figure 3.14 details the relationship between the progeny and the parent strain
S. pneumoniae 285. The moxifloxacin MIC increments observed with each stepwise
quinolone challenge is shown.
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Parent Strain Mutation Step Mutation Frequency
S. pneumoniae 285 1st 2 x 10"7
285/3 'jnd 3 x 10"7
285/31 ^rd 1.5 x 10"8
Table 3.13: Mutation Frequencies of All Parent Strains
Legend: MF values were determined from overnight cultures ofS. pneumoniae 285 using the
following formula: MF= N / VC, where MF = Mutation Frequency, N = Number ofmutants, VC =
Viable count of bacteria in a lOOpl of overnight culture.
The mutational frequency for each generation was determined and is shown in Table
3.13. The mutation frequency becomes higher as the mutants become more resistant.
3.5.12 Antimicrobial Susceptibilities ofMutants Selected from
S. pneumoniae 285
To assess the activity of other fluoroquinolones against the moxifloxacin selected
mutants, MICs were determined using the doubling agar dilution method. The results







Table 3.14: MIC50 and MIC^ Values of Fluoroquinolones Tested Against
Moxifloxacin Challenged S. pneumoniae 285 Mutant Series
Norfloxacin was found to possess the least activity and gemifloxacin was the most
active. Both moxifloxacin and gatifloxacin yielded identical MIC90 values although
moxifloxacin was found to better gatifloxacin by a 2-fold dilution for the MIC50. The
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penicillin MICs were also determined for all the mutants to assess the effect of
quinolone challenge on other antibiotic classes. No increases were observed with any
of the mutants tested where, the penicillin MICs remained at 2mg/l identical to the
parent strain.
3.5.13 Genetic Analysis of the QRDR of Moxifloxacin Resistant
Mutants Derived from S. pneumoniae 285
PCR and dideoxy sequencing was done (See Table 3.15). Despite not sustaining any
target mutations, first generation mutants 285/3 and 285/7 exhibited a 2-4 fold
increase in moxifloxacin MICs.
Strain DNA
Gyrase
Topoisomerase IV Antibiotic MIC




285 — — Val460 -+ He 0.0625 1
285/3 — — Val460 -> lie 0.25 2
285/7 — — Val460 lie 0.125 2
285/22 Ser80 —> Tyr — Val460 -* He 0.25 4
285/24 Ser80 —> Tyr — Val460 -► He 0.25 4
285/31 Ser80 -» Tyr — Val460 He 2 16
285/36 Ser80 —»Tyr — Val460 -> He 1 8
285/59 Ser80 —> Tyr Ser79 Phe Val460 He 8 32
285/65 Ser80 Tyr Ser79 -> Phe Val460 He 8 32
285/70 Ser80 —> Tyr Ser79 Phe Val460 -* He 4 64
285/75 Ser80 —> Tyr Ser79 -> Phe Val460 -» He 8 64
Table 3.15: MIC Distribution and Corresponding Mutations within DNA
Gyrase A and Topoisomerase IV
155 Results
The acquisition of a gyrA mutation (Ser80 —> Tyr) in second-step clones 285/31 and
285/36 induced a 2-8 fold increase in the MIC to ciprofloxacin and a 4-8 fold
increase to the moxifloxacin MIC. Interestingly, 2 second-step mutants 285/22 and
285/24 demonstrated no increases in MIC to moxifloxacin despite sustaining a
mutation in gyrA.
The acquisition of the parC mutation of Ser79 —* Phe in third-step mutants 285/59,
285/65, 285/70 and 285/75 elevated the ciprofloxacin MIC by 2-4 fold. The
substitution Val460 —> He within parE is unlikely to contribute to quinolone
resistance as it is also harboured by the quinolone sensitive parent S. pneumoniae
285.
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3.5.14 Moxifloxacin Generated Mutants from Penicillin Resistant
Strain 158
To further analyse the effects of moxifloxacin challenge on penicillin resistant
S. pneumoniae, a penicillin-resistant clinical isolate was challenged with stepwise
multiples of moxifloxacin. Penicillin-resistant S. pneumoniae 158 was challenged
with the moxifloxacin concentrations of 0.125mg/l, 0.25mg/l and 0.5mg/l. Mutants
were selected and tested as described before. Ten mutants were chosen from the
Mox0.25mg/1 and fifteen colonies from the Mox0.5mg/1 selection plates respectively.
Of the 25 mutants clones analysed, 20 sustained an MIC of 0.125mg/l and five had
an MIC of 0.0625mg/l to moxifloxacin. The parent strain 158 and four first-step
mutants were chosen for further analysis (See Table 3.16).
RFLP analysis of the parent strain and four first-step mutants indicated no loss of the
Hinf\ recognition site in gyrA and parC. Sequencing data confirmed this observation
and no changes were identified in any of the first-step mutants in both the gyrA and
parC. None of the first generation mutants tested exhibited more than a 2-fold
increase in the moxifloxacin MICs.
To ascertain the primary target of moxifloxacin action, second generation mutants
were generated from 158/25. Five mutants were selected from the Mox 0.125mg/l
plate and MICs were determined. Only one mutant 158/45 demonstrated an eight¬
fold increase in the moxifloxacin MIC. The remaining eleven mutants either
maintained the same moxifloxacin MIC (0.0625mg/l) or exhibited a 2-fold increase
(0.125mg/l) in comparison to the parent strain (158/25). With 158/45, the increase in
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the moxifloxacin MIC, was also accompanied by a four-fold increase in the
ciprofloxacin MIC.
Strain DNA Gyrase Topoisomerase IV Antibiotic MIC





158 -— — Val460 — lie 0.0625 2
Generation 1:
158/14 — — Val460 -> lie 0.0625 2
158/19 — — Val460 -> lie 0.0625 2
158/25 — — Val460 -+ He 0.125 2
158/30 — — Val460 -> He 0.125 2
Generation 2:
158/45 — — Val460 He 0.5 8
Table 3.16: MIC Distribution and Corresponding Mutations within DNA
Gyrase A and Topoisomerase IV
The difficulty in raising mutants was most pronounced with this mutation experiment
where, selected clones from the different generations rarely exhibited more than
2-fold increases to moxifloxacin. Interestingly, the increments in MICs to both
agents could not be attributed to mutations within any of the topoisomerase genes
investigated.
3.5.15 Concluding Remarks
The mutation studies performed with all the pneumococcal isolates S. pneumoniae
R6 and S. pneumoniae 285 indicate that in in vitro studies the primary intracellular
target of moxifloxacin action is the gyrA subunit within DNA gyrase. From the
results presented in this chapter, it is apparent that gyrA changes are crucial in the
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evolution of resistance to moxifloxacin. With S. pneumoniae 158, no changes within
the gyrA or parC subunit could be identified, implying that the increments to the
quinolone MICs could be also due to mutations outwith the QRDR or through the
induction of a moxifloxacin specific efflux pump.
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3.5.16 Moxifloxacin Generated Mutants from Efflux Mutant
P1Z1/IN27
The initial thrust of this project was to determine the primary in vitro target of
moxifloxacin in S. pneumoniae R6. During the course of this work, it became
apparent that a considerable proportion of clinical S. pneumoniae hyperexpressed the
efflux pump pmrA. Therefore, to evaluate the effect of moxifloxacin on
S. pneumoniae P1Z1/IN27 (pmrA hyper-expressing strain) mutation studies with
stepwise antibiotic challenge were performed. Efflux mutant P1Z1/IN27 was a gift
received from Dr. N.P. Brenwald, Department of Microbiology, City Hospital NHS
Trust, Birmingham B18 7QH. P1Z1/IN27 is a derivative of S. pneumoniae ATCC
49619 after norfloxacin challenge. Sequence analysis of gyrA, gyrB, parC and parE
QRDR confirmed the absence of sequence differences between the parent strain
(ATCC 49619) and the efflux mutant P1Z1/IN27 (Gill et al, 1999). Phenotypically,
P1Z1/IN27 exhibited increased sensitivity (4-8 fold) to norfloxacin in the presence
of reserpine and also showed 4-8 fold decreases to ethidium bromide sensitivity than
the parent strain ATCC 49619. Moxifloxacin challenge of this strain was done as
described before with concentrations equivalent to 2, 4 and 8 times the MIC.
3.5.16.1 First and Second Step Moxifloxacin Mutants Derived from Efflux
Mutant S. pneumoniae P1Z1/IN27
P1Z1/IN27 was challenged with Mox 0.125mg/l, 0.25mg/l and 0.5mg/l. Ten mutants
were selected from the Mox0.125mg/1 and Mox0.25mg/1 plates respectively. Eleven
colonies were chosen from the Mox0.5mg/1. The antibiotic susceptibilities of the
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selected mutant clones were determined by the agar dilution method prior to other
manipulations.
Second-step mutants were generated from first-step mutant Eff25. Generally, the
older quinolones like norfloxacin and ciprofloxacin were found to be the least active
against the moxifloxacin mutants. Of the newer quinolones tested, gemifloxacin was
the most active with gatifloxacin being the least active. Despite, moxifloxacin being
used as the selecting agent, the MIC90 values reported are four-fold lower than those
for gatifloxacin (See Table 3.17).
Antibiotic MIC Range MIC50 MIC90
Norfloxacin 16 >128 16 32
Ciprofloxacin 4 64 8 16
Moxifloxacin 0.0625 - 0.5 0.0625 0.5
Gatifloxacin 0.125 - 2 0.5 2
Gemifloxacin 0.0312 - 0.125 0.0312 0.125
Table 3.17: MIC50 and MIC90 Values of Fluoroquinolones Tested Against
Moxifloxacin Challenged S. pneumoniae P1Z1/IN27 Mutant Series
3.5.17 Genetic Analysis of the QRDR of Moxifloxacin Resistant
Mutants Derived from S. pneumoniae P1Z1/IN27
Restriction analysis with Hinj\ of the 382 bp gyrA PCR products produced
amplimers for the parent strain P1Z1/IN27, Eftfl and EfflO which were selected from
Mox 0.125mg/l plate. Mutants Eff 22, Eff25, Eff 26, Eff 28 and Eff 31 sustained no
cleavage thereby, indicating the loss of the Ser83 site within gyrA. Restriction of the
366bp parC fragment produced identical patterns to that of the parent strain,
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indicative of a sensitive parC. Sequencing analysis of the mutants are shown in
Table 3.18.
Strain DNA Gyrase Topoisomerase IV Antibiotic MIC




P1Z1/IN27 — — — 0.0625 2
EffO — — — 0.0625 2
Eff 10 — — — 0.0625 2
Eff 21 — — — 0.125 2
Eff 22 Ser80 —> Phe —• — 0.5 4
Eff 25 Ser80 -> Phe — — 0.5 8
Eff 26 Ser80 —> Phe — — 0.5 4
Eff 28 Ser80 —► Phe — — 0.5 4
Eff 31 Ser80 — Phe — — 0.5 4
Table 3.18: MIC Distribution and Corresponding Mutations within DNA
Gyrase A and Topoisomerase IV of Efflux Mutants
No changes were observed in either subunit of topoisomerase IV. Despite, the lack of
parC mutations, the ciprofloxacin MIC increased by four-fold in Eff 25 and two-fold
in Eff 22, Eff 26, Eff 2.8 and Eff 31. The acquisition of the gyrA mutation resulted in
an eight-fold increase in the moxifloxacin MICs (See Table 3.18). This moxifloxacin
MIC value was maintained by all the mutants that sustained the gyrA change. The
substitution of serine, a polar hydrophilic molecule to phenylalanine a non-polar
hydrophobic molecule differs from the other mutational changes observed where
serine converts to tyrosine, also a polar hydrophilic amino acid. This change has been
noted to occur when S. pneumoniae R6 was challenged with norfloxacin. The
contribution of this gyrA mutation in the reduction of ciprofloxacin susceptibility is
clearly indicated in mutant Eff 25.
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3.5.18 Concluding Remarks
The results presented here clearly show that regardless of strain phenotype
moxifloxacin challenged laboratory mutants always sustain primary mutations in
gyrA followed by parC changes. All the mutation studies showed that mutations
within gyrA were able to elevate the MICs of both the older agents like ciprofloxacin
and norfloxacin and newer broad-spectrum agents like moxifloxacin and
gatifloxacin. The parC mutations that were sustained had little effect on the in vitro
potency of moxifloxacin.
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3.6 Efflux Mediated Fluoroquinolone Resistance in
S. pneumoniae
The acquisition of fluoroquinolone resistance has been attributed to mutational
changes that are sustained within the primary targets of quinolone action. In the
previous sections, the contributions of these target mutations have been analysed
through a series of mutation studies. However, the recent identification of the
pneumococcal efflux mechanism questions the exact contributions of these target
mutations in fluoroquinolone resistance development. In Section 3.4.2.1 , we have
shown examples of clinical pneumococcal isolates with efflux expression and no
target mutations within either parC or gyrA exhibiting reduced susceptibility to the
fluoroquinolones. Therefore, to ascertain the role of efflux in the defined sets of
mutants that were generated, efflux inhibition experiments, antibiotic accumulation
assays and analysis of efflux gene expression were conducted.
In order to examine the efflux mechanism, a phenotypic method was used. This was
based on the effect of reserpine, a known efflux inhibitor, on the activity of
fluoroquinolones and on the susceptibility of the strains to unrelated efflux pump
substrates such as ethidium bromide and tetracycline. The effectiveness of this
method for the detection of the efflux mechanism was validated with an in vitro
mutant, P1Z1/IN27, which exhibits decreased fluoroquinolone susceptibility
reversible with reserpine, and sustains no changes within the QRDR of both
topoisomerase IV and DNA gyrase.
The susceptibilities of the mutants and the respective parent isolates were determined
to the fluoroquinolones individually and in combination with reserpine (10mg/l) by
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the standard doubling agar dilution method. Reserpine is an extremely labile agent
and thus antibiotic and reserpine containing plates were made and inoculated on the
same day.
3.6.1 Efflux Profile of Moxifloxacin Selected Mutants




Norfloxacin + Reserpine 2 32
Ciprofloxacin 1 32
Ciprofloxacin + Reserpine 1 32
Moxifloxacin 0.25 8
Moxifloxacin + Reserpine 0.25 4
Tetracycline 1 1
Ethidium Bromide 0.5 0.5
Table 3.19: MIC50 and MIC90 Values of 73 Moxifloxacin Challenged Mutants
from S. pneumoniae R6
For the majority of the mutants tested, no reductions were observed with reserpine
and fluoroquinolone combinations tested. No increments in the ethidium bromide
and tetracycline MICs were exhibited by the mutants. Interestingly, four mutants
(1TS7, 1TS9, 3TS53 and 4TS67) demonstrated an efflux phenotype with
moxifloxacin (See Table 3.20). Only one mutant 1TS9 expressed a reduction in
susceptibility when tested with reserpine to both moxifloxacin and norfloxacin. It has
to be noted that 1TS9 does not sustain any mutations within the QRDR of any of the
target genes. Four mutants (2TS26, 2TS27, 2TS28 and 5TS82) appeared to express a
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reduction with the ciprofloxacin and reserpine combination and three mutants (1TS9,
2TS35 and 5TS86) exhibited an efflux phenotype with norfloxacin. One clone 2TS35
appeared to demonstrate a 2-fold increment in the moxifloxacin MIC and a four-fold
reduction with norfloxacin when tested in combination with reserpine. Generally, no
increases in the MICs of either tetracycline or ethidium bromide were recorded for
any of the moxifloxacin mutants derived from S. pneumoniae R6.














1TS7 0.5 0.5 0.5 0.125 1 1 Ser80 -» Tyr —
1TS9 1 1 0.5 0.125 8 1 — —
2TS26 4 1 0.25 0.25 4 4 Ser80 —»Tyr —
2TS27 2 0.5 0.25 0.25 4 4 Ser80 Tyr —
2TS28 2 0.5 0.2.5 0.25 4 4 Ser80 Tyr —
2TS35 32 32 2 4 64 4 Ser80 Tyr Ser79 Tyr
2TS46 8 2 0.5 0.5 64 16 — —
3TS53 16 16 4 1 64 64 Ser80 —> Tyr Ser79 —> Tyr
4TS67 16 16 4 1 64 64 Ser80 —> Tyr Ser79 —> Tyr
5TS82 32 8 8 8 64 32 Ser80 —> Tyr Ser79 —> Tyr
5TS86 32 32 8 8 64 16 Ser80 —> Tyr Ser79 Tyr
Table 3.20: Minimum Inhibitory Concentration ofMutants Showing an Efflux
Phenotype
The data presented here differ from the phenotypic profile of the pneumococcal
efflux pump pmrA. Firstly, the lack of increase in both the tetracycline and ethidium
bromide MICs and secondly, the reserpine potentiated reduction observed is not only
confined to the hydrophilic quinolones such as ciprofloxacin and norfloxacin but is
also extended to agents like moxifloxacin, which, indicates that the efflux pump
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involved may be different from that ofpmrA or that mutations within the pmrA gene
are responsible for the altered substrate profile.
3.6.1.2 Efflux Profile of Mutants Selected with Ciprofloxacin and Norfloxacin
Challenge of S. pneumoniae R6.
Both the R6 derived norfloxacin and ciprofloxacin mutants were tested against the
reserpine fluoroquinolone combinations. None of the three ciprofloxacin challenged
mutant generations tested, exhibited reductions with either ciprofloxacin and
moxifloxacin. Against the norfloxacin and reserpine combination, only two of the
ciprofloxacin-derived mutants (1C23 and 2C33) demonstrated a four-fold reduction
(See Table 3.21).
Strain Cipro¬ Cipro¬ Moxi¬ Moxi¬ Nor¬ Nor¬
floxacin floxacin + floxacin floxacin + floxacin floxacin +
Reserpine Reserpine Reserpine
1C23 0.125 0.5 0.0625 0.125 4 1
2C33 2 2 0.25 0.25 64 16
P1Z1/IN27 2 0.5 0.125 0.125 16 2
Table 3.21: MICs of Ciprofloxacin Generated Mutants Exhibiting an Efflux
Phenotype
With the norfloxacin generated mutants, the results were similar to that obtained with
the ciprofloxacin mutants. None of the norfloxacin mutants exhibited an efflux
profile with any of the fluoroquinolones tested with reserpine. This result is in direct
contrast to that reported by Brenwald et al (1997). Although, 2-4 fold increments
were noted with the norfloxacin reserpine MICs of some mutants.
In all the susceptibility experiments, the control P1Z1/IN27 was used to validate the
results and exhibited a consistent four-fold decrease to both the norfloxacin and
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ciprofloxacin reserpine combinations in comparison to the fluoroquinolone only
MIC. The susceptibility to both tetracycline and ethidium bromide were not
determined for both sets ofmutants.
3.6.1.3 Efflux Profile ofMutants Selected with Moxifloxacin Challenge of
S. pneumoniae 285.
To determine the differences in the efflux profile of moxifloxacin selected mutants
derived from laboratory strain S. pneumoniae R6 and clinical isolate S. pneumoniae
285. reserpine inhibition studies of the 285 mutant series were done.
The susceptibilities were determined as described before and the results are presented
as MIC50 and MIC90 values to both the fluoroquinolones and other efflux pump
substrates (See Table 3.22).
Antibiotic MIC Range MICso MIC90
Norfloxacin 16 - 128 32 128
Norfloxacin + Reserpine ^0l100 8 16
Ciprofloxacin 2 - 64 4 64
Ciprofloxacin + Reserpine 2 - 16 2 16
Moxifloxacin 0.0625 - 8 1 8
Moxifloxacin + Reserpine 0.0625 - 8 1 8
Tetracycline 0.125 - 0.5 0.25 0.5
Ethidium Bromide 4 - 32 16 32
Table 3.22: MIC50 and MIC90 Values of 72 Moxifloxacin Challenged Mutants
from S. pneumoniae 285
As observed before, no reserpine potentiated reduction was observed with
moxifloxacin in contrast to the reserpine mediated reduction observed with both
norfloxacin and ciprofloxacin. A four to 32-fold reduction was exhibited with the
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norfloxacin and reserpine combination and the ciprofloxacin and reserpine
combination conferred a more moderate 2-8 fold decrease in the ciprofloxacin MICs
of all the mutants tested. Although, three mutants (285/42, 285/47, and 285/54)
demonstrated no reduction in the ciprofloxacin reserpine MICs. Generally, the
majority of the mutants maintained the tetracycline MICs of 0.25mg/l sustained by
the primary parent isolate 285. However, 16 mutants were found to exhibit
tetracycline MICs that was two-fold higher (0.5mg/l) and the remaining 16 sustained
MICs two-fold lower than the parent strain (0.125mg/l).
4 8 16 32
Concentration of Ethidium Bromide (mg/l)
Figure 3.15: Distribution of S. pneumoniae 285 Derived Mutants Exhibiting
Variable Ethidium Bromide MICs
Sixteen mutants retained the ethidium bromide MIC of the parent strain 285
(32mg/l). Interestingly, seven mutants were found to demonstrate an MIC of 4mg/l,
and a further seven clones sustained an MIC of 8mg/l which is a 4 - 8 fold reduction
in comparison to the parent strain (See Figure 3.15). All the mutants that sustained an
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MIC of 4mg/l to ethidium bromide were second generation derivatives of 285/3,
which had an MIC of 32mg/l. Interestingly, the mutants that exhibited a two-four
fold reduction in the ethidium bromide MICs also exhibited a 2-4 fold decrease to
tetracycline.
It appears that the mutants generated from the clinical isolate S. pneumoniae 285,
exhibit a reserpine potentiated efflux phenotype with both ciprofloxacin and
norfloxacin unlike that observed with the moxifloxacin resistant mutants derived
from S. pneumoniae R6. The simultaneous MIC reduction to both tetracycline and
ethidium bromide by some mutants differs from the substrate profile demonstrated
by S. pneumoniae R6 derived mutants and the efflux pump pmrA (Brenwald et al,
1997).
3.6.1.4 Efflux Profile ofMutants Selected with Moxifloxaein Challenge of
Efflux Mutant P1Z1/IN27
Constitutive expression of efflux pumps has been shown to prolong the survival of
bacterial isolates by the export of antibiotics out of the cell before the intracellular
targets are breached (Markham, 1999). Protection conferred by efflux pump
hyperexpression has been shown to possibly precede mutations within the relevant
target genes (Brenwald, et al, 1998; Morrissey et al, 1999). Therefore, to assess the
contributions of the efflux pump pmrA in the development of moxifloxacin resistance
reserpine inhibition studies were performed on the mutant series generated from
pmrA hyperexpresser P1Z1/IN27. Efflux mutant P1Z1/IN27 was challenged with
stepwise multiples of moxifloxacin, where the resulting clones sustained a mutation
in gyrA (Ser80 —* Phe) resulting in MICs of 0.5mg/l to moxifloxacin and 4mg/l to
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ciprofloxacin respectively. The MIC increases can be attributed to a combination of
the single gyrA mutation and constitutive expression ofpmrA. To determine the exact
contribution of the efflux pump in the development of fluoroquinolone resistance,
MICs were done both in the absence and presence of reserpine.
Antibiotic MIC Range MIC5o MIC90
Norfloxacin 16 - >128 16 32
Norfloxacin + Reserpine 8 64 16 16
Ciprofloxacin 4 64 8 16
Ciprofloxacin + Reserpine 1 - 16 2 8
Moxifloxacin 0.0625 0.5 0.0625 0.5
Moxifloxacin -1- Reserpine 0.0625 0.5 0.0625 0.5
Tetracycline 0.25 32 0.5 1
Ethidium Bromide 16 32 32 32
Table 3.23: MIC50 and MIC90 Values of 49 Moxifloxacin Challenged Mutants
from S. pneumoniae P1Z1/IN27
The parent strain P1Z1/IN27 exhibits an MIC of 0.25mg/l to tetracycline and 16mg/l
to ethidium bromide. The mutants generated in this study demonstrated increases to
both these efflux pump substrates. Against tetracycline, 20 mutants sustained an MIC
of lmg/1 and 21 clones had an MIC of 0.5mg/l equivalent to a four-fold and two-fold
increase respectively. The remaining eight mutants retained the original MIC of the
parent strain. Against ethidium bromide, it was found that the MICs of some mutants
decreased by two-fold to 16mg/l. Only, three mutants (Eff42, Eff43 and Eff50) were
found not to sustain a reduction to the ciprofloxacin reserpine combination. Only 6
mutants (Eff 18, Effl9, Eff 24, Eff 25, Eff 49 and Eff 50) yielded a four-fold
reduction with the ciprofloxacin reserpine combination. All other mutants showed a
8-fold reduction with ciprofloxacin. The efflux phenotype identified here differs
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from that of the 285 mutation series where reserpine mediated reductions were
observed with both ciprofloxacin and norfloxacin. Consistently, the moxifloxacin
MICs for all the different mutant series showed no reduction in the presence of
reserpine.
3.6.2 Concluding Remarks
The different mutation series appear to exhibit variable efflux substrate profiles.
Generally, against ciprofloxacin, reductions were observed with both the 285 mutant
series and the P1Z1/IN27 mutants. Norfloxacin reductions were only seen with the
285 mutant series and four of the P1Z1/IN27 series. In contrast, the S. pneumoniae
R6 mutants derived after norfloxacin, ciprofloxacin and moxifloxacin challenge
exhibited minimal reductions when tested with reserpine. The altered tetracycline
and ethidium bromide profiles observed with some of mutants from both the 285
mutant series and the P1Z1 mutant series differs from that reported for pmrA
(Brenwald et al, 1997) and thus, it appears that moxifloxacin challenge
downregulates the effect on these agents.
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3.6.3 Assay for the Accumulation ofMoxifloxacin
Several studies have shown that the amount and rate of accumulation of antibiotics
within the bacterial cell wall is an indication of an efflux pump hyperexpression.
Inhibition studies (presented in Section 3.6.1 ) have shown that moxifloxacin activity
is not affected by reserpine and subsequently may not be a substrate for the efflux
pump pmrA. Given the ubiquity of efflux pumps on bacterial cells, it is possible to
envisage that other efflux pumps may be involved in the uptake and export of
moxifloxacin. Therefore, to ascertain the rate of moxifloxacin uptake in selected
mutants, accumulation studies were done. Determination of the rate of antibiotic
accumulation was performed as described by Mortimer & Piddock (1991). Briefly,
centrifuged pellets of log phase bacterial cultures were resuspended in sodium
phosphate buffer prior to exposure to moxifloxacin at a concentration of lOpg/ml.
The decrease in fluorescence as moxifloxacin exited the cells was measured over a
period of 5 minutes and recorded fluorometrically using a fluorescence
spectrophotometer (excitation X 294nm,: emission X, 504nm) at 37°C. Selected
mutants from the P1Z1/IN27 and S. pneumoniae R6 were analysed by the
accumulation assay (See Figure 3.16 and Figure 3.17). To validate the experiment
efflux mutant P1Z1/IN27 was employed.
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3.6.3.1 Accumulation Assays ofMutants derived from S. pneumoniae
P1Z1/IN27
Time (seconds)
• P1Z1 ♦ Eff 10 ------- Eff21 ------- Eff25 —A—Eff49 ---A---Eff50
Figure 3.16: Accumulation by Parent Strain (P1Z1/IN27) and Mutant Strains
(EfflO, Eff21, Eff25, Eff49 and Eff50)
Fluorescence intensity (in arbitary units) is a measure of the amount of moxifloxacin inside the cells.
Graphs points were plotted as a mean of three experiments.
Figure 3.16 compares the levels of accumulation of moxifloxacin in the parent strain
P1Z1/IN27 and the mutants (EfflO, Eff21, Eff25, Eff49 and Eff50) derived from it
after moxifloxacin challenge. The rate of accumulation observed with the parent
strain P1Z1/IN27 was found to be significantly higher than that of the mutants tested.
There are no notable differences between the rate of moxifloxacin accumulation
between the first generation and second generation mutants. Although, the significant
decrease in the rate of accumulation that exists between P1Z1/IN27 prior to
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moxifloxacin challenge and that of the mutant clones after moxifloxacin selection
does indicate that an efflux pump may be a contributory factor in the decreased
susceptibility of the mutants to moxifloxacin.
3.6.3.2 Accumulation Assays of Mutants derived from S. pneumoniae R6
Time (seconds)
—TS9 —TS35 —TS46 -*-TS67
Figure 3.17: Moxifloxacin Accumulation by Selected S. pneumoniae R6
Mutants
Fluorescence intensity (in arbitary units) is a measure of the amount of moxifloxacin inside the cells.
Graphs points were plotted as a mean of two experiments.
Mutant clones (1TS9, 2TS35, 2TS46 and 4TS67) derived from S. pneumoniae R6
were chosen for accumulation assay analysis (See Figure 3.17). First-step mutant
1TS9 sustained no gyrA or parC changes within the QRDR of either gene and
appears to accumulate significantly higher levels of moxifloxacin than the other
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mutants tested. Mutants 2TS35 and 2TS46 exhibit similar levels of moxifloxacin
accumulation, despite the different target mutations sustained by both mutants (See
Table 3.10). Interestingly, 4TS67 which maintains a mutation both gyrA and parC
demonstrated the least levels of moxifloxacin accumulation with respect to the other
mutants tested. Although 2TS35 and 4TS67 sustain the same genetic changes within
both gyrA and parC, the levels of moxifloxacin accumulation of the mutants are
different.
Both the accumulation assays show that moxifloxacin resistant mutants exhibit
decreased levels of quinolone uptake. This effect is more pronounced in the levels
observed between efflux hyper-expresser P1Z1/IN27 and the mutants derived from
it. The trend observed with the S. pneumoniae R6 derived mutants also indicates that
mutants with higher moxifloxacin MICs accumulate less quinolone. These uptake
assays suggest the possibility that other efflux pump mechanisms may contribute
towards the reduction in moxifloxacin uptake shown here.
3.6.4 Genetic Analysis ofpmrA in S. pneumoniae
The results presented in the previous sections indicates that the phenotype of the
presumptive efflux pump expressed by the mutants selected with moxifloxacin
challenge is different from that ofpmrA. In S. aureus, it has been shown that a single
nucleotide change within the promoter region of NorA can result in either the
overexpression of the efflux pump or the altered substrate profile (Ng et al, 1994).
Therefore, to determine whether moxifloxacin exposure can induce amino acid
changes within the efflux pump gene thereby altering the pump's activity and
substrate specificity, sequencing analysis of the efflux pump was done. Firstly, PCR
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was employed to ensure the presence of pmrA in all the isolates tested. Secondly, to
elucidate, whether genetic changes within the efflux pump pmrA can alter substrate
specificity and phenotypical characteristics, PCR and sequencing involving pmrA
was performed.
Selected moxifloxacin mutants derived from S. pneumoniae R6 that exhibited an
efflux phenotype (See Table 3.20) to moxifloxacin were analysed by PCR to
establish the presence ofpmrA. Clinical isolates of S. pneumoniae were also analysed
to identify possible mutations within pmrA. The PCR was performed as described
before in Chapter 2, Section 2.13 . The resulting sequences were compared against
the pmrA sequence in the GenBank database shown in Figure 3.18.
3.6.4.1 Genetic Analysis ofpmrA of Moxifloxacin Resistant Mutants Derived
from S. pneumoniae R6
The pmrA gene was found to be present in all the mutants generated from the
S. pneumoniae R6 (See Figure 3.19). Similarly, all the clinical isolates tested
exhibited the presence of the efflux pump pmrA. Cla\ digestion of both sets of
isolates indicated the resultant amplimers were consistent with that of Clal restricted
pmrA PCR product amplified from S. pneumoniae P1Z1/IN27 (See Figure 3.20).
Four isolates (R6, 1TS7, 1TS9, 3TS53 and 4TS67) that exhibited a reduction in the
presence of reserpine was chosen for sequence analysis.
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30 tc aga acc age ttc tta ate aag tgc ata tcc ttc ttg agg gag gta ggc aag
84 atg aca gag att aac tgg aag gat aat ctg cgc att gcc tgg ttt ggt aat ttt
M T E I N W K D N L R I A w F G N F
138 ctg aca gga gcc agt att tct ttg gtt gta cct ttt atg CCC ate ttc gtg gaa
L T G A S I S L V V p F M p I F V E
192 aat eta ggt gta ggg agt cag caa gtc get ttt tat gca ggc tta gca att tct
N L G V G S Q Q V A F Y A G L A I S
246 gtc tct get att tcc gcg gcg etc ttt tct cct att tgg ggt att ctt get gac
V S A I S A A L F S p I W G I L A D
300 aaa tac ggc cga aaa ccc atg atg att egg gca ggt ctt get atg act ate act
K Y G R K P M M I R A G L A M T I T
354 atg gga ggc ttg gcc ttt gtc cca aat ate tat tgg tta ate ttt ctt cgt tta
M G G L A F V P N I Y W L I F L R L
408 eta aac ggt gta ttt gca ggt ttt gtt cct aat gca acg gca ctg ata gcc agt
L N G V F A G F V P N A T A L I A S
4 62 cag gtt cca aag gag aaa tea ggc tct gcc tta ggt act ttg tct aca ggc gta
Q V P K E K S G S A L G T L S T G V
516 gtt gca ggt act eta act ggt ccc ttt att ggt ggc ttt ate gca gaa tta ttt
V A G T L T G P F I G G F I A E L F
570 ggc att cgt aca gtt ttc tta ctg gtt ggt agt ttt eta ttt tta get get att
G I R T V F L L V G S F L F L A A I
624 ttg act att tgc ttt ate aag gaa gat ttt caa cca gta gcc aag gaa aag get
L T I C F I K E D F Q P V A K E K A
678 att cca aca aag gaa tta ttt acc teg gtt aaa tat ccc tat ctt ttg etc aat
I P T K E L F T S V K Y P Y L L L N
732 etc ttt tta acc agt ttt gtc ate caa ttt tea get caa teg att ggc cct att
L F L T S F V I Q F S A Q S I G p I
786 ttg get ctt tat gta cgc gac tta ggg cag aca gag aat ctt ctt ttt gtc tct
L A L Y V R D L G Q T E N L L F V S
840 ggt ttg att gtg tcc agt atg ggc ttt tcc age atg atg agt gca gga gtc atg
G L I V S S M G F S S M M S A G V M
894 ggc aag eta ggt gac aag gtg ggc aat cat cgt etc ttg gtt gtc gcc cag ttt
G K L G D K V G N H R L L V V A Q F
948 tat tea gtc ate ate tat etc etc tgt gcc aat gcc tct age ccc ctt caa eta
Y S V I I Y L L C A N A S S P L Q L
1002 gga etc tat cgt ttc etc ttt gga ttg gga acc ggt gcc ttg att ccc ggg gtt
G L Y R F L F G L G T G A L I p G V
1056 aat gee eta etc age aaa atg act ccc aaa gcc ggc att teg agg gtc ttt gcc
N A L L S K M T P K A G I S R V F A
1110 ttc aat cag gta ttc ttt tat ctg gga ggt gtt gtt ggt ccc atg gca ggt tct
F N Q V F F Y L G G V V G P M A G S
1164 gca gta gca ggt caa ttt ggc tac cat get gtc ttt tat gcg aca age ctt tgt
A V A G Q F G Y H A V F Y A T S L C
1218 gtt gcc ttt agt tgt etc ttt aac ctg att caa ttt cga aca tta tta aaa gta
V A F S c L F N L I Q F R T L L K V
1272 aag gaa ate
K E I
Figure 3.18: DNA Nucleotide Sequence of 1.2kb PCR Product Encompassing
the pmrA Gene from S. pneumoniae P1Z1/IN27 (Accession Nu: AJ007367).
Letters under the nucleotide sequence show the deduced protein sequence. Amino acid residues are
numbered at the right by analogy with the start codon ATG. Nucleotide residues highlighted in bold
indicate the forward and reverse primers used in the PCR. Underlined sequence indicates the
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Figure 3.19: PCR Analysis Showing the Presence ofpmrA Derived Products in
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Figure 3.20: Restriction Analysis Showing the Amplimers Generated from the
Cleavage ofpmrA Derived Products
179 Results
Strain PmrA Change MIC
Moxifloxacin Moxifloxacin
+ Reserpine
R6 — 0.0625 0.0625
1TS7 — 0.5 0.125
1TS9 — 0.5 0.125
3TS53 — 4 1
4TS67 — 4 1
Table 3.24: Sequencing Results for pmrA Gene in Mutants Showing an Efflux
Phenotype
There were no variations within the pmrA gene of the sensitive parent strain
S. pneumoniae R6 and the subsequent mutants derived from it (See Table 3.24). This
result indicates that no changes within the region bidirectionally sequenced can be
attributed to the altered efflux phenotype observed with these mutants.
3.6.4.2 Genetic Analysis ofpmrA in Clinical Isolates of S. pneumoniae
To identify any possible genetic changes within the pmrA gene that may contribute to
decreased ciprofloxacin sensitivity in addition to or in the absence of target
mutations, selected clinical isolates of S. pneumoniae were analysed through PCR
and bi-directional dideoxy sequencing (See Figure 3.21). All relevant changes were
compared to the GenBank entry of the gene pmrA that was cloned and sequenced
from P1Z1/IN27.
No changes were observed within the 132 bp region overlap amplified by both the
forward and reverse primers (See Table 3.25). Other nucleotide changes were
observed with both the forward and reverse primers separately but since these were
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not verified with bi-directional sequencing, the changes were not considered to be
true substitutions within the efflux gene.






















Figure 3.21: PCR Analysis Showing the Presence ofpmrA Derived Products in
Clinical Isolates of S. pneumoniae.







P1Z1/IN27 2 0.5 — — —
7368 4 1 Silent n/t change
Gly 128 —► Gly,
AA change
Lys 137 —> Asn
7386 2 0.5 — — —
251 8 2 — — -—•
5770 8 2 — — —
11080 2 0.5 — — —
6113 8 2 — — —
Table 3.25: Sequencing Results for pmrA Gene in Clinical Isolates with
Decreased Ciprofloxacin Sensitivity
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3.6.5 Northern Blot Analysis of Fluoroquinolone Resistant Mutants
The results presented in the previous sections indicate that reserpine mediated
inhibition ofpmrA increases sensitivity to the older quinolones like ciprofloxacin and
norfloxacin. The data presented on S. pneumoniae R6 moxifloxacin mutants
indicates that reserpine inhibition of the efflux pump can also result in the reduction
to moxifloxacin MICs. This is in contrast to the known efflux profile of the pmrA
pump (Brenwald et al, 1997; Gill et al. 1999). Genetic analysis of the pmrA pump
within these moxifloxacin mutants has identified no mutations within the pumps to
explain the altered substrate profile. Accumulation assays done on both the R6 and
P1Z1/IN27 derived mutants have shown a decrease in uptake of the quinolone
thereby indicating the involvement of an uptake barrier. Therefore, to ascertain the
contribution of pmrA efflux expression within characterised moxifloxacin mutants,
gene expression studies were done. The substrate profile of pmrA was further
investigated by induction studies using S. pneumoniae R6, S. pneumoniae 285 and
S. pneumoniae P1Z1/IN27. The strategy used to investigate this, was based upon the
transfer of total RNA onto positively charged membrane and subsequent detection
using DIG luminescent system.
3.6.5.1 Labelling of DIG Probe
PCR was employed to manufacture the probe where DIG label was incorporated into
the PCR product by using a mixture of unlabelled dntps and DIG labelled dntps. The
primers used to amplify the pmrA gene were also used in this reaction. Due to the
labelled dntps, the PCR product size increased in comparison to the unlabelled probe.
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The probe was digested with Cla 1 to ensure that the correct amplimers were




Figure 3.22: Agarose Gel Electrophoresis of P1Z1/IN27 Probe PCR Products
Agarose gel electrophoresis of labelled and unlabelled PCR products for use in the Northern blot
hybridisations. Template DNA used in the PCR was derived from P1Z1/IN27. (L) denotes labelled
product, (U) denotes unlabelled and (R) denotes restricted with Cla\.
3.6.5.2 Agarose Gel Electrophoresis of RNA samples
As described before, the RNA samples were electrophoresced on a 1% denaturing
formaldehyde gel where all samples were denatured prior to loading onto the gel.
Since spectophotometric standardisation of RNA samples was found to be unreliable
and subsequent handling of the tubes introduced RNAses into the samples all
bacterial cultures were standardised to an optical density of 0.6 at 600nm prior to
RNA extraction procedures. Transfers were mounted using a downward alkaline
transfer with 20 x SSC for exactly 3 hours prior to immobilisation ofRNA by baking
the membrane for 2 hours. Following that, all gels were stained with ethidium
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bromide to ensure that the transfer of RNA from membrane to gel was complete.
Hybridisation was performed overnight at 42°C, with the DNA labelled probe.
Detection was done as per the manufacturer's instructions. The developed blot was
visualised upon exposure to X-ray film.
3.6.5.3 Northern Blot Analysis
Three moxifloxacin mutant series were chosen for analysis (S. pneumoniae R6 series,
S. pneumoniae 285 mutant series and S. pneumoniae P1Z1/IN27 mutant series).
Total RNA extracted from both S. pneumoniae 285 mutant series and S. pneumoniae
P1Z1/IN27 mutant series were separated on a denaturing formaldehyde gel (See
Figure 3.23 and Figure 3.24).
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Figure 3.23: RNA Gel Electrophoresis of 285 Series Mutants
Although attempts at RNA extraction from S. pneumoniae R6 mutant series were
successful, upon electrophoresis smears were seen instead of 2 distinct bands
indicating RNA degradation. Since the methodology used in the extraction of RNA
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was similar with the other mutants, other factors such as endogeneous endonucleases
were considered responsible. Due to time constraints, northern blot analysis of this
mutant series was not explored further.
Figure 3.24: RNA Gel Electrophoresis of Efflux Mutant Series
3.6.5.4 Northern Blot Analysis of Efflux Mutant Series Derived from
P1Z1/IN27
The northern blot analysis of efflux mutant series P1Z1/IN27 clearly shows that only
the parent P1Z1/IN27 (pmrA efflux pump hyperexpresser) and first-step mutant
(EfflO) have produced a positive result (See Figure 3.25). A very faint signal is
observed with Eff50. All other mutants (Eff21, Eff25 and Eff49) failed to
demonstrate a positive hybridisation signal with the pmrA probe. Thus, it is possible
to suggest that moxifloxacin challenge downregulates the gene expression ofpmrA in
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Figure 3.25: Northern Blot Analysis of Efflux Mutant Series Derived from
P1Z1/IN27
3.6.5.5 Northern Blot Analysis ofMutant Series Derived from Clinical Isolate
S. pneumoniae 285
Examination of the blot developed from S. pneumoniae 285 and its subsequent
mutants (285, 285/3, 285/7, 285/31, 285/65 and 285/75) yielded no positive signals.
The observation that no transcipted gene message was detected for the pmrA efflux
pump gene possibly indicates either down regulation of the gene after moxifloxacin
challenge or that the expression of this efflux gene is not constitutive but inducible.
However, to confirm the absence of a positive result with the 285 mutant series, a
new strategy was devised. Instead of performing a gel to membrane transfer, a RNA
dot blot was done. Total RNA samples were dot blotted onto positive charged
membrane and probed with pmrA under the same conditions as described before.
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3.6.5.6 Northern Dot Blot Analysis of Efflux Mutant Series Derived from
P1Z1/IN27
Northern dot blot analysis showed parent strain P1Z1/IN27 and EfflO hybridised
with the probe and this observation concurred with the result obtained through
northern blot analysis with one exception. Two second-step mutants (Eff49, Eff50)
also produced a positive signal (See Figure 3.26). The other mutants Eff21 and Eff25








Figure 3.26: Northern Dot Blot Analysis of Efflux Mutant Series Derived from
P1Z1/IN27
3.6.5.7 Northern Dot Blot Analysis of Mutant Series Derived from Clinical
Isolate S. pneumoniae 285
The dot blot analysis confirmed the results obtained with the northern blots where no
positive signals were obtained with any of the mutants (Figure not shown).
3.6.5.8 Induction Experiments with Parent Strains
To investigate whether the expression of pmrA was inducible or constitutive an
induction study was done. The primary parent strains of each mutant series was
induced at half its MIC to both ciprofloxacin and moxifloxacin prior to RNA
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extraction. RNA was also obtained from the uninduced parent strains. All samples
were standardised as described before. The samples were electrophoresced (See
Figure 3.27) and probed. Interestingly, the electrophoresis profiles of the samples
indicated that efflux mutant S. pneumoniae P1Z1/IN27 yielded no RNA when
extracted in the presence of moxifloxacin and ciprofloxacin. Furthermore,
S. pneumoniae R6 produced no RNA when induced with ciprofloxacin and
S. pneumoniae 285 also yielded no RNA with moxifloxacin induction. Both RNA
dot blot and northern blot analysis were done.
Figure 3.27: RNA Gel Electrophoresis of Induced and Uninduced Parent
Strains
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3.6.5.8.1 Dot Blot Analysis of Induced Parent Strains (5. pneumoniae R6,
S. pneumoniae P1Z1/IN27 and S. pneumoniae 285)
Dot blot analysis of the three parent strains are shown in the Figure 3.28 below. All
the isolates produce a positive signal with the pmrA probe. However, there appears to
be a reduction in the intensity of the signal with the moxifloxacin induced strains.
With S. pneumoniae R6 and S. pneumoniae P1Z1/IN27, the signal intensity is less
pronounced in comparison to that produced by S. pneumoniae 285 after moxifloxacin
induction. The presence of positive signals with the moxifloxacin induced strains
indicates that either exposure to moxifloxacin induces the gene expression of pmrA






























Figure 3.28: Dot Blot Analysis of Induced Parent Strains
3.6.5.8.2 Northern Blot Analysis of Induced Parent Strains (5. pneumoniae R6,
S. pneumoniae P1Z1/IN27 and S. pneumoniae 285)
The northern blot analysis results do not concur with those of the dot blot. In this
procedure, only the uninduced RNA samples from S. pneumoniae R6 and
S. pneumoniae P1Z1/IN27 produced a positive hybridisation signal. S. pneumoniae
285 produced no hybridisation signals with both the RNA dot blot and northern blot
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Figure 3.29: Northern Blot Analysis of Induced Parent Strains
3.6.6 Concluding Remarks
Northern blot analysis of the P1Z1/IN27 mutants series does demonstrate the absence
of the relevant gene messages in first-step mutants (Eff21 and Eff25) and second-
step mutant Eff49 which suggests that as the clones acquire gene mutations the efflux
pump expression decreases. Due to the apparent lack of correlation between the
northern blot analysis and dot blot analysis, it is difficult to draw any firm
conclusions from the other experiments.
4 Discussion
4.1 Prologue
In Chapter 1, I addressed some of the questions that required answering when this
project was started, together with the questions that have been raised by the progress
of other researchers. The aims of this thesis were to ascertain the effects of different
mutational changes as different quinolone selection pressures are applied and also the
evolution of resistance mechanisms that develop with quinolone challenge in
S. pneumoniae. The use of molecular techniques such as PCR and dideoxy
sequencing clearly show that quinolone selection induces mutations within type II
topoisomerases particularly within either DNA gyrase A or topoisomerase IV. Unlike
gram-negative bacteria, where fluoroquinolone challenge consistently produces
changes within DNA gyrase A (Tavio et al, 1999) gram-positive bacteria especially
S. pneumoniae develop mutations within either parC or gyrA initially depending on
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the selecting quinolone (Fukuda & Hiramatsu, 1999). The order in which these
mutations arise has been an area of intense investigation, mainly to explain the
differences in the chronology of mutational events that lead to quinolone resistance
and also to correlate these changes to those observed within the clinical population.
The use of fluoroquinolones in the treatment of gram-positive infections particularly
those caused by S. pneumoniae began with ciprofloxacin. However, the use of this
primarily anti-gram negative quinolone against S. pneumoniae has in some cases led
to treatment failure (Perez-Trallero et al, 1990) and to the subsequent emergence of
ciprofloxacin resistant pneumococcal isolates (Piddock et al, 1998; Jones et al,
2000). Recent international initiatives such as the Alexander and Sentry projects
aimed at monitoring the spread of antibiotic resistance, have indicated an increasing
prevalence of 13-lactam or macrolide resistant pneumococci in addition to the
emergence of quinolone resistant pneumococci (Felmingham & Washington, 1999).
This scenario has demanded new therapeutic options and has led to the development
and production of the extended-spectrum quinolones.
Moxifloxacin is a new generation quinolone that has been shown to exhibit enhanced
activity against primary respiratory pathogens such as S. pneumoniae, H. influenzae
and M. catarrhalis (Dalhoff et al, 1996; 1999). Therefore, the initial focus of this
project was to examine the activity of this new quinolone against respiratory
pathogens collected from centres around the United Kingdom. However, when this
survey was proposed, questions regarding the testing protocols used to determine the
sensitivity profiles were raised.
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4.2 To Carbon Dioxide or Not To?
Generally, susceptibility testing procedures rely on the use of standardised methods
that are appropriate for the species being tested. These specifications include
inoculum preparation, usage of appropriate test medium and incubation conditions.
The majority of the newer quinolones are targeted towards respiratory pathogens,
which are traditionally isolated and tested in a carbon dioxide (CCb) rich atmosphere.
The sensitivity testing of these quinolones against respiratory pathogens has often
followed the same incubation conditions despite the knowledge that the antibacterial
action of some antibiotic classes may be antagonised. The BSAC guidelines (Phillips
et al, 1991) state that carbon dioxide incubation has been shown to affect
antibacterial agents such as the macrolides, quinolones and aminoglycosides.
Furthermore, a survey of clinical respiratory isolates examining the activity of BAY
12-8039 (moxifloxacin) by Bruggemann et al (1997) demonstrated that significant
increases in MIC were observed when incubations done in 5-7% CCb were
compared with ambient air conditions. Analysis of pH values on agar surfaces
indicated a significant reduction when incubated in a carbon dioxide rich atmosphere
in comparison to that in air. The reduction in pH is perhaps, able to either diminish
the antibacterial activity of moxifloxacin or affect the growth of the test organisms
due to the low pH.
Therefore, to investigate the effect of 5% carbon dioxide incubation on the
fluoroquinolones, MIC testing under normal atmospheric incubation and in a CCT-
rich atmosphere were assessed by two methods; namely the doubling agar dilution
and the Epsilon test methods. The sensitivities of 18 NCTC standard strains both
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traditional respiratory pathogens and hospital pathogens were measured by both
sensitivity methods and under both incubation conditions. The MICs were
determined, by the doubling agar dilution method and the Epsilon test, for
trovalloxacin, moxifloxacin, grepafloxacin, ciprofloxacin and levofloxacin. The
differences in MIC values were considered significant when 2-4 fold differences
between reduced air (5% carbon dioxide) and air incubations were observed.
Increases in the quinolone MICs were observed with bacteria that are normally
grown in a reduced air atmosphere as well as with those that are not. The greatest
MIC increments were observed with both S. pneumoniae and Ps. aeruginosa when
tested against moxifloxacin. Ciprofloxacin and moxifloxacin recorded the highest
increases against S. pneumoniae where two to eight-fold increases in the MIC were
observed when incubations were done in carbon dioxide. Against Ps. aeruginosa,
moxifloxacin recorded a four-fold increase in the MIC when incubated in carbon
dioxide in comparison to air, although similar increments were not observed with
trovafloxacin and ciprofloxacin. MIC determinations recorded from the Epsilon test
method concur with the results obtained with the doubling agar dilution method. If
the increments observed within the 5% carbon dioxide incubations were, considered
to be genuine, then NCTC strains like S. pneumoniae NCTC 13593 would be
reclassified as being quinolone resistant.
Carbon dioxide incubation has been used in the isolation of respiratory pathogens
such as S. pneumoniae, H. influenzae and M. catarrhalis and subsequently employed
in the susceptibility testing procedures involving these pathogens. Studies
investigating the apparent requirement of reduced air conditions for growth have
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shown that carbon dioxide incubation is not a prerequisite for growth of these
organisms. A study conducted by Flanagan & Paull (1998) showed that most of the
clinical pneumococci and H. influenzae isolates were able to grow in an aerobic
environment following initial isolation in CO2. This observation is concurred by
BSAC where it was found that 40% of S. pneumoniae and 20% of H. influenzae
isolates required CO2 for initial growth (Wise, 1999). Investigators have also found
that when determining the susceptibilities of these pathogens to antibiotics such as
oxacillin, erythromycin, trimethoprim, tetracycline and the macrolides, accurate
results were obtained in ambient air conditions rather than in 5% CO2 (Flanagan &
Paull, 1998; Weightman & Barnham, 2000).
All the studies that have evaluated the activity of antimicrobials when tested under
reduced air conditions have shown that the MIC results presented after carbon
dioxide incubation overestimates the number of resistant strains particularly with the
macrolides in comparison to air incubation (Johnson et al, 1999; Flanagan & Paull,
1998; Weightman & Barnham, 2000). Furthermore, all investigators agree that
reduced oxygen conditions play a role in either degrading the antibiotic or acidifying
the media which compromises the action of the antibiotics tested (Jacobs, 1999;
Bruggemann et al 1997; Phillips et al, 1991; Weightman & Barnham, 2000).
Bruggemann et al (1997) were able to show a reduction in pH on the surface of the
agar after carbon dioxide incubation from pFl 7.6 to 6.97. Although, in this study
actual pH readings were not measured, the results show substantial increases were
observed in reduced air conditions in comparison to incubation in air, suggesting that
the increments with 5% carbon dioxide incubations observed here may also be due to
media acidification.
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Some investigators argue that carbon dioxide incubation is a relevant method of
testing as respiratory pathogens reside in conditions where high partial pressures of
carbon dioxide are known to exist (Johnson et al, 1999). Therefore, evaluating
activity within these conditions portrays the true activity of the antibiotic. Although
this may be a valid suggestion, it has to be conceded that the dynamic in vivo
conditions are impossible to reproduce within the in vitro testing conditions. Perhaps,
one possibility is to modify the test media to eliminate the pH reduction factor and
resolve the subsequent discrepancies observed with the carbon dioxide and air
incubation methods. Studies investigating macrolide sensitivities have shown that the
MIC values vary only by a maximum 2-fold difference between the air and reduced
air conditions when testing was done on pH adjusted media (Johnson et al, 1999;
Ednie et al, 1998).
Controlled standardised methods are essential in evaluating and producing
surveillance data. Here, we have shown that carbon dioxide incubations can
undermine the potency of antimicrobial compounds leading to false interpretations of
susceptibility data. Although MIC determinations are not solely used in the
evaluation of antibacterial activity, it is a standard procedure used in most clinical
and research laboratories, therefore clear recommendations are needed especially
with the recent introduction of anti-gram-positive quinolones. Carbon dioxide
incubation may be a crucial component in the isolation of respiratory strains but is
clearly unsuitable for susceptibility testing.
196 Discussion
4.3 Moxifloxacin Sensitivity Study
Currently, acute respiratory tract infections (RTI) are the third-highest cause of
morbidity and mortality worldwide (WHO report, 1997). Antimicrobial resistance in
the causative pathogens of respiratory tract infections are increasingly common
(Grtineberg et al, 1996). International initiatives such as the Alexander Project and
the Sentry Project have identified a need for continuing surveillance data to monitor
the rise in antibiotic resistance in respiratory pathogens. Both studies have clearly
outlined a rise in antimicrobial resistance within respiratory isolates and regional
variations in resistance patterns have been shown to exist (Baquero et al, 1991).
Although the surveillance data has identified B-lactam and macrolide resistance, the
effects of widespread fluoroquinolone use in community acquired respiratory
infections are largely not known. Therefore, to evaluate the in vitro activity of the
new anti-gram positive quinolones particularly moxifloxacin in comparison to the
currently available antibacterial agents, a UK wide sensitivity survey was performed.
The sensitivity survey chose to focus on the three major respiratory pathogens
S. pneumoniae, H. influenzae and M. catarrhalis. A total of 909 clinical isolates were
collected from nine centres around the UK and sent to Edinburgh prior to sensitivity
testing.
One of the advantages of this study was that organism identification and MIC
determinations were undertaken by the same laboratory thereby removing the doubt
that differences could be attributed to methodological variations and interpretation.
However, a disadvantage is the nature of denominator data, which can introduce a
bias, as the reasons for the sample being sent to the laboratory were not known.
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Furthermore, the genetic relatedness of the clinical isolates and pertinent details such
as previous antibiotic therapy and patient age were not provided. The lack of this
information does compromise the true value of the results produced by the survey.
Nevertheless, the sensitivity data do provide an insight into the efficacy of the newer
fluoroquinolones as therapeutic agents against clinical respiratory isolates. The
results obtained for this survey are presented in Chapter 3, Section 3.3 .
Against S. pneumoniae (n = 257), the 13-lactams (penicillin, cefotaxime) and
clarithromycin were found to exhibit similar activity where 90% of the isolates were
inhibited at lmg/1. Similar in vitro activities for these antibiotics have been reported
previously by Zhanel et al (2000). Generally, the in vitro activities of the 13-lactams
(penicillins and cephalosporins) and macrolides (clarithromycin) are interlinked
since surveillance reports have highlighted an increasing prevalence of
pneumococcal strains that are cross resistant to both the B-lactams and macrolides
(Felmingham & Washington, 1999).
Against S. pneumoniae the rank order of activity was moxifloxacin > grepafloxacin >
trovafloxacin = sparfloxacin > ciprofloxacin = levofloxacin. Ciprofloxacin and
levofloxacin resistance have been reported in S. pneumoniae as both agents have not
been found to be as active as the other new quinolones (Piddock et al, 1998)
Tetracycline demonstrated the least activity against S. pneumoniae with an MIC90 of
32mg/l. Similar to the emergence of B-lactam resistance, the increase in tetracycline
resistance has been found to be proportional to its use in Spain (Baquero et al, 1991).
The lack of such data within the UK does not allow comparisons between clinical
usage of the drug and the elevated tetracycline MIC reported here.
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The results presented here generally agree with previous sensitivity data, where the
newer extended-spectrum quinolones exhibit improved activity against
pneumococcal isolates (Woodcock et al, 1997; Dalhoff, 1999, Felmingham &
Washington, 1999). The fluoroquinolones were found to be equally active against
S. pneumoniae regardless of penicillin susceptibility. Generally, this observation is
confirmed by Felmingham & Washington (1999) and Barry et al (1996), although
some surveillance reports report a link between penicillin and quinolone resistance
(Chen et al, 2000; Goldsmith et al, 1998). The association between penicillin and
quinolone resistance has no theoretical basis, as it is well known that the mechanisms
of resistance to both antibiotic classes are distinct. Surveillance studies have shown
an increasing prevalence of macrolide and penicillin resistant pneumococcal strains,
which evidently require other therapeutic options. Thus, it is possible that the link
between penicillin and ciprofloxacin resistance is due to the increased use of
quinolones against resistant pneumococcal isolates. In fact, two studies by Goldsmith
et al (1998) and Chen et al (2000) have shown that the increased use of ciprofloxacin
against resistant strains corresponded to the rise of penicillin, macrolide and
quinolone resistant pneumococci. A further possibility is the clonal spread of
ciprofloxacin resistant strains although there is no current data to support this.
Against gram-negative rods, all the fluoroquinolones, were found to be extremely
active although ciprofloxacin and levofloxacin were less antibacterial than the other
extended-spectrum fluoroquinolone agents tested. Against H. influenzae,
levofloxacin was found to be less active than ciprofloxacin where 90% of the isolates
were inhibited at 0.0625mg/l. Similar results were observed with M. catarrhalis,
where 90% of the isolates were inhibited at 0.125-0.5mg/l to all the fluoroquinolones
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with moxifloxacin, sparfloxacin, levofloxacin and ciprofloxacin being the most
active. This result is concurred by (Felmingham & Washington, 1999; Woodcock et
al, 1997). The tentative breakpoint recommendation for moxifloxacin versus
S. pneumoniae, H. influenzae and M catarrhalis is >2mg/l for resistant and <lmg/l
for sensitive strains (Andrews et al, 1999). All the respiratory pathogens tested
exhibit sensitivity to moxifloxacin and were well within the recommended
breakpoint value.
The major mechanism of resistance evident amongst clinical isolates of both
H. influenzae and M. catarrhalis is (3-lactamase production. Data from the Alexander
Project (Felmingham & Washington, 1999) and other studies (Doern et al, 1996)
have shown that over 30% of H. influenzae and 90% of M. catarrhalis strains
produce (3-lactamases which effectively renders the use of the aminopenicillins
against these species futile. In the UK, the prevalence of amoxycillin resistance in
H. influenzae has been reported at 14% and in this survey 8.2% of the isolates were
found to be amoxycillin resistant based on the BSAC breakpoints. These results are
similar to those reported by Richard et al (1998).
Against M. catarrhalis, amoxycillin was found to be the least active agent tested
where 90% of isolates were inhibited at 16mg/l. None of the M. catarrhalis and
H. influenzae isolates tested exhibited resistance to the amoxicillin/clavulanic acid
combination (based on NCCLS breakpoint recommendations of 4mg/l) which
concurs with the results of the Alexander Project data (Felmingham & Washington,
1999). Clarithromycin possessed poor activity against all three respiratory pathogens
particularly against H. influenzae (8mg/l). Although, human volunteer studies on the
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intrapulmonary distribution of clarithromycin demonstrated higher concentration of
these agents in epithelial lining fluid than in serum (Rodvold et al, 1999) thereby,
indicating that the MIC value for this agent may not correlate with its in vivo activity.
Generally, the MIC data reported for the fluoroquinolones against H. influenzae in
this survey correspond with the values presented by Bruggemann et al (1997), which
were four times lower than other sensitivity reports (Reinert et al, 1998). The similar
values obtained for H. influenzae in this survey with those of Bruggemann et al
(1997) can be explained by the similar incubation conditions employed. However,
the values obtained for both S. pneumoniae and M. catarrhalis for moxifloxacin are
four and two fold higher than that obtained by Bruggemann et al (1997), although the
MIC data for both pathogens corresponds to the results of other investigators (Sahm
et al, 2000; Bauernfeind, 1997; Andrews, 2000).
4.4 Structure-Activity Relationships
The fluoroquinolones studied here structurally differ at positions Ri, R7 and Xg (See
Figure 1.1a). The sensitivity data presented here allows the analysis of specific
structure-activity relationships of quinolone action against S. pneumoniae. The
enhanced activity demonstrated by the anti-gram-positive quinolones like
moxifloxacin, grepafloxacin, trovafloxacin and sparfloxacin in comparison to
ciprofloxacin (4 to 8 times less active) were found to be restricted to structures that
carry novel modifications at position C7.
Trovafloxacin and moxifloxacin possess an azabicyclo substituent, whereas
grepafloxacin, sparfloxacin and levofloxacin retain a piperazine substituent, in
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contrast to ciprofloxacin which only has an unsubstituted piperazine ring. Substituted
piperazine-containing compounds have been shown to demonstrate greater activity
against gram-positives due to the enhanced penetration potential into bacterial cells
(Domagala, 1994). The methoxy group present at the C8 position in moxifloxacin
seem to have no noticeable effect on antibacterial potency as fluoroquinolones that
do not possess this modification (e.g. trovafloxacin) show equal activity against
S. pneumoniae.
It was difficult to associate structural variations with enhanced antibacterial activity
against both H. influenzae and M. catarrhalis as both organisms demonstrated
similar MIC values to both the older agents and the extended-spectrum
fluoroquinolones.
The unfortunate side effects associated with trovafloxacin, grepafloxacin and
sparfloxacin and the subsequent formulary withdrawal of these agents precludes their
use in the treatment of respiratory infections. Therefore, the widespread use of
moxifloxacin in the treatment of these infections is to be expected.
4.5 Genetic Mutations within Type II Topoisomerases in
Streptococcuspneumoniae: Contribution of Mutations
to Fluoroquinolone Resistance
In this section, the contribution of individual genetic mutations within the type II
topoisomerases will be analysed. The acquisition of quinolone resistance arises
through mutations or amino acid changes within the quinolone resistance
determining region (QRDR) within the subunits of DNA gyrase A (gyrA) and
topoisomerase IV (parC). Recently, the cloning and analysis of gyrB (Pan & Fisher,
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1999) and parE (Perichon et al, 1997) has identified the possible contribution of
mutations within these genes in the development of quinolone resistance. In
Chapter 3, the sequencing results of mutations in both subunits of topoisomerase IV
and DNA gyrase A obtained from clinical isolates with reduced fluoroquinolone
susceptibility and laboratory derived mutants challenged with different quinolones
were presented. The initial aim of these experiments were to determine the
intracellular targets of moxifloxacin in S. pneumoniae and to compare these
mutational changes to those that occur when pneumococci are challenged by other
quinolones. The mutational changes identified within the laboratory mutants were
then compared against the changes sustained within the clinical population.
In Streptococcus pneumoniae resistance to the fluoroquinolones has been shown to
develop in a stepwise manner through mutations within either of the target genes
(DNA gyrase A and topoisomerase IV) or the hyperexpression efflux pumps
(Hooper, 1998; Varon & Gutmann, 2000). The recent introduction of anti-gram-
positive quinolones has prompted the investigation into the development of
fluoroquinolone resistance when challenged with these new compounds. In vitro and
in vivo studies identifying fluoroquinolone induced mutational changes in gram-
negative bacteria have consistently shown that primary mutations occurs within gyrA
(Tavio et al, 1999). In S. pneumoniae, it has been shown that ciprofloxacin challenge
selects for mutations within topoisomerase IV (Pan & Fisher, 1996a). Ciprofloxacin
challenge of other gram-positive bacteria like S. aureus also induce similar changes
within grlA (parC equivalent in S. aureus) prior to changes within gyrA (Ferrero et
al, 1995). These observations led to the assumption that the primary target of the
fluoroquinolones in gram-positive bacteria is topoisomerase IV. However,
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ciprofloxacin is a primarily anti-gram-negative agent unlike moxifloxacin, which is a
broad-spectrum agent with preferential activity against gram-positive bacteria.
Therefore the question arises: do compounds with enhanced anti-gram positive
activity select for different intracellular targets? To investigate this issue, stepwise
selection of laboratory strain S. pneumoniae R6 with moxifloxacin was performed.
Of the nine first-step mutants selected, two mutants 1TS7 and 1TS9 demonstrated a
four-fold increase in the moxifloxacin MIC in comparison to the parent strain
S. pneumoniae R6. Genetic analysis of 1TS7 and 1TS9 demonstrated the presence of
a gyrA (Ser83 —* Tyr) mutation within 1TS7 and no changes in 1TS9. Further
selection of 1TS7 yielded second generation mutants that maintained the gyrA
change and also acquired a parC change. Second-step mutants derived from 1TS9
did not develop any further mutations and did not exhibit further increases in MIC to
any of the fluoroquinolones tested. Sensitivity testing of the first-step and second-
step mutants derived from 1TS7 demonstrated that the acquisition of the gyrA
mutation Ser83 —> Tyr was able to increase the MIC to both ciprofloxacin and
moxifloxacin MICs by 4-fold and eight-fold respectively. The subsequent acquisition
of the parC mutation resulted in an 8-16 fold increase in the MICs to both
ciprofloxacin and moxifloxacin. The differences observed in the MICs to both
ciprofloxacin and moxifloxacin indicate that mutations within both parC and gyrA
are able to mediate quinolone resistance but to varying levels. The initial mutation of
Ser83 —* Tyr within 1TS7 led to a higher increase in the MIC of moxifloxacin in
comparison to ciprofloxacin. The increase in MIC observed with ciprofloxacin
following the acquisition of the gyrA (Ser83 —» Tyr) mutation suggests that
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mutations within parC may not be the sole contributory factor to the decrease in
sensitivity to ciprofloxacin.
Analysis of both the parE and gyrB genes indicated no changes within these genes,
suggesting that moxifloxacin challenge does not select for changes within these
genes and in this mutation study did not contribute to the decrease to both
moxifloxacin and ciprofloxacin susceptibility as previously suggested (Pan & Fisher,
1996a). The results obtained with the S. pneumoniae R6 mutation study suggest that
the intracellular target of moxifloxacin is gyrA.
In order to confirm that gyrA is the intracellular target of moxifloxacin in other
pneumococcal isolates, two clinical pneumococcal isolates penicillin intermediate
isolate 285 and penicillin resistant isolate 158 were used to generate quinolone
resistant mutants.
Sequencing analysis of first-step mutants 285/3 and 285/7 generated from penicillin
intermediate S. pneumoniae 285, were found not to sustain any changes within the
target genes although a 2-4 fold increase to both ciprofloxacin and moxifloxacin was
observed. The increase in MIC in the absence of target mutations within the target
genes could possibly be attributed to an efflux mechanism.
The second-step mutants derived from 285/3 were found to develop a gyrA mutation
(Ser83 —* Tyr) which caused a four-fold increase to both ciprofloxacin and
moxifloxacin. Third-step mutants were found to maintain the gyrA change with an
additional mutation in parC (Ser80 —> Phe). Sensitivity testing did confirm increases
to moxifloxacin, gatifloxacin and ciprofloxacin. The resultant increases in the MIC
were found to affect gatifloxacin and ciprofloxacin more than moxifloxacin.
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With S. pneumoniae 158 both the first-step and second step mutant clones were
found not to sustain any gyrA changes. Although second-step mutants demonstrated
a four-fold increase in MIC to both moxifloxacin and ciprofloxacin. With both the
285 mutant series and the 158 mutant series, a change in parE (Val460 —> lie) was
identified in the parent strain and all subsequent mutant clones derived from it. This
substitution was not considered to contribute to quinolone resistance, as it was
present in both the moxifloxacin sensitive parent strain S. pneumoniae 285 and
S. pneumoniae 158. Furthermore, transformation experiments performed by Pestova
et al (2000) have shown that the Val460 —* He substitution does not contribute to
fluoroquinolone resistance.
Moxifloxacin challenge of different pneumococcal isolates have consistently
indicated the development of gyrA changes prior to any other genetic substitution
within the target genes. Transformation studies with S. pneumoniae R6 done by
Varon et al (1999) reported that dual mutations in both gyrA and parC were required
prior to an increase in the moxifloxacin MIC thereby suggesting that both
topoisomerases might function as simultaneous intracellular targets for moxifloxacin.
This contrasts to our findings where gyrA mutations were always the first change to
be characterised and the acquisition of the gyrA change in the mutants studied was
always accompanied by a significant MIC increase to moxifloxacin and gatifloxacin
compared with mutants that only sustain a parC change. Pestova et al (2000)
reported similar findings where the acquisition of a gyrA change resulted in a four¬
fold increase to moxifloxacin MIC (2mg/l) in comparison to the presence of a parC
change where the MIC of moxifloxacin remained at 0.25mg/l.
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Recent surveys investigating decreased fluoroquinolone susceptibility in clinical
pneumococcal isolates have indicated that the majority of clinical isolates express an
efflux phenotype (Brenwald. et al, 1998; Morrissey et al, 1999). The new
fluoroquinolone agents such as moxifloxacin are targeted towards this phenotype
within the clinical population. Therefore, the impact of moxifloxacin challenge of
pmrA efflux hyperexpresser P1Z1/IN27 was performed to ascertain the changes
induced by moxifloxacin challenge against a strain already expressing an efflux
phenotype. The stepwise selection of P1Z1/IN27 generated first-step mutants with a
Ser83 —> Phenyalanine mutation in gyrA. The acquisition of this change contributed
to a 2—4 fold decrease in sensitivity to ciprofloxacin and moxifloxacin.
From these results, it is apparent that moxifloxacin challenge institutes changes
within the gyrA gene regardless of the expression of other resistance mechanisms
(See Table 4.1).
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Table 4.1: Summary of Results presented in Thesis and Relevant Published
Data.
The different mutational studies performed here indicate a general trend v/here the
primary mutation after moxifloxacin challenge occurs in gyrA. Laboratory strain
S. pneumoniae R6 and pmrA efflux nyperexpresser P1Z1/IN27 were found to sustain
a gyrA change within the first-step mutants. Penicillin intermediate clinical isolate S.
pneumoniae 285 sustained a gyrA mutation within the second-step mutants. The sole
exception to this pattern was demonstrated by the penicillin resistant clinical isolate
S. pneumoniae 158 which sustained no changes within the QRDR of both gyrA and
parC.
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It is evident that resistance to moxifloxacin arises either through an initial mutation
within gyrA or through the induction of an efflux pump or via mutations outwith the
QRDR. It is also perhaps significant that the clinical strain S. pneumoniae 285
demonstrated the emergence of a gyrA change in the second-step mutants and S.
pneumoniae 158 sustained no mutational changes within both the first and second
generation mutants, which is in contrast with the resistance development observed
within the first step mutants generated from the laboratory strains S. pneumoniae R6
and the pmrA efflux hyperexpresser P1Z1/IN27. This observation implies that fitter
strains are able to stave off the emergence of genetic mutations through adaptation or
by employing other mechanisms of resistance.
Generally, factors that contribute to the antibacterial potency of the fluoroquinolones
are the kinetics of drug uptake and the ability to inhibit DNA gyrase or
topoisomerase IV. The results presented in this thesis show that the extended-
spectrum quinolones like moxifloxacin that primarily target S. pneumoniae mediate
through DNA gyrase. The different antibacterial activity of both moxifloxacin and
ciprofloxacin against S. pneumoniae suggest that the quinolones interact with the
pneumococcal topoisomerases in a different manner.
To investigate, mutants were generated from both ciprofloxacin and norfloxacin
challenge. Both ciprofloxacin and norfloxacin generated mutants that sustained
mutations within topoisomerase IV. Sequencing analysis of these parC mutations
indicated the change to be either Serine80 —> Phenylalanine or Serine80 —> Tyrosine
(This thesis, Pan & Fisher, 1997; Fukuda & Fliramatsu, 1999). Sensitivity testing of
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these characterised mutants demonstrated that the parC mutations had a minimal
effect on the antibacterial activity of both moxifloxacin and gatifloxacin.
Studies by Pestova et al (2000) have also identified a similar effect attributing the
enhanced antibacterial activity to the structural modifications in moxifloxacin and
gatifloxacin which, indicate that the primacy of target mutations is dependent on the
selecting agent. The selective preference of DNA gyrase A or topoisomerase IV by
the fluoroquinolones appear to be dependent on the structural characteristics of the
fluoroquinolone molecule.
Sequencing analysis of the QRDR of quinolone-resistant S. pneumoniae challenged
with different quinolones has demonstrated a general trend. The first group of
quinolones, whose prototypes are ciprofloxacin (Pan & Fisher, 1996a; This thesis)
and norfloxacin (Fukuda & Hiramatsu, 1999; This thesis) select for parC or parE
mutations, suggesting that these drugs act preferentially through topoisomerase IV in
vitro, whereas a second group, typified by sparfloxacin (Pan & Fisher, 1997)
gatifloxacin (Fukuda & Ffiramatsu, 1999) and moxifloxacin (Pestova et al, 2000;
This thesis) select for gyrA mutants in vitro. Clinafloxacin (Pan & Fisher, 1998) and
gemifloxacin (Fleaton et al, 2000) appear to act through both enzymes. The major
structural variations sustained by all the quinolones are found in either the C7 or C8
position.
Recent studies by Alovera et al (2000) have also shown that substitutions at the C7
position within the quinolone pharmacore can markedly affect the potency of the
quinolone and change the specificity target of the quinolone from topoisomerase IV
and DNA gyrase in S. pneumoniae. Furthermore, studies involving the mammalian
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topoisomerase II have shown that the inhibitory action of quinolones is dramatically
increased when methyl groups are added to the C7 position, this observations
suggesting that topoisomerase II directly interacts with the C7 substituent (Elsea et
al, 1993; Gootz et al, 1994). Structural analysis of moxifloxacin and ciprofloxacin
indicates that moxifloxacin possesses an azabicyclo modification at position 7 and in
contrast ciprofloxacin has an unsubstituted piperazinyl ring. The in vitro mutation
studies presented here involving both quinolones show a selective targeting of DNA
gyrase by moxifloxacin and topoisomerase IV by ciprofloxacin. In the light of
studies by Alovera et al (2000) and Gootz et al (1994), it is tempting to speculate that
modifications within the C7 position are responsible for target preferences between
these proteins. However, since the involvement of the other quinolone modifications
have not been determined it is perhaps premature to attribute the preferential
targeting of gyrA over parC to the C7 position only. Furthermore quinolones such as
trovafloxacin which also possess modifications at position C7 mediate through
topoisomerase IV instead of DNA gyrase A which questions the contributory role of
substituents at position 7 (Gootz et al, 1996).
The results of the mutation studies have shown that substitutions within different
genes i.e. DNA gyrase A or topoisomerase IV have variable effects on
fluoroquinolone sensitivity. The results from the mutations involving S. pneumoniae
R6, S. pneumoniae 285 and S. pneumoniae 158 mutants series have clearly shown
that gyrA mutations affect the activities of both moxifloxacin and ciprofloxacin. The
parC changes in both the ciprofloxacin and norfloxacin mutants have shown that
these changes have a minimal effect on quinolones like moxifloxacin and
gatifloxacin.
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Fukuda and Hiramatsu (1998) have used these differences as a marker to determine
the intracellular targets of the different quinolones. The results from their
experiments showed that mutants could be classified into three types: mutants
possessing single-point mutations within the QRDR of the parC gene and found to
be cross resistant to the selecting agents (ciprofloxacin and levofloxacin) and not
sparfloxacin and gatifloxacin; the second mutant type sustained point mutations
within the QRDR of the gyrA gene where cross resistance was observed towards the
selecting agents gatifloxacin and sparfloxacin but not towards the other quinolones;
and the third type which sustain no mutations within the QRDR but are cross
resistant to compounds like ethidium bromide and thus are categorised as efflux
mutants.
Our findings are generally in agreement to that identified by Fukuda and Hiramatsu
(1999). Although, the results presented in Chapter 3, Section 3.5 , indicates that the
acquisition of a single gyrA mutation is able to confer increases to both the older and
newer agents and parC changes are limited to instituting increases to agents such as
norfloxacin and ciprofloxacin. Analysis of the first-step mutants with no target
mutations but increased moxifloxacin MICs does suggest that these clones may be
efflux mutants, although no concurrent increases to other efflux substrates like
tetracycline and ethidium bromide were observed.
The fundamental question, however, is whether these results generated in vitro
reflect the progression of resistance in clinical isolates. It is difficult to assess the in
vivo emergence of resistance to any antibiotic as the acquisition of target mutations
can be due to pre-selection by other agents of the same class or that clinical isolates
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generally sustain multiple mutations. Genetic analysis of pneumococcal isolates with
high-level resistance to the fluoroquinolones indicates the presence of at least one
mutation within either DNA gyrase or topoisomerase IV (Jones et al, 2000; Bast et
al, 2000a).
Sequencing analysis of clinical isolates indicates that low level resistance to
ciprofloxacin typically arises following an amino acid substitution for Ser79 or
Asp83 in ParC and that intermediate to high level resistance is achieved through
subsequent mutations at Ser81 or Glu85 in GyrA (Janoir et al, 1996) where, the
acquisition of these gyrA mutations in combination with a parC change is able to
increase the MIC to both the older comparators like ciprofloxacin and the newer
extended-spectrum quinolones like moxifloxacin (This thesis; Pestova et al, 2000).
This observation supports our results, where gyrA mutations singly or in combination
with parC changes have been shown to decrease sensitivity to all the
fluoroquinolones tested. The vast majority of studies analysing the mutations within
fluoroquinolone resistant isolates indicate that substitutions within parC occur more
frequently than changes within gyrA which always develop in combination with
parC changes (Pestova et al, 2000). However, recent data by Jones et al (2000)
showed that of 69 pneumococcal isolates tested 5 isolates sustained single point
mutations in gyrA and this one change was sufficient to induce resistance to both the
extended-spectrum quinolones and older agents such as ciprofloxacin.
The in vitro studies presented in this thesis also indicate a similar role for gyrA. The
appearance of sole gyrA mutations indicate that these mutations are stable in vivo and
provide support for the results obtained in the in vitro mutation studies presented
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previously. However, it has to be conceded that the number of clinical studies
illustrating the role of single gyrA mutations are few and further data are required.
The cloning of parE and gyrB has identified other quinolone target sites within
bacteria. Analysis of clinical isolates and laboratory mutants has identified a role for
parE and gyrB changes in contributing to fluoroquinolone resistance, although we
have not been able to assign a significance to either change in our studies. The only
parE (Val460 —» lie) change identified here has been shown not to contribute to
fluoroquinolone resistance (Pestova et al, 2000). Also, the majority of in vitro studies
and genetic analysis of clinical isolates have been unable to identify mutations within
gyrB that can be attributed to fluoroquinolone resistance (This thesis; Jones et al
2000; Janoir et al, 1996). The obvious rarity of gyrB and parE changes question the
contribution of these changes to quinolone resistance and the stability of these
mutations in vivo.
Current sequencing data of clinical isolates have shown a multitude of single amino
acid changes in fluoroquinolone resistant pneumococci (Jones et al, 2000; Bast et al,
2000a), however the primary question is whether all mutations within the
topoisomerases contribute to fluoroquinolone resistance. Generally, sequencing data
obtained from clinical isolates are compared against standard NCTC strains available
within the GenBank database. Unfortunately, these comparisons underscore the
biovariation that exists when investigating a diverse collection of clinical isolates in
contrast to studying the contributions of individual mutations within isogenic
laboratory mutants. This observation is exemplified by the results that many isolates
with significant mutation(s) exhibit MICs overlapping those for wild type isolates
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(See Chapter 3, Table 3.7). This overlap is most apparent with MICs required by
isolates possessing single alterations such as Lysl37 —> Asn and Asp83 —> Asn in
ParC or Val460 —> He in ParE demonstrating the minimal impact of these mutations
on susceptibility. Only, transformation studies or site-directed mutagenesis can
ascertain the role of these changes in the development of fluoroquinolone resistance.
The mutations (Ser83 —■> Tyr/Phe in gyrA and Ser80 —* Tyr/Phe in parC) identified
in this thesis have been shown to directly affect the activities of the fluoroquinolones
through transformation studies (Pestova et al, 2000; Janoir et al, 1996; Varon et al,
1999) and thus indicate that changes within gyrA and parC are predominant
mutations that impact significantly in the development of fluoroquinolone resistance.
The data presented so far has elucidated the role of target mutations in
fluoroquinolone resistance. The recent identification of the pneumococcal efflux
pump pmrA suggests that this mechanism could contribute to fluoroquinolone
resistance both in the absence and presence of target mutations. Recent studies have
shown that efflux mediated resistance contributes to decreased fluoroquinolone
susceptibility in 10-20% of clinical pneumococcal isolates (Brenwald et al, 1998;
Morrissey et al, 1999) and has been shown to contribute to low levels of
fluoroquinolone resistance in clinical isolates (Brenwald et al, 1998). In this study,
the contribution of efflux pump expression in moxifloxacin challenged mutants and
wild type clinical isolates was examined.
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4.6 Contribution ofEfflux pump expression to
Fluoroquinolone Resistance in S. pneumoniae
To examine the contribution of efflux pumps a phenotypic method was employed
using the efflux pump inhibitor reserpine. Initially, the MICs of all the mutants from
the different mutation series were determined and the results are presented in
Chapter 3, Section 3.6 . All the mutation series did not exhibit reserpine potentiated
reduction with either moxifloxacin or gatifloxacin which is consistent with the
observation that pmrA does not seem to have any effect on the newer generation
quinolones such as grepafloxacin (Morrissey et al, 1999) and gemifloxacin (Heaton
et al, 1999, Broskey et al 2000). Reductions in susceptibilities to norfloxacin and
ciprofloxacin both hydrophilic quinolones were observed indicating that reserpine
potentiation of the fluoroquinolones is only restricted to the older quinolone agents.
The lack of reserpine potentiated reduction in susceptibility to moxifloxacin, also a
hydrophilic quinolone (Piddock & Jin, 1999) suggests that either moxifloxacin is not
a substrate ofpmrA or is affected by other efflux proteins not inhibited by reserpine.
Our results showed 2-4 fold reductions in the moxifloxacin MIC in four mutants
derived from S. pneumoniae R6 which is in contrast to the reported substrate profile
of pmrA (Brenwald et al, 1997). Although, a similar reserpine mediated reduction
was observed with S. aereus when moxifloxacin and sparfloxacin was tested in
combination with reserpine (Schmitz et al, 1998b). The data presented in this thesis
and Schmitz et al (1998b) does suggest that in some strains moxifloxacin may be
partly excreted by a reserpine sensitive efflux pump.
Therefore, to investigate moxifloxacin uptake into these mutants a fluorescence assay
was performed. The uptake profile of mutants generated from P1Z1/IN27 was also
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analysed. The first-step mutant 1TS9 which, sustained no gyrA or parC changes
within the QRDR of either gene appeared to accumulate significantly higher levels of
moxifloxacin than the other mutants. In contrast, 4TS67 which sustained mutations
in gyrA and parC accumulated the least levels of moxifloxacin. No differences in
moxifloxacin accumulation was observed with mutant 2TS35 which also possessed
mutations in both gyrA and parC. The moxifloxacin accumulation profiles of the
efflux mutant series exhibited dramatically decreased levels of uptake in comparison
to the parent strain P1Z1/IN27. The trend that is apparent from both the
accumulation assays indicated lower levels ofmoxifloxacin accumulation by mutants
that were more resistant. This observation is concurred by the work done with
ciprofloxacin resistant mutants which accumulate lesser quinolone as they become
more resistant (Piddock et al, 1997; Zeller et al, 1997; Kaatz & Seo, 1995).
Comparisons of the uptake assays between the S. pneumoniae R6 mutants and the
P1Z1/IN27 mutant series indicate that the differences in the levels of accumulation
are less apparent in the latter group. Some studies have suggested that the presence of
a capsule can affect the uptake profiles of bacteria. In this case, S. pneumoniae R6 is
a non capsulated strain and P1Z1/IN27 possesses a capsule. Capsules have been
shown to generate a higher degree of non-specific binding of the antibiotics to
surface components (Zeller et al, 1997), therefore creating a background and
decreasing the apparent differences in quinolone uptake.
Therefore to further examine the possible role of pmrA expression northern blot
analysis of both the S. pneumoniae R6 and P1Z1/IN27 derived mutants were
conducted. RNA degradation issues prevented the gene expression analysis of the
S. pneumoniae R6 mutant series. With the P1Z1/IN27 series, northern blot analysis
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of parent P1Z1/IN27, first-step mutants (EfflO, Eff21 and Eff25) and second-step
mutants (Eff49 and Eff50) was done. Increased transcription levels were obtained
with P1Z1/IN27 and first-step mutants EfflO and a very faint signal was obtained for
Eff50. The RNA dot blot analysis was generally in agreement with the northern blot
data but with an additional second-step (Eff 49) mutant yielding a positive signal.
The analysis of the efflux mutants by MIC testing with the inhibitor failed to show an
reserpine potentiated decrease in susceptibility to either ciprofloxacin and
norfloxacin contrary to that demonstrated by the parent strain prior to moxifloxacin
challenge. The combination of the MIC data and northern blot results indicates either
a possible downregulation of the pmrA pump thereby explaining the altered substrate
profile observed with the MIC data or the involvement of another pmrA like pump.
Earlier studies have indicated that the absence of reserpine inhibition of moxifloxacin
disqualifies its role as a substrate of pmrA (Brenwald et al, 1997). Therefore, to
investigate, the levels of pmrA expression were analysed after ciprofloxacin and
moxifloxacin induction. In the RNA dot blot analysis all the parent strains tested
(S. pneumoniae R6, S. pneumoniae P1Z1/IN27 and S. pneumoniae 2.85) showed
positive results with ciprofloxacin and moxifloxacin induction. In contrast positive
signals were only observed with the parent strains S. pneumoniae R6 and
S. pneumoniae P1Z1/IN27 with the northern blot analysis. Due to the apparent
discrepancies of these results, it is difficult to extract any firm conclusions from these
experiments.
Given the ubiquity of efflux pumps on bacterial surfaces it is possible to suggest that
another efflux pump which is similar to pmrA or pmrA itself is involved in the import
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and export of other hydrophilic quinolones such as moxifloxacin. It may be possible
to suggest that both ciprofloxacin and moxifloxacin induce the expression ofpmrA or
a pmrA like pump based on the MIC results and uptake assays. Mutations described
within the promoter region of NorA and the efflux pump have been shown to alter
the substrate profile of the drug (Kaatz & Seo, 1995). Genetic analysis of the pmrA
gene in both laboratory generated mutants and clinical isolates demonstrated no
mutations, as. the region analysed and verified by bidirectional sequencing is small.
It is possible that changes within the promoter or regulator region could explain the
altered substrate profile described here.
The results presented in this thesis clearly suggest that DNA gyrase is the primary
target of moxifloxacin in laboratory generated mutants. The preferential targeting of
DNA gyrase by moxifloxacin appears to be confined to the A subunit of the
topoisomerase as no mutations were found within gyrB. The absence of target
mutations in some of the first-step mutants despite MIC increases does suggest a role
for efflux mutations, although the specific role ofpmrA in moxifloxacin resistance or
any other efflux pump could not be determined. The development of moxifloxacin
resistance is represented in the diagram below (See Figure 4.1). Transformation
studies analysing genetic mutations provide support that the mutations described here
are clinically relevant, although it is conceded that the events that trigger in vivo
emergence of resistance can differ significantly from in vitro environments.
The results presented here illustrate the possibility of spontaneous emergence of
resistance to moxifloxacin and other agents. Generally, the emergence of antibiotic
resistant mutants occurs at antibiotic concentrations that are not sufficiently
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bactericidal to all the phenotypes present in a given bacterial population. Recent
work by Dong et al (1999) have shown that the emergence of drug resistant mutants
is curtailed if sufficiently high antibiotic concentrations are used. This concentration
is known as the mutant prevention concentration which is determined by applying
1010 cells to agar plates containing various concentrations of quinolones, usually to a
concentration above the MIC where no resistant mutants were recovered (See
Figure 4.1). When a relationship between quinolone structure and resistance
development was assessed, it was found that quinolones that possess the C8-methoxy
lowered the MPC concentration as these agents were particularly bactericidal against
first-step gyrA mutants (Zhao et al, 1997). In the clinical situation, the model
proposed by Dong et al (1999) could provide an advantage (See Figure 4.1).
Generally antibiotic concentrations below the MPC concentration are likely to select
for resistant mutants and concentrations that are above this value may be toxic to the
patient. The MPC has been shown to block the growth of the most resistant single-
step mutant (Dong et al, 1999) and for resistance to develop mutants must harbour
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Figure 4.1: Mutant Selection Window
The development of double mutations in one mutation step is rare as has been
exemplified by in vitro studies with both clinafloxacin (Pan & Fisher, 1998),
gemifloxacin (Heaton et al, 2000) and moxifloxacin (This thesis, 2000). Thus, drug
resistant mutations will be rare at the MPC prescribed antibiotic concentrations. It
may be worthwhile to establish the use of MPC in drug dosages to prolong the use of
potent antimicrobials and limit the in vivo emergence of resistant strains.
5 Conclusions
The sensitivity survey of respiratory clinical isolates has shown that
fluoroquinolones particularly the extended-spectrum agents tested exhibit enhanced
activity over the other clinically available options. In the face of 13-lactam and
macrolide resistance, these agents provide an alternative, and the data presented here
has shown the improved activity of these quinolones against previously resistant
bacteria. It is conceded that the validity of these in vitro observations must await
clinical studies after the widespread use ofmoxifloxacin.
The in vitro development of resistance to moxifloxacin in S. pneumoniae was found
to arise through two pathways the first was the acquisition of a single gyrA mutation
which resulted in an eight-fold increase in the moxifloxacin MIC and in the second
pathway, regardless of the lack of target mutations an eight-fold increase in the MIC
was observed suggesting that either the induction of an efflux pump or mutations
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outwith the QRDR may be responsible. Mutation studies involving clinical
pneumococcal isolates S. pneumoniae 285 and S. pneumoniae 158 reveal similar
pathways of resistance development. Moxifloxacin selection of efflux
hyperexpressing strain P1Z1/IN27 also demonstrated the development of a gyrA
mutation prior to any other target changes. On the basis, of these results, it is
proposed that moxifloxacin resistance arises initially through either an efflux
mutation or by a gyrA change regardless of the strain phenotype.
In previous studies, it has been suggested that moxifloxacin is impervious to efflux
mechanisms. The data presented on moxifloxacin accumulation and northern blot
analysis indicates that efflux expression may play a role in the development of
moxifloxacin resistance although the exact contribution was not determined. The
gyrA and parC mutations identified in this study have been described in clinical
pneumococcal isolates which is indicative of the stability and prevalence of these
changes in in vivo situations. In this study no gyrB or parE mutations were identified
after moxifloxacin challenge possibly indicating the rarity of these mutations and the
secondary role they play in the development of resistance.
The target specificity of moxifloxacin differs from the older agents like ciprofloxacin
and norfloxacin where topoisomerase IV changes have been shown to develop prior
to any other target mutations. The topoisomerase IV mutations that develop after
ciprofloxacin and norfloxacin challenge have been shown to have a minimal effect
on the antibacterial activity of moxifloxacin. This observation was also confirmed by
the enhanced activity of moxifloxacin against clinical pneumococcal populations
which express an efflux mechanism and possess a target mutation.
Appendix I
Details of Strains Sent from Participating Centres








Royal Infirmary, Aberdeen — —- 48 48
Southmead Hospital, Bristol 32 26 40 98
St. James's Hospital, Dublin 37 17 14 68
Edinburgh Royal, Infirmary 74 64 39 177
Southern General, Glasgow 131 26 21 178
General Infirmary, Leeds 50 50 49 149
Royal Free, London — 19 — 19
Hallamshire Hospital, Sheffield 43 18 12 73
University Hospital, Wales 32 37 30 99
Total 399 257 253 909
Appendix II
Minimum inhibitory concentrations and factor increases for moxifloxacin
resistant mutants derived from S. pneumoniae R6.
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All MICs were determined by the doubling agar dilution method according to the BSAC guidelines
(Phillips et al, 1991).
Mutants highlighted in bold are parent strains used to generate subsequent progeny.
All MIC increments are calculated in comparison to the original parent strain S. pneumoniae R6.
Appendix III
Minimum inhibitory concentrations and factor increases for moxifloxacin
resistant mutants derived from S. pneumoniae R6.




























































































All MICs were determined by the doubling agar dilution method according to the BSAC guidelines
(Phillips et al, 1991).
Mutants highlighted in bold are parent strains used to generate subsequent progeny.
All MIC increments are calculated in comparison to the original parent strain S. pneumoniae 285.
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